user_id,prompt id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
edin,82,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
edin,17,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", cervical Bishop's score , placebo , antibiotic therapy ,0,
edin,75,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
edin,64,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
edin,79,2875419,No significant difference,"The proportions of patients achieving A1C <7% were also similar (44.1 and 47.8%, respectively, P = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C <6.5% (16.5 and 22.7%, respectively, P = 0.017).",  number of patients with A1C <7%  ,  glargine  ,  detemir  ,0,
edin,13,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
edin,88,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
edin,42,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
edin,51,524504,Significantly decreased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
edin,43,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,48,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
edin,77,3281242,Cannot tell based on the abstract,, time to make first quit attempt , placebo , varenicline ,0,
edin,77,3281242,Significantly increased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).", time to make first quit attempt , placebo , varenicline ,0,
edin,53,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
edin,60,524504,No significant difference,Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS,  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
edin,70,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,40,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,62,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
edin,95,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).,The maximum IVD dwell time was 1,023 hours (43 days) in the clinical replacement group, and this cannula was still working well on removal for completion of therapy.",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
edin,39,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
edin,55,524504,Cannot tell based on the abstract,,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,55,524504,No significant difference,Uterine Hyperstimulation	2 (2.5%)	1 (1.2%)	NS,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,3,3298351,Cannot tell based on the abstract,, venous ulcer healing , no treatment , compression therapy ,0,
edin,3,3298351,Significantly increased,The changes of ulceration area were statistically significant regardless of the type of compression therapy., venous ulcer healing , no treatment , compression therapy ,0,
edin,15,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
edin,26,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,26,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,30,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,30,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,46,2674549,Cannot tell based on the abstract,, serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,46,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.,During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,93,2944158,No significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,81,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
edin,34,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,27,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,27,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,90,2944158,Significantly increased,"This review included six trials (n = 3,455) and reported no clinically important or statistically significant difference in catheter-related bloodstream infection or phlebitis between IVDs that were routinely resited (at 48-96 hours) or resited on clinical indication, yet there were significantly lower costs in the group resited on clinical indication",  cost per patient  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,18,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", white blood cell count , placebo , antibiotic therapy ,0,
edin,23,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,16,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,0,
edin,56,524504,Cannot tell based on the abstract,,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,56,524504,No significant difference,Meconium stained AF	15 (18.8%)	7 (9.6%)	NS,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,54,524504,Significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).",  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
edin,67,1764008,No significant difference,Active phase of first Stage of labor (h)	2.49 ± 1.40	2.40 ± 1.55	NS,  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,37,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,85,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
edin,76,3281242,Cannot tell based on the abstract,,  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,76,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,41,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,89,2944158,Significantly increased,"The overall number of IVDs per patient was significantly less (P = 0.004) for those replaced on clinical indication (mean 1.5, SD 0.8, median 1, quartiles 1 and 2) than for those routinely replaced (mean 1.8, SD 1.1, median 1, quartiles 1 and 2)",  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,49,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
edin,58,524504,No significant difference,"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia,Neonatal resuscitation	9 (11.3%)	9 (10.8%)	NS",  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
edin,96,2858204,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,n the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",  frequency of healed index ucler after 1 year  ,  placebo  ,  HBOT   ,0,
edin,80,2875419,Significantly increased,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", number of patients with A1C <6.5% , glargine , detemir ,0,
edin,91,2944158,No significant difference,"Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.", IVD complications per person , staff inclination replacement , routine replacement ,0,
edin,44,2674549,Cannot tell based on the abstract,, serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,44,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients", serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,22,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,92,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., phlebitis , staff inclination replacement , routine replacement ,0,
edin,65,1764008,No significant difference,"Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS,Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,4,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , two-layer bandage , four-layer bandage ,0,
edin,74,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001)", continuous abstienence at week 12 , placebo , varenicline ,0,
edin,97,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
edin,86,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
edin,71,1764008,No significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,20,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,83,2875419,Significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001),Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (3,10,11). At present there is no clear explanation for the increased dose requirements for detemir",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
edin,2,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
edin,66,1764008,Cannot tell based on the abstract,,  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,66,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,29,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,29,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,45,2674549,Cannot tell based on the abstract,, serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,45,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.


Conclusion:", serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,73,1764008,No significant difference,"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.",  neonatal outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,10,3298351,Cannot tell based on the abstract,,  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,10,3298351,No significant difference,"Table I
Comparable characteristics of patients treated with Maxis compression stockings and ProGuide two-layer and Profore four-layer compression systems,Ulceration area [cm2] (x ± SD)	4.7 ±4.18	5.3 ±3.93	6.0 ±3.98	p > 0.05,In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system. The differences were statistically significant (p > 0.05).",  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,31,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,9,3298351,Significantly increased,"However, greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.",  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
edin,63,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
edin,38,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., symptoms of RA , methotrexate , golimumab and methotrexate ,0,
edin,84,2875419,Cannot tell based on the abstract,,  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,84,2875419,Significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,94,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)	RR 0.77 (0.21, 2.80), p = 0.75,There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,87,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., infections , staff inclination replacement , routine replacement ,0,
edin,7,3298351,No significant difference,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.",  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
edin,5,3298351,No significant difference,"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05",  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
edin,33,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
edin,28,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,28,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,19,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,12,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
edin,24,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , twice weekly single iron tablet , daily single iron tablets ,0,
edin,35,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,11,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
edin,72,1764008,No significant difference,"Women in both groups were similar in both obstetric and demographic characteristics,The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric intervention  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,36,3233526,No significant difference,"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks,,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).",  ferritin levels at week 38  ,  daily single iron tablets  ,  weekly supplements of two iron tablets  ,0,
edin,59,524504,No significant difference,The mean cord pH and the base deficit were comparable in the two groups.,  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,Cannot tell based on the abstract,,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,No significant difference,Perinatal death	0	1(1.2%)	NS,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,61,524504,No significant difference,Birth trauma 3	0	2 (2.5%)	NS,  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
edin,98,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
edin,32,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,69,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).,  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,14,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
edin,21,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
edin,8,3298351,Cannot tell based on the abstract,,  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,8,3298351,No significant difference,"greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week. The value of the same parameter in patients treated with the two-layer ProGuide compression system was 0.55 cm2/per week and of those treated with compression stockings 0.44 cm2/per week. Although the changes of ulceration area in each analysed group were statistically significant (p < 0.001), inter-group differences were not found (H = 4.45, p > 0.05).",  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,52,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05)", Caesarean section rate , misoprostol , dinoprostone ,0,
edin,78,2875419,No significant difference,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", improved A1C , glargine , detemir ,0,
edin,50,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
edin,68,1764008,Cannot tell based on the abstract,,  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,68,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,6,3298351,No significant difference,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
edin,25,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,25,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,47,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
edin,191,2517154,Cannot tell based on the abstract,,  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,191,2517154,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,159,2708184,Cannot tell based on the abstract,,  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,159,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,128,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,128,2871176,Invalid Prompt,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I don't have required information in abstract and I can't open the rest of article. I keep getting 404 page not found error 
edin,114,2871176,Cannot tell based on the abstract,,  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,114,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,211,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,211,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.,Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,179,2864284,Cannot tell based on the abstract,,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,179,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,132,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,132,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,134,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,134,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,103,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,143,2871176,Cannot tell based on the abstract,,  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,143,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,188,2517154,Cannot tell based on the abstract,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,188,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates. Routine pathology (FC) also showed no obvious differences between the two groups.",  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,163,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,163,2708184,No significant difference,"<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,189,2517154,Cannot tell based on the abstract,,  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,189,2517154,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,176,2864284,Cannot tell based on the abstract,,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,176,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,Cannot tell based on the abstract,,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,147,2871176,Cannot tell based on the abstract,,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,147,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002).,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,197,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25?1.69) and SU (37.9%; RR 1.45, 95% CI 1.22?1.73) (Table 2).",  Pain relief: Acupuncture  ,  Normal unit & Special unit  ,  Midwife-led unit  ,0,
edin,192,1852268,No significant difference,"In this study, ertapenem was as effective as piperacillin?tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin?tazobactam.,The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2?4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin?tazobactam were cured (95% confidence interval for the difference, adjusting for strata, ?4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillin?tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,204,4106715,Cannot tell based on the abstract,,  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,204,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20).",  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,164,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,164,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,121,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,121,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,1, I get 404 not found error when I want to see the whole article 
edin,160,2708184,Cannot tell based on the abstract,,  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,160,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,201,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,130,2871176,Cannot tell based on the abstract,,  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,130,2871176,Significantly decreased,"Although weight effects were modest, liraglutide produced more favourable weight effects compared with rosiglitazone, which produced substantial weight gain.",  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,135,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,135,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,208,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20)."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,169,2864284,Cannot tell based on the abstract,,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,169,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,137,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,137,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,209,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,209,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,120,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,120,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I got 404 Not Found error
edin,100,2871176,Cannot tell based on the abstract,,  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,100,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).",  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,154,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,154,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,205,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,205,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,156,2708184,Cannot tell based on the abstract,, Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,156,2708184,No significant difference,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,198,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
edin,112,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,112,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,212,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,177,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,155,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,155,2708184,No significant difference,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,184,2517154,Cannot tell based on the abstract,, Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,184,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,117,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,117,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,119,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,119,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,166,3001156,Cannot tell based on the abstract,, Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,166,3001156,Significantly increased,"Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital, and decreases were observed in care-seeking from unqualified providers in the intervention arm.", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,123,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,199,3187863,No significant difference,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth. An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively."," Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
edin,207,4106715,Significantly increased,"3?AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14?6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,99,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,99,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,206,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19?52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19?52) with high Ab levels ,0,
edin,172,2864284,Cannot tell based on the abstract,, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,172,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,107,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,107,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,195,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59?0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56?0.86) (Table 2).", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
edin,182,2517154,Cannot tell based on the abstract,, Nodules diameters , Placebo , Infliximab ,0,
edin,182,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
edin,202,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,202,4106715,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,168,2864284,Cannot tell based on the abstract,, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,168,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,190,2517154,Cannot tell based on the abstract,, Pain killers intake , Placebo , Infliximab ,0,
edin,190,2517154,Significantly increased,"The strong and significant placebo effect and the absence of an infliximab effect were consistently found for all pain estimations in this study, i.e. the five scorings by the clinician and the calculated total scores (i.e. dysmenorrhea, deep dyspareunia, chronic pain, pelvic tenderness, the sum of the 3 BB pain scores and the total BB score) and the pain recorded in the dairy by the patients (i.e. the 3 BB scores, the visual analog scales, the pain killer intake and both calculated total scores, i.e. with or without taking pain killer intake into account).", Pain killers intake , Placebo , Infliximab ,0,
edin,194,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65?0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59?0.89) (Table 2).", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
edin,186,2517154,Cannot tell based on the abstract,, Surgery duration , Placebo , Infliximab ,0,
edin,186,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
edin,136,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,136,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,116,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,116,2871176,Significantly decreased,"By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,173,2864284,Cannot tell based on the abstract,, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,173,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,167,3001156,Cannot tell based on the abstract,, Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,167,3001156,No significant difference,"At the time of the baseline household survey in January 2003, there was no significant difference between the intervention arm and the comparison arm of the study in the proportion of sick newborns who were taken outside the home for care from any qualified provider (including Kumudini Hospital), to the Kumudini Hospital specifically, or to an unqualified provider, most commonly an unlicensed ?village doctor?.", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,139,2871176,Cannot tell based on the abstract,, HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,139,2871176,No significant difference,"There were no significant differences between treatments for HOMA-IR.

Table 2", HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,213,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,110,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,110,2871176,Significantly increased,"The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,144,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,144,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,165,3001156,Cannot tell based on the abstract,, Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,165,3001156,No significant difference,Figure 2 demonstrates that there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8)., Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,109,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,109,2871176,Significantly decreased,"Rosiglitazone also was superior to placebo (P < 0.0001).,he greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,106,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,106,2871176,Significantly decreased,"Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,149,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,149,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,104,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,180,2864284,Cannot tell based on the abstract,, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,180,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,111,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,111,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).

FIGURE 4", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,187,2517154,Cannot tell based on the abstract,, Bleeding during surgery , Placebo , Infliximab ,0,
edin,187,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
edin,157,2708184,Cannot tell based on the abstract,, Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,157,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,122,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,122,2871176,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,126,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,126,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,158,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,158,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,125,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,183,2517154,Cannot tell based on the abstract,, Endometrial thickness , Placebo , Infliximab ,0,
edin,183,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3?18) and 7.8 (1.9?11) mm and for the placebo group 7.7 (1.8?23) and 8.2 (3?15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
edin,175,2864284,Cannot tell based on the abstract,, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,175,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,133,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,133,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,171,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,146,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,146,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,127,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,127,2871176,Significantly increased,"he percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,174,2864284,Cannot tell based on the abstract,, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,174,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,118,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,118,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,185,2517154,Cannot tell based on the abstract,, Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,185,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,142,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,142,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,162,2708184,Cannot tell based on the abstract,, Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,162,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,129,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,129,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,131,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,131,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,140,2871176,Cannot tell based on the abstract,, HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,140,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,203,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,203,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,170,2864284,Cannot tell based on the abstract,, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,170,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,150,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,150,2871176,No significant difference,"Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,124,2871176,Cannot tell based on the abstract,, Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,124,2871176,Significantly decreased,reatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5?2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone., Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,113,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,113,2871176,Significantly increased,"he estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,145,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,145,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,161,2708184,Cannot tell based on the abstract,, Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,161,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,102,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,102,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,108,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,108,2871176,No significant difference,"All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,181,2517154,Cannot tell based on the abstract,, Severity of pain , Placebo , Infliximab ,0,
edin,181,2517154,No significant difference,"Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). However, no effect of infliximab was observed for any of the outcome measures.", Severity of pain , Placebo , Infliximab ,0,
edin,141,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,141,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,153,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,153,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,210,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,210,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,196,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11?1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16?2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
edin,115,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,115,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,193,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
edin,200,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,200,2688140,No significant difference,"The overall mortality at 28 days was 37%. Mortality at 28 days was 33% in the control group and 40% in the decremental PEEP titration group (Table 2). Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,138,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,138,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,148,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,148,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002), Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,151,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,151,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,400,2690844,Cannot tell based on the abstract,, Complications after surgery , Midline incision , Transverse incision ,0,
edin,400,2690844,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30), Complications after surgery , Midline incision , Transverse incision ,0,
edin,442,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,442,2600646,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,376,3580134,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Awakening-free nights percentage improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,472,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,472,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,344,3580134,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ? 0.004) and with budesonide/formoterol 320/9 ?g compared with formoterol (p = 0.026) [figure 6]., Time to first COPD exacerbation , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,474,2847809,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03)., The primary arteriovenous fistula failures at two months , Placebo , Clopidogrel ,0,
edin,315,3580134,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,279,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Information recall , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,480,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,324,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours at end of treatment , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,406,2690844,Cannot tell based on the abstract,, Scar width , Midline incision , Transverse incision ,0,
edin,406,2690844,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001)., Scar width , Midline incision , Transverse incision ,0,
edin,481,2899760,Significantly increased,"Fusion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).", Fusion rate , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,224,1475568,Cannot tell based on the abstract,, Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,224,1475568,Significantly decreased,"The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,Patients enrolled in the control group received a general heart failure education pamphlet written at approximately the 7th grade level, and continued with usual care from their primary physician.", Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,374,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].,Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Sleep score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,319,3580134,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ? 0.012), Peak expiratory flow in the morning and evening  , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,440,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,440,2600646,No significant difference,"<td colspan=""8""><hr></td>", mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,268,2691927,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure., Need for opiates , Conventional open approach , Laparoscopic surgery ,0,
edin,286,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Quit attempt of 1 week or longer reported at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,309,2817867,Significantly increased,Sixty percent of patients suffered local recurrences after RFA compared to 7% after hepatic resection., Local recurrence rate through the study , Hepatic resection , Radiofrequency ablation ,0,
edin,241,3090298,Cannot tell based on the abstract,, Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,241,3090298,No significant difference,"Total root-mean square (RMS) HOAs, coma, trefoil, and spherical aberrations are compared in Figure 2. There were no significant differences between groups in any HOAs throughout the study (P ? 0.101), with all P values at 6 months ?0.63.", Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,216,1475568,Cannot tell based on the abstract,, Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,216,1475568,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.", Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,307,2817867,Cannot tell based on the abstract,, Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,307,2817867,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).", Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,432,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,432,3187863,Significantly increased,"There were statistically significant differences in augmentation (midwife-led unit versus normal unit RR 0.73, 95% CI 0.59?0.89; midwife-led unit versus special unit RR 0.69, 95% CI 0.56?0.86), in epidural analgesia (midwife-led unit versus normal unit RR 0.68, 95% CI 0.52?0.90; midwife-led unit versus special unit RR 0.64, 95% CI 0.47?0.86) and in acupuncture (midwife-led unit versus normal unit RR 1.45, 95% CI 1.25?1.69; midwife-led unit versus special unit RR 1.45, 95% CI 1.22?1.73).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,302,2817867,Cannot tell based on the abstract,, Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,302,2817867,Significantly decreased,Operative blood loss (median 1400?mL (range 100 to 9000) versus 150?mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA., Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,326,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Baseline-adjusted average 12-hour FEV1 at end of treatment , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,443,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66),", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,341,3580134,Significantly increased,"Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ? 0.018) [figure 5b].,Both dosages of budesonide/formoterol resulted in a 350 mL (?25%) improvement from baseline to the average over the randomized treatment period in 1-hour post-dose IC, and formoterol resulted in a 210 mL (17%) improvement in 1-hour post-dose IC. Fig. 5", 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,403,2690844,Cannot tell based on the abstract,, Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,403,2690844,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).Table 4", Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,347,3580134,Significantly decreased,"In addition, significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ? 0.004) [see figure S2 in the supplementary material].", Amount of exacerbations per patient-treatment year , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,231,3090298,Cannot tell based on the abstract,, Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,231,3090298,Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA.", Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,389,2690844,Cannot tell based on the abstract,, Smaller incision  , Midline incision , Transverse incision ,0,
edin,389,2690844,Significantly increased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).", Smaller incision  , Midline incision , Transverse incision ,0,
edin,482,2899760,No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused., clinical outcomes , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,367,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Overall use of daily rescue medication improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,402,2690844,Cannot tell based on the abstract,, Urinary retention , Midline incision , Transverse incision ,0,
edin,402,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Urinary retention , Midline incision , Transverse incision ,0,
edin,283,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Overall survival , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,397,2690844,Cannot tell based on the abstract,, Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,397,2690844,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65)., Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,233,3090298,Cannot tell based on the abstract,, Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,233,3090298,No significant difference,Visual acuities were not statistically different between the groups at 3 or 6 months., Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,254,1831737,Cannot tell based on the abstract,, Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,254,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,282,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Time to treatment failure , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,447,2607225,Cannot tell based on the abstract,, cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,447,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months.", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,385,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Bladder training plus tolterodine (Co) ,0,
edin,467,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,305,2817867,Cannot tell based on the abstract,, Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,305,2817867,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.", Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,273,2691927,Cannot tell based on the abstract,, Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,273,2691927,No significant difference,"Nasogastric decompression could be stopped after 2?3 days in both groups (Table 4).Table 4,<td align=""left"">Median duration of nasogastric decompression (days) + IQR</td><td align=""char"" char=""("">2.0 (3.0)</td><td align=""char"" char=""("">3.0 (1.3)</td><td align=""char"" char=""."">0.334</td>", Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,456,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,456,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,269,2691927,Cannot tell based on the abstract,, Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,269,2691927,No significant difference,"Time to discharge was similar for the two groups, with a median difference of 1.5 days (Table 4),<td align=""left"">Median hospital stay (days) + IQR</td><td align=""char"" char=""("">6.5 (9.3)</td><td align=""char"" char=""("">8.0 (7.3)</td><td align=""char"" char=""."">0.235</td>", Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,463,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,238,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,238,3090298,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).", Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,265,2691927,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 3 , Conventional open approach , Laparoscopic surgery ,0,
edin,395,2690844,Cannot tell based on the abstract,, Average patient's weight , Midline incision , Transverse incision ,0,
edin,395,2690844,No significant difference,"Furthermore, no differences were found in the body mass and average length between the two groups (Table 1).", Average patient's weight , Midline incision , Transverse incision ,0,
edin,264,2691927,Significantly decreased,"he VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 1 , Conventional open approach , Laparoscopic surgery ,0,
edin,278,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Anxiety , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,370,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Cough score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,479,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,261,1831737,Cannot tell based on the abstract,, Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,261,1831737,Significantly increased,"In the general population sample interviewed in the follow-up survey, 1,779 (35%) and 647 (13%) of 5,098 respondents reported attending an HIV/AIDS meeting and a programme meeting, respectively (Table 5). More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33?1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52?5.17], p < 0.001),", Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,387,2721929,Cannot tell based on the abstract,, Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,387,2721929,No significant difference,"No difference was observed between the To and Co groups.,When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively).", Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,276,2375236,Cannot tell based on the abstract,, Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,276,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,237,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,237,3090298,Significantly decreased,"The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131), while patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively", Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,298,1871574,Cannot tell based on the abstract,, Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,298,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,428,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,428,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,292,1871574,Cannot tell based on the abstract,, Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,292,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>,<td></td><td colspan=""5""><hr></td>", Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,423,1187893,Significantly increased,"<td colspan=""7""><hr></td>", Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months , No exercise , Exercise ,0,
edin,323,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours on the day of randomization , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,295,1871574,Cannot tell based on the abstract,, Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,295,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,316,3580134,Significantly increased,"lthough improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,217,1475568,Cannot tell based on the abstract,, Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,217,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men.,Regardless of these differences, none were statistically significant.", Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,258,1831737,Cannot tell based on the abstract,, Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,258,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,448,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,448,2607225,Significantly decreased,"Appetite loss decreased from 3 to 6 months (mean=5.1?3.7, s.d.=14.2?11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,441,2600646,Cannot tell based on the abstract,, Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,441,2600646,No significant difference,"<td colspan=""8""><hr></td>", Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,377,3580134,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 ?g and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 ?g and formoterol groups (p = 0.044) at end of treatment., 24-hour urinary cortisol at 6 months , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,218,1475568,Cannot tell based on the abstract,, Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,218,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking ?-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.", Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,255,1831737,Cannot tell based on the abstract,, Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,255,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,393,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day three after surgery , Midline incision , Transverse incision ,0,
edin,289,1871574,Cannot tell based on the abstract,, Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,289,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,473,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008)., First hemodialysis success , Placebo , Clopidogrel ,0,
edin,228,1475568,Cannot tell based on the abstract,, Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,228,1475568,No significant difference,"Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81).", Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,275,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis enquiry , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,401,2690844,Cannot tell based on the abstract,, Cardiac complications , Midline incision , Transverse incision ,0,
edin,401,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Cardiac complications , Midline incision , Transverse incision ,0,
edin,310,3580134,Significantly increased,Time to discontinuation was significantly (p ? 0.004) prolonged in both budesonide/formoterol groups versus placebo., Time to discontinuation , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,355,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Breathlessness Cough and Sputum Scale improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,287,1871574,Cannot tell based on the abstract,, Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,287,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,427,1187893,Cannot tell based on the abstract,, Functional performance improvement , No exercise , Exercise ,0,
edin,427,1187893,No significant difference,"<td colspan=""7""><hr></td>", Functional performance improvement , No exercise , Exercise ,0,
edin,290,1871574,Cannot tell based on the abstract,, Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,290,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,391,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day one after surgery , Midline incision , Transverse incision ,0,
edin,384,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Tolterodine only (To) ,0,
edin,259,1831737,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities., Self-reported STI symptoms , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,407,2690844,Cannot tell based on the abstract,, Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,407,2690844,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance., Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,226,1475568,Cannot tell based on the abstract,, Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,226,1475568,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).", Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,368,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Dyspnoea score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,611,5577662,Cannot tell based on the abstract,, percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,611,5577662,Significantly decreased,"<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,571,5602855,No significant difference,The EQ-5D-3L summary index is shown in Fig.Â 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (pÂ =Â 0.26) or inadequate (pÂ =Â 0.71) motivation/capability during the three years of follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,578,4577567,Significantly decreased,"Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.,In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).", internal work , free stride frequency , stride frequency manipulation ,0,
edin,495,2253708,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th>", 7-day point prevalence abstinence , Practitioner-delivered brief advice , Tailored letters ,0,
edin,619,4139977,No significant difference,Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910)., Improvement in bowel habit ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,608,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>,<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,595,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ??time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85),", Full return to normal work/employment , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,593,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Wearing clothes that show the legs , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,551,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,617,5062234,Significantly decreased,"The visual analog scale scores at rest and on coughing were significantly higher in the local infiltration group in the immediate postoperative period (P = 0.034 and P = 0.007, respectively).", The visual analog scale scores at rest and on coughing , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,544,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,544,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, I was not able to find any connection in text between health care workers with IgG against Severe acute respiratory syndrome and the risk of SARS infection. 
edin,556,4785315,Significantly decreased,"The prespecified comparison for women with two or more social risk factors showed a statistically significant reduction in mean EPDS (MD â??0.79 (95% CI â??1.56 to â??0.02) p=0.05), although no significant differences were seen in the mean EPDS (mean difference (MD) â??0.59 (95% CI â??1.24 to 0.06)) for all the women recruited.", Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS) , standard maternity care ," additional lay support (in this instance Pregnancy Outreach Workers, POWs) ",0,
edin,519,1261533,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023).", Decrease in haematocrit level at day 7 , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,620,4139977,No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372), Table 2.", quality-of-life  ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,583,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â?? 2 ).", Bending the legs without discomfort , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,599,4819709,Significantly decreased,"Return to â??walking short distances without discomfortâ??, â??walking long distancesâ??, â??looking after childrenâ?? and â??full return to normal work/employmentâ?? took longer for the EVLA group than the UGFS group."," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasoundâ??guided foam sclerotherapy , Endovenous laser ablation ,0,
edin,582,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,582,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, Required info can't be found in abstract and there are no other sections for this article. 
edin,560,2888205,Significantly decreased,"<th></th><th colspan=""6""><hr></th>", pain , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,485,2806484,No significant difference,"184 (24%) patients having home and 145 (27%) facility care either had virological failure, were lost to follow-up, or withdrew from the trial (adjusted rate ratio [RR] 0Â·88, 95% CI 0Â·70â??1Â·10).", Virological failure , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,500,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in consistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,561,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", six-minute walk test , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,534,3198285,Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean Â± SEM 47 Â± 1 vs. 53 Â± 1; P < 0.001)., lowâ??glycemic index , high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,502,2956883,No significant difference,No deaths or serious adverse events were regarded as related to study gels., Adverse events , Placebo gel , PRO2000 gels ,0,
edin,589,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Having a bath or shower , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,601,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , glucose 5% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,510,1964758,Significantly increased,"<td colspan=""4""><hr></td>", 8-year survivorship in patients with osteoarthritis , BioModularÂ® shoulder prosthesis , Initial Nottingham TSR design prosthesis ,0,
edin,615,5062234,No significant difference,The 24 h morphine requirement (mean Â± standard deviation) was 34.57 Â± 14.64 mg in TAP group and 32.76 Â± 14.34 mg in local infiltration group (P = 0.688)., The 24 h morphine requirement , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,602,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,512,2829413,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 Â± 11.38 vs. - 30.07 Â± 10.46%, p < 0.001), LDL-C (48.04 Â± 14.45 vs. 39.52 Â± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 Â± 13.15 vs. - 35.52 Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Â± 18.85 vs. - 32.57 Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Levels of LDL cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
edin,610,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>", global assessment of improvement ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,572,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,522,1261533,Significantly increased,"Of 452 patients, 119 (26.3%) had P. vivax parasitaemia detected during follow up. There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).", P. vivax parasitaemia diagnosed during follow up , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,531,2364680,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4)., wound problem , opening subcutaneous tissues with scalpel , opening subcutaneous tissues with electrocautery ,0,
edin,491,2363351,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).", Overall survival at 3 years , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Î³  ",0,
edin,536,3198285,No significant difference,"Table 4
Pregnancy outcomes by diet group,<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,501,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in inconsistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,498,2364533,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).", Preterm delivery , Placebo , Erythromycin ,0,
edin,487,2806484,Significantly decreased,"Table 6 shows mean yearly health services cost per patient calculated during 4 years, (including capital and recurrent expenses, and those of the starting phase and subsequent years). A large proportion of the costs were for drugs and staff salaries. The main cause of excess expenditure for the facility-based group was the increased number of contacts with health staffâ??especially with nurses and medical officers. These costs outweighed those of transport for field officers in the home-based group. Patient costs (transport of patient and companion, lunches, child care, and time lost from work) were much higher for the facility-based than for the home-based group (table 6).", Costs for the health service , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,609,5577662,Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (PÂ â?¤Â 0.0139 for all)., Mean change in nodular consistency and hardness ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,591,4819709,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Doing housework</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">2Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">2Â·10 (1Â·72, 2Â·56)</td>,Table 2
Behavioural recovery: ultrasoundâ??guided foam sclerotherapy versus surgery", Doing housework , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,539,2722000,Significantly decreased,"The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).", rebleeding , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,543,2650992,No significant difference,"Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,573,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,573,5602855,No significant difference,"At the four monthsâ?? follow-up, 112 (80.6%) subjects with good motivation/capability and 26 (39.4%) with inadequate motivation/capability continued self-assessment of pulse daily.,Irregular pulse findings were not significantly associated with the composite outcome variable (pÂ =Â 0.06), stroke/TIA (pÂ =Â 0.48), pacemaker implantation (pÂ =Â 0.10) or death (pÂ =Â 1.00).,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up.", Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,533,3221331,Cannot tell based on the abstract,, did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,533,3221331,No significant difference,"In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.", did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,314,3580134,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 Î¼g compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a]., Pre-dose FEV1 improvement , Placebo , Budesonide/formoterol pMDI 320/9 Î¼g ,0,
edin,604,5062194,No significant difference,There were no between-group differences regarding the neonatal outcome., neonatal outcome ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,741,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,741,3446002,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001), Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,922,3015551,No significant difference,"Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).", Outpatient recovery , undergo a tubal resection after bipolar coagulation with Kleppinger forceps , undergo a tubal resection after Pomeroy ligation ,0,
edin,966,5372931,Cannot tell based on the abstract,, 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,966,5372931,Significantly increased,"The linear dose response for each plasma metabolite was assessed and of the 60 identified metabolites, 14 (poly)phenol metabolites displayed a linear dose-response curve (r2 â¥ 0.89) in plasma (Figure 1) with slopes significantly different from zero (p < 0.05): caffeic acid 4-O-Ã-d-glucuronide and quercetin-3-O-Ã-d-glucuronide displayed r2 > 0.98, while ferulic acid 4-O-Ã-d-glucuronide, 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, ferulic acid, caffeic acid 3-O-Ã-d-glucuronide, sinapic acid, ferulic acid 4-O-sulfate, 3-hydroxybenzoic acid and syringic acid exhibited r2 > 0.90.,The time to reach Cmax (Tmax) varied depending on the metabolite and depending on the amount of (poly)phenols in the juice (Supplementary Figure S1). The level of TP in cranberry juice seemed to impact the Tmax of individual metabolites, for example the Tmax for 3-(4-hydroxyphenyl) propionic acid varied between 7.2 h (409 mg TP juice) and 13.8 h (787 mg TP juice).", 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,869,5332972,Significantly increased,"The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", TUG: Timed âUp &amp; Goâ? test; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,881,5539984,Cannot tell based on the abstract,, Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,881,5539984,No significant difference,"Mixed-models for EPAS total score (see Table 3) indicated a significant effect of time (bÂ =Â 0.07, pÂ <Â 0.001), but no significant group by time interaction effect (bÂ =Â 0.02; pÂ =Â 0.258). This means with regard to the parameterisation of the mixed effects model that there was a significant change of overall empowerment in the control group, but NWpG-IC treatment had no additional effect on improvement of overall empowerment during the 18Â month study period.", Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,635,4106715,Cannot tell based on the abstract,, Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,635,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19â52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,829,4819709,Cannot tell based on the abstract,, Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,829,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Walking long distances (&gt;â20 min)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">8Â·0</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·76 (1Â·45, 2Â·14)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ),The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ", Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,676,3387601,Cannot tell based on the abstract,, side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,676,3387601,No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients., side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,699,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,699,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â0.89) (Table 2).", Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,948,4693888,Cannot tell based on the abstract,, CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,948,4693888,No significant difference,"CKMB AUC (878 Â± 549 vs. 778 Â± 439 h*U/l, non-inferiority p < 0.001) and Troponin-T AUC (12990 Â± 8347 vs. 13498 Â± 6513 h*pg/ml, non-inferiority p < 0.001) was similar in both groups.", CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,688,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,919,3616124,Cannot tell based on the abstract,, preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,919,3616124,No significant difference,"Hp phenotype was not significantly associated with the risk of the primary outcome, preeclampsia, severe preeclampsia, or early onset preeclampsia in white/other, Hispanic or black women (Table 2).", preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,778,2722000,Cannot tell based on the abstract,, The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,778,2722000,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).", The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,833,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ?time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85), looking after children (1Â·45, 1Â·04 to 2Â·02) and walks of short (1Â·48, 1Â·19 to 1Â·84) and longer (1Â·32, 1Â·05 to 1Â·66) duration.", Looking after children , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,943,5551012,Significantly decreased,"However, antibiotic use less than 24Â h to delivery was associated with a decrease in mean APGAR score.", mean Apgar , no antibiotics , antibiotics in less than 24 h to parturition ,0,
edin,812,5602855,No significant difference,Quality of life and number of outpatient clinic visits remained unchanged during follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,897,1198254,Significantly increased,ME-3 was well tolerated and a significant increase in total faecal lactobacilli yet no predominance of ME-3 was detected in all study groups., total fecal counts of lactobacilli , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,871,5209819,Cannot tell based on the abstract,, Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,871,5209819,No significant difference,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8â69.6%) with no difference between intervention districts., Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,825,4819709,Cannot tell based on the abstract,, Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,825,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Lifting heavy objects without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">9Â·8</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·97 (1Â·59, 2Â·44)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,647,1201146,Cannot tell based on the abstract,, Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,647,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,814,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,814,5602855,Invalid Prompt,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,1," There is Self-detected pulse irregularity and outcome events section of the article. However, motivation/capability is not mentioned in it or I was not able to find it. "
edin,941,3039191,Cannot tell based on the abstract,, the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,941,3039191,No significant difference,"The results of FDT perimetry testing are shown in Figs. 1, 2, and 3. There were no statistically significant differences for MD and PSD between the clear IOL and Hoya YA60BBR IOL groups (MD: clear IOL, -5.09 Â± 4.72 Db; Hoya YA60BBR IOL, -3.68 Â± 3.83 dB; p = 0.21 / PSD: clear IOL, 4.26 Â± 2.45 dB; Hoya YA60BBR IOL, 3.81 Â± 1.99; p = 0.27, Mann-Whitney U-test).", the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,937,4918678,Significantly increased,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Reading , nothing , soundfield amplification devices in the classroom ,0,
edin,793,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", pain during movement , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,880,4088715,Cannot tell based on the abstract,," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,880,4088715,Significantly increased,"Subjects in the nCPAP group had a greater improvement for various parameters compared with the standard group including TV (0.8 l, 0.3 l), EtCO2 (30 mmHg, 38 mmHg) and RSBI (39, 150), respectively."," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,846,5062194,Significantly increased,"Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,Preeclamptic parturients premedicated with midazolam (0.035 mg/kg) before spinal anesthesia have lower anxiety and higher postoperative satisfaction levels, with no adverse effects on the newborns.", postoperative satisfaction ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,907,5816054,Cannot tell based on the abstract,, The duration of nebulization , 0.9% saline , furosemide ,0,
edin,907,5816054,No significant difference,"The duration of nebulization was not significantly different across treatments: 0.9% saline, 35.7 Â± 1.0 min; 40 mg furosemide, 36.4 Â± 1.2 min; and 120 mg furosemide, 39.2 Â± 1.1 min (p = 0.075).", The duration of nebulization , 0.9% saline , furosemide ,0,
edin,956,3330821,Cannot tell based on the abstract,, The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,956,3330821,Significantly increased,The overall satisfaction score for the services was 3.57 (3.31 to 3.81) for the EAP alone group and 4.42 (4.17 to 4.67) for the tCBT +EAP group (p<0.001)., The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,884,5514258,Significantly increased,"Patients in the high-risk group had greater survival (hazard ratio [HR], 0.76; P = .002; 95% confidence interval [CI], 0.64-0.91) if they received adjuvant radiation therapy.", survival , major salivary gland cancer in high risk group without adjuvant radiation therapy , major salivary gland cancer in high risk group plus adjuvant radiation therapy ,0,
edin,677,2430614,Significantly decreased,"In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, pâ=â0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, pâ=â0.005).", the parasitological and clinical failure rate at day 28 post treatment , artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,673,3387601,No significant difference,"hose in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,In children with GBS requiring MV, PE is superior to IVIG regarding the duration of MV but not PICU stay or the short term neurological outcome.", Pediatric Intensive Care Unit (PICU) stay , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,942,5551012,No significant difference,"Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores."," birthweight, incidence of congenital birth defect and mean Apgar scores ", no antibiotics , antibiotics ,0,
edin,638,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,638,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,868,5332972,Cannot tell based on the abstract,, FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,868,5332972,Significantly increased,"**Significant difference p<0.01. SD: standard deviation; FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; TUG: Timed âUp & Goâ? test; 10MWT: 10-m walk test; CGS: comfortable gait speed; FGS: fast gait speed,The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,650,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,650,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,824,4819709,Cannot tell based on the abstract,, Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,824,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,859,4139977,No significant difference,"After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).", decrease in abdominal pain and distension severity ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,683,2447617,Significantly increased,The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01)., The modified Functional Independence Measure scores , placebo , progesterone ,0,
edin,770,2361948,Cannot tell based on the abstract,, 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,770,2361948,Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42â72%) and 27% (95% CI: 14â40%) for patients receiving 16âGy/2 fr, and 30% (95% CI: 18â42%) and 11% (95% CI: 3â20%) for patients receiving 20âGy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).", 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,959,2656477,Significantly increased,<td></td><td></td><td></td><td></td><td></td><td></td>, self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors. , usual care , lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification ,0,
edin,717,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,811,5256321,Cannot tell based on the abstract,," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,811,5256321,Significantly increased,"Table 3 shows that the experimental group showed significant improvements in all testsâBBS (p=0.001), TUG (p=0.001), forward FRT (p=0.001), affected lateral FRT (p=0.001), and unaffected lateral FRT (p=0.002)âwhen the values before and after training were compared in each group"," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,935,4264479,No significant difference,All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR)., blood-stage infection , minimally exposed volunteers for both antigens , definitely exposed volunteers for both antigens  ,0,
edin,730,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question formed and no provided answers. 
edin,885,5514258,No significant difference,"In contrast, patients in the intermediate- (HR, 1.01; P = .904; 95% CI, 0.85-1.20) and low-risk groups (HR, 0.85; PÂ =Â .427; 95% CI, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.", survival , major salivary gland cancer in low/intermediate risk group without adjuvant radiation therapy , major salivary gland cancer in low/intermediate risk group plus adjuvant radiation therapy ,0,
edin,939,4918678,Cannot tell based on the abstract,, Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,939,4918678,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">âEG</td><td align=""center"" colspan=""1"" rowspan=""1"">131.8</td><td align=""center"" colspan=""1"" rowspan=""1"">59.9</td><td align=""center"" colspan=""1"" rowspan=""1"">112.9</td><td align=""center"" colspan=""1"" rowspan=""1"">52.8</td><td align=""center"" colspan=""1"" rowspan=""1"">1.31 (9)</td><td align=""center"" colspan=""1"" rowspan=""1"">.221</td>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,658,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,658,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,938,4918678,Cannot tell based on the abstract,, Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,938,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,680,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,680,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,809,5256321,Cannot tell based on the abstract,, The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,809,5256321,Significantly increased,"The 10mWT improved significantly (p=0.001) in the experimental group (using the Spine Balance 3D system) but not in the control group, and core muscle strength, which we checked using Spine Balance 3D system evaluation program, improved more in the experimental group as well.", The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,783,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", overall drain output , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,675,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,712,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,622,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,622,3187863,No significant difference,here was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,911,2774638,Cannot tell based on the abstract,, obtained calcium from dairy  , black women , white women ,0,
edin,911,2774638,Significantly increased,"White women obtained more calcium (630 [423] mg) from dairy than did black women (424 [373] mg, P < .004).", obtained calcium from dairy  , black women , white women ,0,
edin,777,3198285,Cannot tell based on the abstract,," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,777,3198285,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,691,2899760,Cannot tell based on the abstract,, Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,691,2899760,Significantly increased,"he fusion rate shown by the radiological analysis is presented in TableÂ 4. All patients in group III (clearly non-fused) showed at least 4Â° of mobility (the limit for the group set by the classification was 3.0Â°). There was no statistically significant difference in the fusion rate between smokers (92%) and non-smokers (74%) (PÂ =Â 0.2). Smokers operated on with TM showed an 87% fusion rate. Kappa analysis showed 0.63 and 0.66 for the intra-observer correlation, and 0.58 for inter-observer correlation.TableÂ 4,Radiological fusion

Fusion group	TM	SR
No.	Percentage	No.	Percentage
I (clearly fused)	18	46	35	89
IIA (probably fused)	9	23	1	3
IIB (probably non-fused)	5	13	0	0
III (clearly non-fused)	7	18	3	8
Fusion rate (IÂ +Â IIA)		69		92,his study of uninstrumented single-level ACDF showed a lower fusion rate with Trabecular Metal than with the SmithâRobinson technique with autograft after single-level anterior cervical fusion without plating.", Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,909,2774638,Significantly increased,"The CFFFQ estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).", Estimation of total daily calcium intake , 24-hour recall , calcium-focused food frequency questionnaire (CFFFQ) ,0,
edin,887,5801479,Significantly decreased,"Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1Î² (P = 0.02), tumor necrosis factor alpha (TNF-Î±) (P = 0.02) and interferon gamma (IFN-Î³) (P = 0.03) in PBMCs of diabetic HD patients."," gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?)  ", placebo (n = 30) every 2 weeks for 12 weeks ," vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks ",0,
edin,781,2722000,Cannot tell based on the abstract,, Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,781,2722000,No significant difference,Total mortality and 30-day mortality were not different between the two groups (Table 7)., Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,672,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", Period of mechanical ventilation  , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,703,3187863,No significant difference,"here were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,719,1201146,Significantly increased,"<td colspan=""3""><hr></td>"," Pain, physical function, PGA, stiffness  ", vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,841,4819709,Cannot tell based on the abstract,," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,841,4819709,Significantly increased,"Participants randomized to EVLA recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 3). Return to âhaving a bath or showerâ was quicker after surgery than after EVLA. There was no difference in time to return to the participation behaviour of âwearing clothes that show the legsâ.,<td align=""left"" colspan=""1"" id=""bjs10081-ent-0450"" rowspan=""1"" valign=""top"">Participation items</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0451"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0452"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0453"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0454"" rowspan=""1"" valign=""top""></td>"," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,726,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,726,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,784,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,877,2974815,No significant difference,There was no difference in the percentage of patients with controlled blood pressure in the âphone callsâ? group and âno phone callsâ? group or in the âtraditionalâ? and âcurrentâ? groups., The percentage of patients with controlled blood pressure (&lt;140/90 mmHg) , âno phone callsâ? group , phone callsâ? group ,0,
edin,646,1201146,Cannot tell based on the abstract,, good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,646,1201146,Significantly increased,"<td colspan=""3""><hr></td>", good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,740,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,740,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,727,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,906,4320624,Cannot tell based on the abstract,," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,906,4320624,Significantly increased,"Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â24 was significantly higher for all doses of abediterol versus placebo (pâ<â0.0001 for all, TableÂ 2), with dose-related effects observed."," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,918,3616124,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Hispanic</td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>", preeclampsia risk  in Hispanic Hp 2-2 women. , placebo from 9-16 weeks gestation until delivery. , daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery. ,0,
edin,864,4078386,No significant difference,"We didnât find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05).", mean of HCV-RNA numbers 6 months after treatment  , placebo , 20 mg atorvastatin nightly for 3 months ,0,
edin,720,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,720,1201146,Significantly decreased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,823,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,823,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, There is no question in this prompt. It contains only a statement 
edin,696,2858204,Cannot tell based on the abstract,," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,696,2858204,Significantly increased,"In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009) (Fig. 2)."," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,632,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,632,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53â12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,873,5729252,Cannot tell based on the abstract,, hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,873,5729252,Significantly increased,"At the time of survival time analysis, hospital-free survival was 358.87âÂ±â68.65Â days (meanâÂ±âSE) (median, 331Â days) in the untreated group, which was significantly different from that in the drug-treated group (603.44âÂ±â50.074Â days) as assessed by proportional hazard analysis (hazard ratio of the drug-treated group to the untreated group, 0.19, Pâ=â0.017; log-rank test, Pâ=â0.019; and Wilcoxon test, Pâ=â0.014).", hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,928,4192987,Cannot tell based on the abstract,, Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,928,4192987,No significant difference,The difference in median was not statistically significant for serum 17-hydroxyprogesterone and testosterone levels [Tables 2 and 3]., Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,639,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,639,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,645,1201146,Cannot tell based on the abstract,, 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,645,1201146,Significantly increased,"<td colspan=""3""><hr></td>", 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,747,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,890,5519461,No significant difference,"The eradication rates of the EAC and RAC regimens were 79.8% (95% confidential interval: 71.7-89.0%) and 74.7% (66.0-83.4%), respectively, in a per protocol (PP) analysis (p=0.488). The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286).", H. pylori eradication ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,736,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,736,2720945,Significantly increased,"<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>,As primary outcome measure the sum of exacerbations for frequency, duration and severity at all 6 following visits as composite endpoint (equally weighted) were calculated according to the Wei-Lachin Test procedure for multiple criteria and showed a statistically significant difference for the primary outcome measure between both treatment groups (p = 0.0120) Table 3."," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,865,5680306,Significantly increased,Serum 25(OH)D concentrations increased with vitamin D supplementation compared to placebo (pâ<â0.001)., Serum 25(OH)D concentrations ," the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks "," vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily ",0,
edin,732,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,732,2607225,Significantly decreased,"Global quality of life, emotional functioning, cognitive functioning, pain, insomnia, appetite loss, anxiety, depression, intrusion and avoidance improved from baseline to 3 months. Financial difficulties worsened from baseline to 3 months. Global quality of life, physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea/vomiting, appetite loss, diarrhoea, financial difficulties, and depression improved from 3 to 24 months.,Appetite loss decreased from 3 to 6 months (mean=5.1â3.7, s.d.=14.2â11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,967,5372931,Cannot tell based on the abstract,," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,967,5372931,Significantly increased,"Linear regression analysis was performed between the TP level in the intervention and the AUC of each class of compounds. The AUC for flavonols produced the highest r2 (0.97, p < 0.001), followed by the valerolactones (r2 = 0.89, p < 0.005), benzoic acids (r2 = 0.85, p < 0.01), cinnamic acids (r2 = 0.72, p < 0.05), phenylacetic acids (r2 = 0.71, p < 0.05), benzaldehydes (r2 = 0.65, p < 0.05); hippuric acids, pyrogallols, and catechols did not show a linear dose response."," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,792,125315,Cannot tell based on the abstract,, The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,792,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>,<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,934,4264479,Cannot tell based on the abstract,, blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,934,4264479,No significant difference,"ll volunteers were diagnosed with malaria [see Table S5 for criteria for treatment and Table S6 for time to diagnosis (TTD) and parasitemia at diagnosis] with the exception of one volunteer in Group 2 (Volunteer 110), who was asymptomatic and blood film negative at all time-points, despite blood-stage infection confirmed by qPCR", blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,961,2656477,Cannot tell based on the abstract,, depression , no weight lost , lost weight ,0,
edin,961,2656477,No significant difference,"<td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td>", depression , no weight lost , lost weight ,0,
edin,660,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,660,2720945,Significantly decreased,"Table 3
Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*,<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>"," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,891,5519461,No significant difference,The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286)., Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype. ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).,<td align=""left"">âMortality at 60 days</td><td align=""center"">15 (55.6)</td><td align=""center"">14 (46.7)</td><td align=""center"">0.599</td>,Table 2
Clinical outcomes according to treatment group", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,679,2430614,Cannot tell based on the abstract,, parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,679,2430614,No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups (Table 6)., parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,883,5539984,Cannot tell based on the abstract,, reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,883,5539984,No significant difference,"However, as indicated by the non-significant group by time interaction, there was no difference between groups regarding the reduction of total needs (bÂ =Â 0.09; pÂ =Â 0.217) or the increase of met needs (bÂ =Â 0.01; pÂ =Â 0.621).", reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,Cannot tell based on the abstract,, prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,No significant difference,"<td>number of psychiatric inpatient admissions [+ 1]</td><td>1.131</td><td>1.045</td><td>-</td><td>1.225</td>,The results of the mixed effects logistic regression model (not presented) did neither show differences of the prevalence of psychiatric inpatient admission between groups during the six months before baseline assessment (OR 0.99; pÂ =Â 0.985), nor a change over time (OR 0.62; pÂ =Â 0.086) in either groups or a difference between the groups (OR 0.97; pÂ =Â 0.878) during the study period.", prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,900,1198254,Significantly increased,"Faecal recovery of ME-3 was documented by molecular methods only in fermented milk group, however the significant improvement of blood TAA (Total Antioxidative Activity) and TAS (Total Antioxidative Status) indices was seen both in case of fermented goat milk and capsules"", yet glutathione re-ox ratio values decreased only in case of fermented by ME-3 goat milk.", Total Antioxidative Activity , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,923,5295802,Cannot tell based on the abstract,, cytokine levels at baseline , placebo , levocarnitine ,0,
edin,923,5295802,No significant difference,"here was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown).", cytokine levels at baseline , placebo , levocarnitine ,0,
edin,636,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,694,2858204,Significantly increased,"n the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).", complete healing of the index ulcer at 1-year of follow-up , placebo , hyperbaric oxygen therapy ,0,
edin,925,5295802,Cannot tell based on the abstract,," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,925,5295802,No significant difference,"There was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown)."," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,763,2447617,Cannot tell based on the abstract,, The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,763,2447617,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034)., The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,794,2830179,Cannot tell based on the abstract,, Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,794,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>,<td align=""left"">Pain on rest (0-10)</td><td align=""center"">3.0 (2.7)</td><td align=""center"">1.4 (1.8)</td><td align=""center"">1.1 (2.2)</td><td align=""center"">2.0 (2.6)</td><td align=""center"">-1.9 (2.3)</td><td align=""center"">0.6 (1.0)</td><td align=""center"">-2.0 (-3.8 to -0.2)</td>,<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,813,5602855,Cannot tell based on the abstract,, Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,813,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,936,4918678,Cannot tell based on the abstract,, Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,936,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,896,4140547,Cannot tell based on the abstract,, Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,896,4140547,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>,<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>", Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,644,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,644,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,684,2447617,Significantly decreased,The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05)., The mortality rate , placebo , progesterone ,0,
edin,764,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,716,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,742,1913177,Cannot tell based on the abstract,, Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,742,1913177,No significant difference,"Major wound complications were found in 10 of the 19 patients in the CST group: wound infection (n = 3), skin necrosis (n = 2), hematoma (n = 1). Four patients developed seroma; these were not associated with the aforementioned complications.,Major wound complications were found in 13 of the 18 patients in the e-PTFE group: wound infection (n = 2), skin necrosis (n = 3), hematoma (n = 1).", Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,892,5618071,Cannot tell based on the abstract,," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,892,5618071,Significantly decreased,"As a global result (G1 + G2), a significant decrease in the total score was observed in ADI-R, ABC, and ATEC scales one month after the intervention (Wilcoxon matched pair test; ABC, Z = 3.823, p = 0.000131; ADI-R, 3.337, p = 0.000846; ATEC, Z = 3.723, p = 0.000196)."," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,665,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,665,3446002,Significantly decreased,"Clofibrate group (group I) was given a single dose of 50 mg/kg clofibrate before starting phototherapy. I,<td align=""left"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>TSB<xref ref-type=""table-fn"" rid=""TF0002"">*</xref> (mg/dl)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.24 (1.48)</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.42 (1.44)</td>,TSB: total serum bilirubin,<td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>Control (II)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">30</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">12.6 (1.44)</td>", Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,640,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,843,2891743,Significantly increased,"<td colspan=""4""><hr></td>,<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,1180,5002324,Significantly increased,"After training, participants in the balance-based exergaming group showed significant improvements in LOS performance, and in the eyes-closed condition of the OLS test.", the limits of stability (LOS) performance and one-leg stance (OLS) tests , a balance training group for an 8-week balance training period. , a balance-based exergaming group for an 8-week balance training period. ,0,
edin,1115,3423952,Cannot tell based on the abstract,," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1115,3423952,Significantly increased,"Main effects for PGE2 concentrations in synovial fluid were not detected (P > 0.05); however, after adjusting the data by subtracting the PRE value from each POST value, and evaluating changes relative to pre-exercise values, effects of exercise (P = 0.03) and joint (P = 0.04) were detected (Figure 2(b)).,Similar to synovial fluid CS concentrations, there were greater relative increases (P = 0.04) in PGE2 concentrations in hock joints when compared to carpus joints (Figure 2(b))."," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1061,3787573,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Western Ontario and McMaster Universities Osteoarthritis Index for stiffness , Exercise alone , NMES plus exercise ,0,
edin,1004,3442969,Cannot tell based on the abstract,, Disease control rates , CAPOX , FUFOX ,0,
edin,1004,3442969,No significant difference,"Disease control rates (DCR) were 77%, 81% and 88%, respectively, which was not statistically significant (Table3, pâ=â0.29).", Disease control rates , CAPOX , FUFOX ,0,
edin,1168,5354011,Cannot tell based on the abstract,, willingness?to?pay. , before treatment , after treatment  ,0,
edin,1168,5354011,Significantly increased,"The average maximum WTP for treatment for menorrhagia was approximately Â£27 (US$41) per month (see Table 2). The average combined MMAS score for treatment doubled from approximately 43 at preâtreatment to 85 following treatment, generating a statistically significant improvement in health status as measured by this instrument (P = 0.000).", willingness?to?pay. , before treatment , after treatment  ,0,
edin,1080,4565804,Significantly decreased,"Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores.", morphine doses , Placebo , gabapentin (10 mg/kg) ,0,
edin,987,2920262,Cannot tell based on the abstract,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,987,2920262,Significantly increased,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,1130,5225252,Significantly increased,"Gag-specific IFN-Î³ enzyme-linked immunospotâdetermined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for â¥8 months after completion of the prime-boost regimen.", Gag-specific IFN-? enzyme-linked immunospotâdetermined response rates and geometric mean responses , a single dose of Ad35-GRIN or SeV-Gag , groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) ,0,
edin,1015,5101425,No significant difference,No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 Â± 266.2 in group D vs. 406.3 Â± 341.6 in group P (control group); P = 0.208)., Bleeding rate after surgery , Placebo , Desmopressin ,0,
edin,1104,4109867,No significant difference,"Dietary SW supplementation had no effect on saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles."," saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles ", basal diet , 2% seamustard ,0,
edin,1042,5746685,No significant difference,"There were no significant between-group differences in the primary outcome of change in BMI (basic â0.5 (1.9) kg/m2, enhanced â0.5 (1.6) kg/m2, p = 0.93).", Change in body mass index , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1082,5610854,Cannot tell based on the abstract,, intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1082,5610854,Significantly decreased,"7 of the 38 eyes (44.7%, CI: 28.9%â60.5%) in group 1 required a mean of 1.8 IOP-lowering medications while seven of the 111 eyes (6.3%, CI: 1.8%â10.8%) in group 2 required a mean of 1.1 medications (Pearson's chi-square valueâ=â30.940, p < 0.001).", intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1020,3159986,Cannot tell based on the abstract,, Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1020,3159986,No significant difference,"Baseline lung function was normal for all patients with VC being 95.5 Â± 3.7%, FEV1 90.5 Â± 3.6%, PEF 86.9 Â± 4.5%, MVV 93.8 Â± 6.6%, and maximal inspiratory pressure (PImax) 75.1 Â± 5.4% predicted. RMET induced mild but not significant increases in VC (P1: 95.9 Â± 3.5%, P4: 99.2 Â± 4.1%, P = 0.39), FEV1 (P1: 93.1 Â± 2.7%, P4: 96.3 Â± 3.8%, P = 0.28), PEF (P1: 90.0 Â± 4.8%, P4: 95.7 Â± 5.4%, P = 0.07), MVV (P1: 95.6 Â± 6.0%, P4: 101.0 Â± 6.5%, P = 0.24), and PImax (P1: 79.2 Â± 5.4%, P4: 78.0 Â± 6.4%, P = 0.42).", Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1128,5936036,No significant difference,There was no significant difference among the drop-out rates in the three groups., drop-out rates , the SCBT with medication group or regular medication group , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,976,3798949,Cannot tell based on the abstract,, Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,976,3798949,Significantly decreased,"The contribution of extra clinic visits and investigations, in particular CT scans used for response assessment, was significantly higher for commercial compared with non-commercial trials.", Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,1024,4895766,Cannot tell based on the abstract,, Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1024,4895766,Significantly increased,"In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.,The surrounded skin color became normal skin color within 7 days in maximum patients (76%) of Group A, whereas only 32% patients showed normal peri-wound skin color in Group B.", Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1099,4109867,Cannot tell based on the abstract,, IgG concentrations , basal diet , 2% seamustard ,0,
edin,1099,4109867,Significantly increased,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgG concentrations , basal diet , 2% seamustard ,0,
edin,1210,4306068,No significant difference,"The mean timing to analgesic administration for the displayed and non-displayed groups were 81.3âÂ±â41.2 (95% C.I 65.9, 96.7) and 88.7âÂ±â45.4 (95% C.I 69.0, 108.3), respectively (pâ>â0.05).", The mean timing to analgesic administration , not displayed in the control. , pain score display group ,0,
edin,1122,5489138,Cannot tell based on the abstract,"he 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1122,5489138,Significantly increased,"3M CDP = 3-month confirmed disability progression;,The 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1132,5225252,Cannot tell based on the abstract,, The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1132,5225252,Significantly increased,"The GMTs were significantly higher (P < .0001, by the Kruskal-Wallis test) in the ASH group after the SeV boost than in the other groups (53, 53, 245, 50, and 59 in the SLA, SHA, ASH, SHSH, and placebo groups, respectively; Figure 4).", The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1165,4223523,Cannot tell based on the abstract,, awake time , placebo , olanzapine ,0,
edin,1165,4223523,Significantly decreased,"As well as an increase in TST, olanzapine treated participants experienced significantly fewer awakenings (TableÂ  2) and less overall time awake compared to treatment with placebo (2-way repeated measures ANOVA; main effect of treatment, number of awakenings, F[1,23]â=â10.0, pâ=â0.004; awake time, F[1,23]â=â4.8, pâ=â0.037).", awake time , placebo , olanzapine ,0,
edin,1141,3895597,No significant difference,"The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.", The incidence of adverse events , octylonium 20 mg , tiropramide 100 ,0,
edin,1106,5064802,No significant difference,"Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), pÂ =Â 0.13].", Postoperative troponin T , no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1177,3752932,Cannot tell based on the abstract,," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1177,3752932,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th>"," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1074,1562433,Significantly increased,"<td colspan=""4""><hr></td>", vastus medialis obliquus (VMO) EMG activity  , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1107,5064802,No significant difference,"No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-Îµ in the human heart."," activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart ", no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1079,4667210,Significantly increased,"Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in < 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).", disappearance in &amp;lt; 3 h  of the MSG symptom complex , maltodextrin (placebo) , Capsules (300 mg) containing Lactobacillus brevis G101 (1Ã1010 CFU/individual) ,0,
edin,1113,3423952,Significantly increased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide."," erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood ", no exercise , exercise ,0,
edin,1013,5018157,No significant difference,"The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 Â± 0.7 versus 7.2 Â± 1.5) (P = 0.001), but there was no significant difference in the five-minute Apgar scores between the two groups.", Five-minute Apgar score , Low-dose bupivacaine spinal anesthesia in healthy parturients , Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients ,0,
edin,1086,4395717,Significantly decreased,"After the intervention, the error angle was significantly smaller in flexion and right left side-bending, and pain was significantly reduced in the upper thoracic manipulation group.", repositioning error in flexion and right and left side-bending and reduction in pain , cervical stability training (CST) , upper thoracic manipulation (UTM) ,0,
edin,979,5619630,Cannot tell based on the abstract,, Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,979,5619630,No significant difference,there was no significant difference between the groupsâ PSLES scores at any follow-up point., Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,1159,3296686,Cannot tell based on the abstract,, serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1159,3296686,Significantly decreased,Pioglitazone treatment decreased at day-14 serum ALT levels (mean changeâ=â7.5 IU/ml; 95% CI: 2.1 to 12.9; Pâ=â0.012) and to a smaller degree serum AST levels (mean changeâ=â2.6 IU/ml; 95% CI: â0.6 to 5.8; Pâ=â0.096) ( Table 5 )., serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,981,5490116,Cannot tell based on the abstract,, Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,981,5490116,Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P < 0.005) higher in Group B compared to Groups A and C at 24 h as shown in Table 2., Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,1198,3743641,Cannot tell based on the abstract,, sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1198,3743641,Significantly increased,"Additionally, in SMART-3 (subjects with vulvovaginal atrophy), the Menopause-Specific Quality of Life questionnaire results at week 12 showed significant improvements in sexual function and total scores with both BZA/CE doses versus placebo or BZA 20 mg (P < 0.001).", sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1054,2223531,No significant difference,"he median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9).,In conclusion, oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.", Median AUC(inf) , Oral etoposide , Oral etoposide phosphate ,0,
edin,1001,3878029,No significant difference,The intervention had no effect on smoking status (p =â.73) or on the number of cigarettes smoked per day (p =â.56)., Cigarettes smoked per day , Relaxation , Hypnotherapy ,0,
edin,999,3074545,Significantly increased,"<td align=""left"">SF36</td><td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>", Improvements in physical and mental wellbeing , Non-mentored group , Non-professional mentor support ,0,
edin,1158,3296686,Cannot tell based on the abstract,, day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1158,3296686,Significantly decreased,Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean changeâ=â8.2 mg/dL; Pâ=â0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean changeâ=â18.8 mg/dL; Pâ=â0.001) ( Table 4 )., day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1191,3743641,Cannot tell based on the abstract,, mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1191,3743641,Significantly decreased,"At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a decrease (P < 0.001) in the adjusted mean daily number of moderate to severe hot flushes, reaching a 74% and a 80% reduction, respectively, representing a clinically meaningful reduction of approximately 7â8 hot flushes per day, compared with a 51% reduction (representing a reduction of approximately five hot flushes per day) in the placebo group (Figure 1).18", mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1075,1562433,No significant difference,"<td colspan=""4""><hr></td>", vastus lateralis longus (VLL) EMG activity , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1038,4588874,Cannot tell based on the abstract,, Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1038,4588874,No significant difference,There were no serious adverse events reported and no subjects were discontinued due to AEs., Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1126,3611646,Cannot tell based on the abstract,, high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1126,3611646,Significantly increased,"With regard to the biochemical parameters, Group A showed highly significant decrease (P`0.01) in serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels, while high density lipoprotein (HDL) increased highly significantly (P`0.01) and a significant decrease (P`0.05) was found in blood urea (13.80%) as well as serum AChE (3.67%) within normal limits [Table 6].,Group A (Trial Group)
Patients of this group were administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar.", high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1057,3787573,No significant difference,"ollowing the interventions, a statistically significant improvement in both groups was observed in all outcomes assessed. For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Numerical Rating Scale , Exercise alone , NMES plus exercise ,0,
edin,1142,3895597,Cannot tell based on the abstract,, the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1142,3895597,Significantly increased,"Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).", the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1100,4109867,Cannot tell based on the abstract,, IgM concentrations , basal diet , 2% seamustard ,0,
edin,1100,4109867,No significant difference,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgM concentrations , basal diet , 2% seamustard ,0,
edin,1145,5851630,Significantly increased,"However, in the ET+TA treatment, ABP values were greater after exercise, except for Fp1.", absolute beta power (ABP) after exercise , PlaceboâPL , Taurine combined with Ethanol (TA+ET) ,0,
edin,1192,3743641,Cannot tell based on the abstract,, mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1192,3743641,Significantly increased,BZA 20 mg/CE 0.45 or 0.625 mg showed a significantly greater increase from baseline in the mean proportion of superficial cells compared with placebo (P < 0.001)., mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1208,4526336,Significantly increased,"Compared to those with normal cognitive function, MCI participants generated a greater proportion of words out of the total number of words during the timed conversation sessions (p=0.01).", proportion of words out of the total number of words , healthy , mild cognitive impairment (MCI) ,0,
edin,1174,4821313,Significantly increased,There was a significant increase in serum creatinine and a decrease in eGFR 48 hr post-intervention in group 1 (short regimen) with no statically difference regarding those parameters group 2 (long regimen)., serum creatinine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1084,5610854,Cannot tell based on the abstract,, The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1084,5610854,No significant difference,The absolute risk for â¥2 lost lines of vision in the trabeculectomy group was 18% (20 of 111) compared to 16% (6 of 38) in the LPI group., The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1156,3296686,Significantly increased,"Although Prednisone did increase serum HCV RNA at day-4 (nâ=â10; change from baselineâ=ââ42,786 IU/ml; 95% CI â85,500 to â15,700; Pâ=â0.049), the log10 HCV RNA titers were statistically not different from baseline day-0.", HCV RNA at day-14 , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1062,5100099,No significant difference,"There were no statistically significant differences on blood pH levels between the two modes of ventilation (7.32âÂ±â0.02 vs. 7.32âÂ±â0.04, Pâ=â0.34).", Blood pH levels , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1028,4486943,Cannot tell based on the abstract,, Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1028,4486943,No significant difference,"TableÂ 3
Estimates of abstinence at 6 and 12âmonths, N=1785,<td colspan=""1"" rowspan=""1"">âStandard</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">66.0 (61.2 to 70.9)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">60.6 (55.6 to 65.6)</td><td colspan=""1"" rowspan=""1"">363</td><td colspan=""1"" rowspan=""1"">65.3 (60.4 to 70.2)</td><td colspan=""1"" rowspan=""1"">362</td><td colspan=""1"" rowspan=""1"">61.6 (56.6 to 66.6)</td>,<td colspan=""1"" rowspan=""1"">âStandard plus TEQ-10</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">69.6 (64.9 to 74.3)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">65.2 (60.4 to 70.1)</td><td colspan=""1"" rowspan=""1"">370</td><td colspan=""1"" rowspan=""1"">67.0 (62.2 to 71.8)</td><td colspan=""1"" rowspan=""1"">371</td><td colspan=""1"" rowspan=""1"">63.1 (58.2 to 68.0)</td>,<td colspan=""1"" rowspan=""1"">âDifference compared to standard</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">1.3 (â5.6 to 8.2)<break>p=0.7121</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">0.5 (â6.6 to 7.6)<break>p=0.8947</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â2.7 (â10.0 to 4.6)<break>p=0.4655</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â5.0 (â12.5 to 2.4)<break>p=0.1871</break></td>", Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1111,4940009,No significant difference,"Overall, the incidence of POM in Group K was significantly less, when compared with Group N (P<0.05), but both groups were comparable based on the grade 2 of POM.", grade 2 of POM ," Group N, the same volume (5 mL) of normal saline was injected "," Group K, 0.5 mg/kg of ketamine was injected intravenously, ",0,
edin,1199,3743641,Cannot tell based on the abstract,, lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1199,3743641,Significantly increased,"In addition, in SMART-1, a statistically significant increase in lumbar spine BMD from baseline to month 24 was observed for both the BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg treatment groups compared with a decrease in lumbar spine BMD in the placebo group (P < 0.001).", lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1203,4280954,Cannot tell based on the abstract,, serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1203,4280954,Significantly decreased,The addition of flaxseed or/and vitamin E to the high-fat diet led to significant reductions of serum glucose levels compared with those in the DM group (Table II)., serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1193,3743641,Cannot tell based on the abstract,, reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1193,3743641,Significantly decreased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P < 0.001) and a significantly greater increase from baseline in the mean proportion of intermediate cells (P < 0.05) compared with placebo at weeks 4 and 12., reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1129,5936036,Cannot tell based on the abstract,," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1129,5936036,No significant difference,"As stated in Table 1, participants in the SCBT group and SCBT with medication group were not significantly different in satisfaction factors, such as the quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met."," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1025,4486943,Cannot tell based on the abstract,, Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1025,4486943,Significantly increased,"Programme engagement was measured as the number of counselling calls completed by participants:1 planned programme counselling calls,2 participant-initiated inbound calls, or3 IVR-transferred counselling calls (table 2). Overall, the average number of total calls completed was 3.9 (SD=1.7; range 2â19). There was a statistical difference between groups; the TEQ-10 and TEQ-20 groups completed slightly more calls than the standard study group due to the additional IVR-transferred counselling calls they received after a positive screen (p<0.001).", Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1017,5101425,Cannot tell based on the abstract,, Hb levels , Placebo , Desmopressin ,0,
edin,1017,5101425,No significant difference,"A paired T-test revealed that the Hb levels decreased significantly in each group after surgery (P = 0.0001), but the difference was not statistically significant between the groups (0.134).", Hb levels , Placebo , Desmopressin ,0,
edin,1144,4893237,Cannot tell based on the abstract,, mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1144,4893237,Significantly increased,"In this study 13 participants died within 30Â days of sustaining the index hip fracture. T,The participants who died during hospitalization due to a cardiovascular event all had a history of cardiovascular disease. The three participants who died after discharge but within 30Â days of the index hip fracture did so due to a cerebrovascular event, a myocardial infarction and a pulmonary emboli, respectively.", mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1201,3743641,Cannot tell based on the abstract,," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1201,3743641,No significant difference,"No apparent increased risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, was observed with either dose strength of BZA/CE."," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1114,3423952,Significantly decreased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide.", plasma nitric oxide , no exercise , exercise ,0,
edin,1022,4895766,Cannot tell based on the abstract,, Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1022,4895766,Significantly increased,The strength and positive finding of this study is Katupila Kalka had the potential to cure the diabetic wounds early than Betadine ointment., Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1136,4627811,Cannot tell based on the abstract,, Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1136,4627811,No significant difference,There was no significant change in the SF-36 total score (Table 5)., Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1189,5122238,Cannot tell based on the abstract,," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1189,5122238,No significant difference,Mean central temperature from 0 to 60 min recovery in the three groups (P = 0.64)," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1064,5100099,Significantly increased,"With regard to hemodynamics, systolic arterial pressures were higher using NAVA: +8.4Â % (95Â % CI: +3.3 to +13.6Â %, Pâ=â0.03).", Systolic arterial pressure , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1041,5746685,No significant difference,"There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%) and limited change in secondary outcomes for either program.", Weight rebound after 12 months , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1173,4821313,Cannot tell based on the abstract,, the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1173,4821313,No significant difference,"Regarding the pH of urine, we found that it was (5.95 Â± 0.26) in group 1 and (5.97 Â± 0.24) in group 2, showing no statistical difference and highlighting the fact that both regimen had almost the same alkalinizing efficacy with no proven extra benefit for patients with pH values greater than 6.", the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,971,3491047,No significant difference,"No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.", Total adherence to the program , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,968,5372931,Cannot tell based on the abstract,, 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,968,5372931,Significantly increased,"A positive, linear dose response for total excretion over 24 h of each urinary metabolite was assessed and of the 60 identified metabolites, 12 (poly)phenol metabolites displayed a positive linear dose-response curve (r2 â¥ 0.66) in urine with slopes significantly different from zero (p < 0.05); they were: 2,3-dihydrobenzoic acid (r2 = 0.79), 2,4-dihydrobenzoic acid (r2 = 0.77), dihydrocaffeic-3-O-sulfate (r2 = 0.66), ferulic-O-4-sulfate (r2 = 0.89), o-courmaric acid (r2 = 0.72), quercetin-3-O-Ã-d-glucuronide (r2 = 0.89), 2,5-dihydroxybenzoic acid (r2 = 0.80), chlorogenic acid (r2 = 0.72), p-coumaric acid (r2 = 0.90), sinapic acid (r2 = 0.85), benzoic acid (r2 = 0.99), isoferulic acid (r2 = 0.74).", 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,1157,3296686,Significantly decreased,"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (nâ=â10; difference of meansâ=â205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001).", HCV RNA at day-14 , baseline , Prednisone (40 mg/day for 4 days) ,0,
edin,1101,4109867,Significantly decreased,Dietary SW significantly reduced meat cholesterol concentration (p<0.05)., Meat cholesterol concentration , basal diet , 2% seamustard ,0,
edin,969,3491047,Significantly increased,Short-term program adherence was greater in WB compared to C (p<0.012) after 3 months., Short-term adherence to the program at 3 months , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,1046,4748685,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = â9 mmHg; p = 0.03; 95 % CI = [â17.29, â0.71]), LDL (pseudo-median of the differences = â7.9 mg/dl; p = 0.04; 95 % CI = [â18.5, â0.5]) and triglyceride values (pseudo-median of the differences = â12.5 mg/dl; p = 0.04; 95 % CI = [â26, â0.5]) in the intervention group, while no such changes could be observed in the control group.", Triglyceride levels , Standard care , CAPSYS system ,0,
edin,1089,4082484,Significantly increased,"On the other hand, the consumption of the curry meal increased FMD from 5.2âÂ±â2.5% to 6.6âÂ±â2.0% (Pâ=â0.001), and the postprandial FMD after the curry meal was higher than that after the control meal (Pâ=â0.002).", postprandial FMD , spice-free control meal , single serving of curry meal ,0,
edin,1009,5003313,Cannot tell based on the abstract,, Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,1009,5003313,No significant difference,Also the results of t-test show that the changes in the severity of RLS symptoms before intervention and after 4 weeks were not statistically meaningful between intervention and control groups., Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,980,5619630,Cannot tell based on the abstract,, Relapse rates , Medication only , Medication plus exercise ,0,
edin,980,5619630,No significant difference,"Relapse rates were also recorded via subjective reports and as a measured increase of >50% from baseline HRSD scores (Neumeister et al, 1997). In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisherâs exact test: one-tailed, P = 0.07; two-tailed, P = 0.14).", Relapse rates , Medication only , Medication plus exercise ,0,
edin,1195,3743641,Cannot tell based on the abstract,, vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1195,3743641,Significantly decreased,"Additionally, treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P < 0.001) and a greater improvement in the womenâs most bothersome vulvovaginal atrophy symptoms (P < 0.05) compared with placebo (Figure 4).19", vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1202,4280954,Cannot tell based on the abstract,," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,1202,4280954,Significantly increased,"Serum and liver TBARS, as indices of lipid peroxidation, were significantly increased in the DM group compared with those in the control group, while the addition of flaxseed or a combination of flaxseed and Î±-tocopherol to the high-fat diet of the hamsters with DM significantly decreased these two markers compared with those in the unsupplemented DM group."," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,993,3074545,Cannot tell based on the abstract,, Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,993,3074545,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.", Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,1250,5225191,Cannot tell based on the abstract,, GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1250,5225191,Significantly increased,"After evocation, participants who underwent the conditioning procedure with amitriptyline reported significantly more antidepressant-specific side effects than those who never received amitriptyline, even though both groups received a placebo.", GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1321,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (r = 0.61, p = 0.01).,In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2âÂ±â0.4âkg/m2; 27âÂ±â1.3 years, meanâÂ±âSEM) underwent 50âg OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions.", the 2-hour plasma ghrelin , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1306,5789132,Cannot tell based on the abstract,, The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1306,5789132,Significantly decreased,"The mean pain score using FRS scale for 26 gauge conventional syringe was found to be 3.25, whereas mean pain score for 30 gauge insulin syringe was found to be 1.35 (Table 1). The mean difference found was statistically significant (p = 0.05).", The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1293,3636800,No significant difference,"Although there were no significant differences in participantsâ quantitative feedback for the two delivery modalities, most participants reported preferring the native smartphone application (67%; n=16) and found it easier to use (71%; n=16). 33% of participants reported that they would be willing to complete mobile phone assessment for 5 weeks or longer.", the total quantitative feedback score , completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation , completing 6 days of assessment (four sets of questions per day) with a native smartphone application ,0,
edin,586,4819709,Cannot tell based on the abstract,, Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,586,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">15Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">28Â·7</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,1223,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1223,3917123,Significantly decreased,"ost-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1213,5397544,Cannot tell based on the abstract,, Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1213,5397544,No significant difference,There were no significant changes in Î±-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups (Tables IV and V)., Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1343,5320660,Cannot tell based on the abstract,, Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1343,5320660,No significant difference,Mean overall satiety score did not differ within or between groups (Pâ=â0.230)., Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1279,5928476,Significantly decreased,SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements., bulk-fill composite resinsâ bond strengths , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,724,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,724,2600646,No significant difference,Final mean Hb levels were 7.15 mmol/l Â± 1.07 for the DP treatment group and 6.79 mmol/l Â± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05)., mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,1238,5228611,Cannot tell based on the abstract,, quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1238,5228611,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had statistically significant declines in both measures of quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) at week 48 vs. increases in the baseline regimen group (Fig. 4)., quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1219,5741263,Significantly increased,"In contrast to the reported positive effects of training on writing size, the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group.", Stroke duration , Placebo , Amplitude training ,0,
edin,637,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,1243,3466198,Significantly decreased,The median vaginal and cervical pH was significantly lower 2 hours after application of Acidform and was associated with an increase in the bactericidal activity of CVL against E. coli., The median vaginal and cervical pH , hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1278,3585965,Cannot tell based on the abstract,, the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1278,3585965,No significant difference,"When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV).", the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1264,3933059,Significantly decreased,Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (7%; P = 0.013) and DBP (6%; P < 0.010).," Systolic blood pressure (SBP), diastolic blood pressure (DBP) ", baseline , Pomegranate juice (PJ) ,0,
edin,1304,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1304,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,No clinically meaningful interactions were observed when EG was co-administered with other commonly used medicinal products and no dose adjustment was recommended"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1285,4132637,No significant difference,"Regardless of revascularization or not, ticagrelor consistently reduced the primary outcome (HR 0.86 vs. 0.85, interaction P = 0.93), and all-cause death (HR 0.75 vs. 0.73, interaction P = 0.89) with no significant increase in overall major bleeding.", All-cause death , clopidogrel , ticagrelor ,0,
edin,1269,3655855,Cannot tell based on the abstract,," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1269,3655855,No significant difference,"<td align=""left"">CRP (nmol/L)</td><td align=""center"">20.7</td><td align=""left"">21.8</td><td align=""center"">17.3</td><td align=""left"">18.7</td><td align=""left"">+0.12</td><td align=""left"">0.34</td><td align=""left"">0.53</td>,The effects of supplementation on components of the metabolic syndrome, plasma lipids, vascular measures, and cytokines are shown in TableÂ 3. The daily treatment dose of 1.7Â g of O3 for four weeks had no effect on any of these measures compared to the safflower placebo. Not shown are BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10, all of which also showed no effect."," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1267,4709985,Cannot tell based on the abstract,, would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,1267,4709985,Significantly increased,"The role of educational status was examined in response these questions and we found women with tertiary education would have liked more information on acupuncture (pâ<â0.009), no other associations were found.", would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,702,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,702,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25â1.69) and SU (37.9%; RR 1.45, 95% CI 1.22â1.73) (Table 2).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,1342,5320660,Significantly decreased,"Within the HAM-RS2 group, the area under the curve (AUC) glucose (Pâ=â0.028), AUC leptin (Pâ=â0.022), and postprandial 120-min leptin (Pâ=â0.028) decreased independent of changes in body composition or overall energy intake at the end of 6Â weeks."," glucose, AUC leptin, and postprandial 120-min leptin ", muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1301,3924124,Cannot tell based on the abstract,, CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1301,3924124,Significantly increased,"Significant (P < 0.05) interaction was observed for the secondary outcome measure CD4/8, which was used to represent participants' immunological function.,Significant (P < 0.05) effects were observed in CD4+ and CD4/8, which were maintained in the high adherence group, but tended to decrease in the low adherence and control groups", CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1310,3258678,Significantly decreased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., hippocampus volume (HV) change , 78-week treatment with placebo , 78-week treatment with tramiprosate 150 mg BID ,0,
edin,1331,4716419,No significant difference,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44)."," Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) ",  intravenous cyclophosphamide (CYC) 0.5â1?g/m2 monthly , enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months ,0,
edin,820,5294349,Cannot tell based on the abstract,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,0,
edin,820,5294349,Invalid Prompt,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,1," No datasets of 3D coordinates or anything similar was mentioned in results, discussion or conclusion section of the article. "
edin,768,3108665,Cannot tell based on the abstract,, Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,768,3108665,Significantly decreased,"Finally, with the help of logistic regression we concluded that the patients who did not receive somatostatin (control group) had a 6.2 times higher probability of developing complications than the treatment group.", Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,1292,5551214,Cannot tell based on the abstract,," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1292,5551214,Significantly decreased,"There was a significant interaction effect between pre- to post-test change in CARS2 scores and intervention condition (F(1, 22) = 7.219, p = 0.013, r = 0.5).,Whilst the control group had the same mean CARS2 scores at pre-test and post-test (42.61), the intervention groupâs mean score was significantly lower at post-test (40.05) than at pre-test (40.95) (Figure 1)."," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance.", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01),", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1255,4864053,Cannot tell based on the abstract,, mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1255,4864053,Significantly decreased,"For a composite gray matter region, a oneâsample tâtest showed that lâdopa was associated with an 11% mean decrease in [11C]Ro15â4513 BP (tÂ =Â â2.29, 9 degrees of freedom, PÂ =Â 0.048).", mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1298,5951568,Cannot tell based on the abstract,, Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1298,5951568,No significant difference,Overall pain scores between the intervention (20.91Â±2.33mm) and non-intervention group (25.30Â±2.44mm) in the NCS cohort did not differ significantly (p = 0.15)., Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1271,4401879,No significant difference,"Serumlevels of fasting blood sugar, insulin and homeostatic model assessment of insulin resistance slightly decreased in zinc group, but these changes were not statistically significant."," fasting blood sugar, insulin and homeostatic model assessment of insulin resistance ", placebo for eight consecutive weeks , 30mg/day zinc gluconate for eight consecutive weeks ,0,
edin,734,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,734,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,1226,4996255,Significantly increased,"Across the two Phase IIIa active comparator studies, patients consistently stated a preference for the Elliptaâ¢ DPI over HandiHalerÂ® regarding the number of steps to use (59% vs 17%), time taken to use (62% vs 14%), and ease of use (63% vs 15%) regardless of which inhaler contained active drug."," the number of steps to use, time taken to use and ease of use ", HandiHalerÂ® , Elliptaâ¢ DPI ,0,
edin,1240,5228611,Cannot tell based on the abstract,, HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1240,5228611,No significant difference,E/C/F/TAF plus DRV was noninferior to baseline regimens for the primary outcome (HIV-1 RNA <50 copies per mililiter at week 24; FDA-snapshot algorithm) using the full analysis set (96.6% vs. 91.3%; difference 5.3%; 95.001% CI: â3.4% to 17.4%) (Fig. 3)., HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1265,3933059,No significant difference,"However, changes in FMD (20%) as well as circulating levels of CRP, ICAM-1, VCAM-1, E-selectin, and IL-6 did not reach statistical significance (P = 0.172).", flow-mediated dilation (FMD) , baseline , Pomegranate juice (PJ) ,0,
edin,1312,3258678,Significantly increased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., Alzheimer Disease Assessment Scale â cognitive subscale (ADAS-cog) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1281,4132637,Cannot tell based on the abstract,, The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1281,4132637,Significantly decreased,"The incidence of the primary composite endpoint was reduced with ticagrelor vs. clopidogrel (10.0 vs. 12.3%; HR 0.83; 95% CI = 0.74â0.93; P = 0.0013) (see Supplementary material online, Figure S1A).", The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1319,5494586,Cannot tell based on the abstract,, glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1319,5494586,Significantly decreased,"As for the comparison among the incremental peak values of glycemia (Figure 1(a), 1(b), and 1(c)), the repeated measures ANOVA with Greenhouse-Geisser correction resulted significant (p < 0.001) and the Tukey-Kramer post hoc test revealed that B1 (36.2âÂ±â3.8âmg/dL), B2 (19.6âÂ±â2.9âmg/dL), and B3 (27.3âÂ±â4.0âmg/dL) had significantly smaller glucose incremental peaks than A (55.9âÂ±â6.1âmg/dL) with p values associated to such post hoc comparisons that were p = 0.04, p < 0.001, and p = 0.002, respectively.", glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1291,5551214,Cannot tell based on the abstract,, the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,1291,5551214,No significant difference,"No significant Spearmanâs correlations were found between change and baseline scores on the CARS2, nor between change and baseline scores on the Hyperactivity subscale of the ABC-C.,The mixed ANOVA for the Irritability subscale of the ABC-C found no significant main or interaction effects (Table 2).", the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,710,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,710,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32â11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,1253,3172326,Significantly increased,The interval time for the first analgesic request was 23.1 Â± 6.7 minutes for the case group and 18.1 Â± 7.3 minutes for the control (P = 0.02)., The interval time for the first analgesic request , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,548,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,548,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1," Health care workers with IgG are only mentioned in methods section where groups are explained. In the results section IgG is not mentioned, there only higher risk of infection for workers working on the frontline"
edin,1340,4012222,Cannot tell based on the abstract,, Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1340,4012222,No significant difference,"Global performance status and STS appeared somewhat better, but these changes did not achieve statistical significance (Fisherâs exact test p =â0.15 comparing categories of PS; mean reduction in STSâ=ââ1.2s, Pâ=â0.3).", Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1320,5494586,Cannot tell based on the abstract,,  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1320,5494586,Significantly decreased,"All three commercial breakfasts showed somewhat smaller insulin excursions with respect to the one elicited by glucose administration (Figure 2(a), 2(b), and 2(c)).",  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1280,5928476,No significant difference,"SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements. However, no statistically significant differences were observed between bulk-fill composite resins values and calcium silicate cement values.", bulk-fill composite resin values and calcium silicate cement values , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,1245,3466198,Significantly decreased,"While there was no increase in inflammatory cytokines or chemokines, CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, were significantly lower following Acidform compared to HEC placebo gel application."," CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, ", hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1335,5673730,Significantly decreased,Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021)., numbers of babies were delivered after 38 weeks of pregnancy , insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B) , oral metformin 500 mg TDS (Group-A) ,0,
edin,1325,5236513,Significantly increased,"At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as ânormalâ compared to Placebo (respectively 3.13 Â± 1.197 a.u. vs 2.58 Â± 1.020 a.u., P = 0.0003).", stool consistency , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
edin,1237,5228611,Cannot tell based on the abstract,, eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1237,5228611,No significant difference,There were no differences between the 2 groups in median changes from baseline in eGFR (week 48: +7.4 mL/min vs. +3.9 mL/min; P = 0.18)., eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1344,5320660,Cannot tell based on the abstract,, The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1344,5320660,No significant difference,The mean score for the question âhow full do you feel?â in the HAM-RS2 group increased from baseline to the end of the study and approached significance (Pâ=â0.058) (data not shown)., The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1252,3172326,Significantly decreased,"For all of the evaluated times, the VAS score was significantly lower in the ketamine group compared to the control.", visual analogue scale (VAS). , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,1287,4132637,Significantly increased,"Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95â1.19), but ticagrelor was associated with an increase in non-CABG major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI = 1.05â1.56).", non-CABG-related major bleeding , clopidogrel , ticagrelor ,0,
edin,1233,5506592,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (differenceÂ âÂ 0.05, 95% CIca â0.100 to â0.010).", the proportion of households who purchased anti-mosquito products in the last month , baseline , education and mobilisation activities ,0,
edin,654,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question 
edin,1333,3917204,Cannot tell based on the abstract,, Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,1333,3917204,No significant difference,Clinical improvement was noticed in both moderately deep pocket sites and deep pocket areas. But comparison of groups showed them to be statistically nonsignificant [Tables 4 and 5]., Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,791,125315,Cannot tell based on the abstract,, The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,791,125315,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343)., The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,1303,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1303,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,The calculated pharmacokinetic parameters were closely related to previous studies conducted in white German subjects using 25âmg EG. The insignificant difference in ANOVA statistical results (TableÂ 2) of the pharmacokinetic evaluation in Egyptians and white German subjects13, 15, 20, 38 suggests that no dose adjustment should be considered with administration of 25âmg EG to Egyptian population.Table 2"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1225,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1225,3917123,Significantly increased,"Post-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1364,4365564,Cannot tell based on the abstract,, Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1364,4365564,No significant difference,"The rate of approach-related complications in all 304 patients was 9.9% (30/304) and was similar between the 2 groups, with 9.8% (20/205) in the investigational group and 10.1% (10/99) in the control group (Table 2).,<td align=""left"" colspan=""1"" rowspan=""1"">Retrograde ejaculation, no. (%)<xref ref-type=""table-fn"" rid=""TF0002"">a</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">3 (3.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">3 (5.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">.515</td>", Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1471,4367028,Cannot tell based on the abstract,, PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1471,4367028,Significantly increased,Again PACU stay was longer (P < 0.05) in TBG >30Â° group compared to TBG <30Â° group [Table 6]., PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1420,2361654,Cannot tell based on the abstract,, colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1420,2361654,Significantly increased,"Compared with the conventional arm, clearly more colposcopy referrals were made in the hrHPV screening arm (RR 1.51, CI 95% 1.03â2.22).", colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1498,3846239,Significantly decreased,The analgesic requirement was significantly lower in the B+D group compared with the B group., The analgesic requirement , bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1515,2361520,Cannot tell based on the abstract,, time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1515,2361520,No significant difference,The time to disease progression from randomisation to after chemotherapy was similar in the immediate- and delayed-treatment groups for both studies (Table 3), time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1428,5553001,Cannot tell based on the abstract,, PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1428,5553001,No significant difference,"Table 1
Baseline characteristics of parents.,<td colspan=""1"" rowspan=""1""><break></break></td><td colspan=""1"" rowspan=""1"">PCL-C<sup>j</sup></td><td colspan=""1"" rowspan=""1"">49.1 (10.3)</td><td colspan=""1"" rowspan=""1"">51.5 (9.4)</td><td colspan=""1"" rowspan=""1"">46.6 (10.7)</td><td colspan=""1"" rowspan=""1"">.06</td>", PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1378,3628658,No significant difference,There was not statistical significance on union time and Harris values in the two position groups., Harris hip values and union time of fractures , Supine position , Lateral decubitus position ,0,
edin,1369,5311860,Cannot tell based on the abstract,," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1369,5311860,No significant difference,"However, when the term for âwatchful waitingâ is excluded from public health response, the results were not significant (TableÂ 5).Table 5"," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1380,4659198,Significantly decreased,"On the third day, the massage group showed significantly higher defecation frequency (pâ=â0.045) and significantly lower bilirubin levels (pâ=â0.03) compared with the control group.", Bilirubin levels after 3 days , Phototherapy only , Phototherapy plus massage ,0,
edin,1459,4600230,Cannot tell based on the abstract,, a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1459,4600230,Significantly increased,"A significantly higher number of participants from the intervention group passed a pre-established pass/fail level of 50.0% in OSAUS score compared with the control group (85.7% vs 8.3%, respectively; P < 0.001).", a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1507,5850185,Significantly increased,he subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=â1.54; P=0.004) than those in the unilateral TENS+TOT group., the TUG completion time at A1 and A2 , baseline , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
edin,1372,5285426,Significantly increased,Composite male urological and sexual function score changes from baseline were better in the robotic cohort (pÂ <Â 0.001)., Male sexual function scores , Laparoscopic surgery , Robotic surgery ,0,
edin,1412,5578640,Significantly increased,The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21)., The ESAS QoL-score after 1 month , untreated (control) , vitamin D 4000 IE/day ,0,
edin,1482,4881089,Cannot tell based on the abstract,, prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1482,4881089,No significant difference,McNemar test showed no significant difference in the prevalence rates of musculoskeletal symptoms in all regions before and after intervention., prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1525,4092926,No significant difference,"There was no influence of the treatments on any of the mean values of the evaluated measures (p>0.05): 21.78 kg (body weight at slaughter), 8.65 kg (hot carcass weight), 8.59 kg (cold carcass weight), 40.27% (hot carcass yield), 39.20% (cold carcass yield), 7.73 cm2(rib eye area), 46.74 cm (carcass outer length), 45.68 cm (carcass internal length), 36.92 cm (leg length), 26.04 cm (leg perimeter), 48.66 cm (hind perimeter), 58.62 cm (thoracic perimeter), 0.20 (carcass compactness index), 68.48% (total muscle of the leg), 2.79% (total leg fat), 55.19% (subcutaneous leg fat), 28.82% (total bone), 81.66 g (femur weight), 14.88 cm (femur length), 0.38 (leg muscularity index), 2.53 (muscle:bone ratio) and 33.42 (muscle:fat ratio).", goats body weight at slaughter , soybean meal , sunflower cake ,0,
edin,1511,4134501,Cannot tell based on the abstract,, Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1511,4134501,No significant difference,"At the end of cycle 3, 10 (67%) and 7 (58%) patients in Arms A and B, respectively, had achieved a partial response, whereas an additional 4 patients in each arm (27% and 33%, respectively) had stable disease.", Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1497,4274342,Cannot tell based on the abstract,, pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1497,4274342,No significant difference,"There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups. Two women had bladder prolapse (one ospemifene participant and one placebo participant), and one ospemifene participant had a report of cystocele.", pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1512,2361520,No significant difference,"Median survival was not significantly better with immediate treatment (median 13.0 vs 11.0 months; hazard ratio, 1.15; 95% confidence interval (CI) 0.79â1.72; P=0.49).", Median survival , receive delayed treatment , receive immediate treatment ,0,
edin,1261,5414544,Significantly increased,"he rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratioâ=â1.54, Pâ<â0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.", The rate of HBsAg positivity , Uganda , Zimbabwe ,0,
edin,1501,2627861,Cannot tell based on the abstract,, maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1501,2627861,Significantly decreased,"In the intent-to-treat analysis (n = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (p = 0.004) (Table 2).", maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1493,5021748,No significant difference,"he initial bolus heparin dosages required to produce an ACT 15Â min after the initial bolus that was identical to the control (333Â Â±Â 32Â s) were 120 U/kg (318Â Â±Â 29Â s) and 130 U/kg (339Â Â±Â 43Â s) for dabigatran, 130 U/kg (314Â Â±Â 31Â s) for rivaroxaban and 130 U/kg (317Â Â±Â 39Â s) for apixaban.,The NOAC groups required significantly larger doses of total heparin than the warfarin group.,The results of the comparison with warfarin (the control) indicated that dosages of 120 or 130 U/kg for dabigatran, and 130 U/kg for rivaroxaban and apixaban, were adequate initial heparin dosages.", heparin dosages required to produce an ACT 15 min after the initial bolus  that was identical to the control (110U/kg) , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1473,4222592,Significantly decreased,"ompared to the C test meal, the AA test meal increased satisfaction by 23% (P=0.05) and decreased the desire to eat by 28% (P=0.04) for the AUC(0-5h).", desire to eat  for the AUC(0-5h) , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Added (AA) ,0,
edin,1461,4600230,Cannot tell based on the abstract,, knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1461,4600230,No significant difference,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095).", knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1453,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1453,3406743,No significant difference,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.,The UCG did not change between baseline and follow-up; 75% of women in this group reported moderate physical activity at baseline, and 77% at follow-up.", engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1495,4274342,Cannot tell based on the abstract,, vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1495,4274342,No significant difference,"aginal bleeding or spotting was reported in 10 of 851 women (1.2%) with an intact uterus in the ospemifene 60 mg/day group (incidence rate, 2.17 per 100 patient-years) and in 5 of 543 women (0.9%) in the placebo group (incidence rate, 2.72 per 100 patient-years; P = 0.7; Table 3).", vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1499,3846239,Significantly decreased,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain values were significantly lower in the B+D group than in the B group."," At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores ", bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1444,5610684,Cannot tell based on the abstract,," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1444,5610684,No significant difference,"There were no significant condition differences for tension F(1, 91) = 1.56, p = 0.21, 95% CI [â0.29, 1.25], Î·2 = 0.02; anxiety F(1, 88) = 0.004, p = 0.95, 95% CI [â1.01, 0.95], Î·2 = 0.00; or well-being F(1, 91) = 0.33, p = 0.57, 95% CI [â0.49, 0.90], Î·2 = 0.004."," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1416,5456350,Cannot tell based on the abstract,, wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1416,5456350,No significant difference,"There were no significant differences in responses to survey items (pertaining to desire to receive a DEKA Arm, self-rated skill in use, perception of weight, ratings of socket comfort, or preferences for DEKA Arm over personal prosthesis) administered at the end of Part A and the end of Part B (Table 2).", wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1435,5336430,Significantly increased,"At 8Â weeks after the end of treatment, CCC was significantly higher with 5-FU 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (OR) 3.9 (95% CI) 1.7, 8.7; PÂ =Â 0.0006].", The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint) , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1523,4107254,Significantly increased,"Centers admitting â¥ 200 patients/year (70.7% vs. 45%; p = 0.039), and those with stroke units (95 vs. 20; p = 0.031) were more willing to join a randomized trial evaluating any of the methods.", willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients , centers without stroke unit , centers with stroke unit ,0,
edin,1430,5566825,Cannot tell based on the abstract,, total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1430,5566825,Significantly decreased,"Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (P < 0.01) and the proportionate difference was about 2 times (1.91) [Figure 3].", total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1503,5854362,Cannot tell based on the abstract,, anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1503,5854362,No significant difference,"Our first and primary hypothesis, that CBM-I would result in reduced anxiety and depressive symptoms compared to Placebo, was not confirmed, as no significant Condition x Time interactions were observed for SCARED and CDI scores.", anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1522,4107254,Cannot tell based on the abstract,, Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1522,4107254,No significant difference,"Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, p = 0.05).", Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1494,4274342,Cannot tell based on the abstract,, The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1494,4274342,Significantly increased,"The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â¤ 0.001, Welchâs test) at all three evaluations.", The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1510,4134501,No significant difference,The safety profiles were similar between arms and treatment was well tolerated., The safety profiles , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1393,4599543,Significantly decreased,"Postoperative bleeding was significantly (P=0.042) less in the treatment arm (median, 300Â mL; interquartile range, 200 to 400Â mL) than in the control arm (median, 355Â mL; interquartile range, 250 to 600Â mL).", postoperative bleeding , received saline solution (placebo) , received fibrinogen concentrate ,0,
edin,1466,2837815,No significant difference,The Merle dâAubigne Postel score was the maximum of 18 points for all patients in both groups., The Merle dÃ¢â¬â¢Aubigne Postel score , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
edin,1374,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Hospital stay , Supine position , Lateral decubitus position ,0,
edin,1359,3842830,Significantly decreased,"The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (â0.99 hours, Pâ=â.003) and istradefylline 40 mg/day (â0.96 hours, Pâ=â.003) groups compared with the placebo group (â0.23 hours).", Daily OFF time , Placebo , Istradefylline 20 mg or 40 mg ,0,
edin,1452,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1452,3406743,Significantly increased,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.", engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1375,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Loss of blood during surgery , Supine position , Lateral decubitus position ,0,
edin,1496,4274342,Cannot tell based on the abstract,, endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1496,4274342,No significant difference,There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials., endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1441,5336430,Cannot tell based on the abstract,, DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1441,5336430,No significant difference,"<td align=""left"" colspan=""4"">DLQI total score</td>", DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1467,4367028,Cannot tell based on the abstract,, SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1467,4367028,No significant difference,"Baseline hemodynamic parameters like SBP, DBP, mean arterial pressure (MAP), pulse rate and also hemoglobin were found to be comparable [Table 3] among two groups.,Head down tilt was associated with a rising trend in SBP and DBP which was higher in TBG >30Â° than TBG <30Â° group however the results were not statistically significant [Table 4].", SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1401,5766333,Cannot tell based on the abstract,, the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1401,5766333,Significantly decreased,"On the other hand, the minimum pulse rate was significantly lower in the Combination group than in the PF group (47 [34âââ61] bpm vs. 59 [36âââ72] bpm, P â<â0.001, median [range]),", the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1460,4600230,Cannot tell based on the abstract,," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1460,4600230,Significantly increased,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095)."," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1394,5724392,Cannot tell based on the abstract,"Final model-based TCD velocities (mean Â± standard error) on Standard versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1394,5724392,Significantly increased,"The final model-based TCD velocities (mean Â± standard error) on the Standard Arm versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and a post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1456,3406743,Significantly increased,A culturally tailored adaptation of the WISEWOMAN program that used community health workers significantly improved both self-reported readiness to engage in physical activity and vigorous physical activity among low-income Latinas., readiness to engage in vigorous physical activity , baseline , enhanced intervention (EIG) ,0,
edin,1419,5456350,Cannot tell based on the abstract,, rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1419,5456350,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;DEKA arm function</td><td align=""center"" colspan=""1"" rowspan=""1"">31</td><td align=""center"" colspan=""1"" rowspan=""1"">5.3 (1.4)</td><td align=""center"" colspan=""1"" rowspan=""1"">17</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (1.0)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">4.7 (1.6)</td><td align=""center"" colspan=""1"" rowspan=""1""><bold>0.0468</bold></td>,<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;External Battery Life</td><td align=""center"" colspan=""1"" rowspan=""1"">32</td><td align=""center"" colspan=""1"" rowspan=""1"">5.7 (1.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">18</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (0.8)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">5.5 (1.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.9928</td>", rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1470,4367028,Cannot tell based on the abstract,, Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1470,4367028,Significantly increased,Nitroglycerine and fentanyl use in TBG >30Â° group was higher and statistically significant (P < 0.05) when compared with TBG <30Â° [Table 6]., Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1370,5285426,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.", Urological function scores in females , Laparoscopic surgery , Robotic surgery ,0,
edin,1478,4673066,Cannot tell based on the abstract,, performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1478,4673066,Significantly increased,"Schema-based instruction was associated with increased performance on the diagnostic performance test (64â%âÂ±â22 vs 44â%âÂ±â25, pâ<â0.001).", performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1383,4659198,Cannot tell based on the abstract,, Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1383,4659198,No significant difference,"TableÂ 1 shows the medical characteristics of participating neonates. We observed no significant differences between the two groups in terms of type of feeding, gestational age at birth, body weight at birth, body weight on the date of admission, phototherapy duration, or physical weight loss.Table 1", Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1485,4881089,Cannot tell based on the abstract,, any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1485,4881089,No significant difference,Table 5 also shows that there was no significant difference in any of the scales of the Thai version of the COPSOQ questionnaire before and after intervention in the control group., any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1526,4092926,Cannot tell based on the abstract,," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1526,4092926,No significant difference,Weights and carcass yields as well as rib eye area showed no differences (p>0.05) with the substitution of soybean meal by sunflower cake.," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1434,5566825,Cannot tell based on the abstract,, CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1434,5566825,Significantly increased,Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [Table 7]., CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1492,5021748,Cannot tell based on the abstract,, protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1492,5021748,No significant difference,"No significant differences in protamine usage for haemostasis were found among the control and three NOAC groups (control, 13Â Â±Â 20; dabigatran, 26Â Â±Â 23; rivaroxaban, 25Â Â±Â 25; apixaban, 28Â Â±Â 28Â mg).", protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1377,3628658,Significantly decreased,"he hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Surgery time , Supine position , Lateral decubitus position ,0,
edin,1440,5336430,Cannot tell based on the abstract,, the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1440,5336430,No significant difference,"No statistically significant differences were observed between the study arms for the TSQM convenience (70.7 and 71.2, respectively) and side effect (92.4 and 96.4, respectively) domain scores.", the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1365,4365564,Significantly increased,There was a higher rate of superficial wound infection in the investigational group but no deep wound infections in either group., Rate of superficial wound infection , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1355,3179725,Significantly increased,"<td align=""left""><bold>After four treatments</bold></td><td></td><td></td><td></td>", Dyspnea improvement , Sham chest wall oscillation treatment , Active chest wall oscillation treatment ,0,
edin,1637,5420386,Significantly increased,"<td colspan=""5"">5D-ASC scale</td>"," ratings of blissful state, insightfulness, and changed meaning of percepts ", 100&amp;amp;nbsp;ÃÂ¼g dose of LSD , oral administration of 200 ÃÂ¼g LSD ,0,
edin,1623,3719224,Significantly increased,"Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 Â± 1.38 vs. 3.53 Â± 1.61), perceived susceptibility (14.05 Â± 1.51 vs. 12.37 Â± 2.11), and perceived benefits (28.41 Â± 2.14 vs. 27.51 Â± 3.05), at follow-up time after 3 months (P < 0.05)."," the variables, knowledge ", received just routine education , received educational intervention plus routine education ,0,
edin,1551,4396724,Cannot tell based on the abstract,, Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1551,4396724,No significant difference,"Maximal heart rate achieved at the end of the graded exercise test, body mass, and waist circumference did not change significantly from baseline to one-month follow-up in either HIIT or MICT (P's > 0.05).", Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1632,5420386,No significant difference,"On the MEQ, 200Â Î¼g LSD induced mystical experiences that were comparable to those in patients who underwent LSD-assisted psychotherapy but were fewer than those reported for psilocybin in healthy subjects or patients.", Mystical Experience Questionnaire (MEQ) scores , placebo , oral administration of 100 and 200&amp;nbsp;ÃÂ¼g LSD ,0,
edin,1536,5941723,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5âmm penetration versus 1âmm skin press and 10âmm penetration versus 2âmm skin press.", Needle pain intensity , Placebo , Acupuncture ,0,
edin,1531,5343624,Cannot tell based on the abstract,, Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1531,5343624,No significant difference,"The radiologic analysis of the BO graft revealed volumetric reduction in all patients.,The volume reduction of the BO graft was not significant.,The radiologic analysis of the NB graft revealed volumetric reduction in all patients.,The volume reduction of the NB graft was not significant.", Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1588,3810136,Cannot tell based on the abstract,, Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1588,3810136,Significantly decreased,"In addition, lower free IGF-1 levels were measured in the T-HS/Ctr group than PF group at day 4 and it reached statistical difference by day 6 (p<0.01), indicating that the depressed IGF-1 expression was sustained 6 days following T-HS after eliminating the interference of reduced food intake.", Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1667,5017045,Cannot tell based on the abstract,, number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1667,5017045,No significant difference,There were no significant differences in the number of operated patients between the two groups (pâ=â0.432)., number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1563,3094237,Cannot tell based on the abstract,, Adverse side effects , Placebo , L-lysine ,0,
edin,1563,3094237,No significant difference,"urthermore, the L-lysine treatment was not found to induce any adverse side effects including extrapyramidal effects.", Adverse side effects , Placebo , L-lysine ,0,
edin,1600,5434251,Cannot tell based on the abstract,, PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1600,5434251,No significant difference,"<td colspan=""2"" rowspan=""1"">PTQ<sup>g</sup> (perseverative thinking), mean (SD)</td><td colspan=""1"" rowspan=""1"">38.50 (10.97)</td><td colspan=""1"" rowspan=""1"">45.32 (9.95)</td><td colspan=""1"" rowspan=""1"">t<sub>35</sub>=â1.98; <italic>P</italic>=.06</td>", PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1561,5916905,No significant difference,"After BM-intervention, fat mass increased (+1.0âÂ±â1.8âkg; pâ<â0.05) and postprandial insulin sensitivity tended to decrease (ÎMatsudaISI: â0.89âÂ±â2.3; pâ=â0.06).,Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ>â0.05).",  Insulin sensitivity after meals , Orange juice intake with each meal (WM)  , Orange juice intake in-between meals (BM) ,0,
edin,1591,2714198,No significant difference,No difference in survival time was observed across the different groups., Survival time , Control groups , Suture groups ,0,
edin,1609,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Pregnancy , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1574,5791393,Cannot tell based on the abstract,, Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1574,5791393,No significant difference,"There was also no significant difference in the post-operative hospital stay between the groups, both in total and separately in women and in men.", Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1564,3094237,Significantly decreased,"<td align=""left""><underline>PANSS</underline></td><td></td><td></td><td></td><td></td><td></td>", Symptom severity by PANSS measure , Placebo , L-lysine ,0,
edin,1583,5642191,Cannot tell based on the abstract,, Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1583,5642191,No significant difference,No differences in baseline characteristics were found between the three intervention groups (Table 1)., Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1575,5791393,No significant difference,"Catheterisation does not influence: the number of additional doses of ketoprofen and pethidine administered during the 1st day after the operation, the duration of hospitalization, the occurrence of fever, significant bacteriuria, the postoperative acute urinary retention and the post-void residual urine volume.", Fever , Without catheter (group I) , With catheter (group II) ,0,
edin,1666,5017045,Cannot tell based on the abstract,, The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1666,5017045,Significantly increased,"In the subgroup analyses restricted to patients who required casting, we observed a significantly longer mean consultation time in the RMC group (29.0Â min) compared to the UNN group (22.6Â min, pâ=â0.0063).", The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1672,2941605,Cannot tell based on the abstract,, Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1672,2941605,Significantly increased,Skin reaction was also lower in the Vinorelbine arm when compared with the other arm., Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1630,3640164,Cannot tell based on the abstract,," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1630,3640164,Significantly increased,"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time were shorter in the spinal anesthesia group than in the PSNB group (P < 0.01)."," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1604,4335741,Significantly decreased,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences, but vocal cords were significantly more patent in group R than those in group A (P = 0. 028).", Vocal cords patency , Remifentanil , Alfentanil ,0,
edin,1675,4737200,Cannot tell based on the abstract,, second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1607,4335741,Cannot tell based on the abstract,, Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1607,4335741,No significant difference,"As shown in Table 3, the scores for ease of laryngoscopy (A), jaw relaxation (C), and limb movement (D) did not differ significantly between the two groups (Mann-Whitney test), but vocal cord patency (B) in group A was significantly higher than that in remifentanil group (P = 0. 028).", Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1611,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Live birth rate , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1550,4396724,Cannot tell based on the abstract,, Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1550,4396724,No significant difference,"There were no main effects for group or group by time interactions for these fitness parameter variables, indicating that there were no differences in the degree of change experienced between HIIT and MICT over time.", Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1658,2291328,Cannot tell based on the abstract,, hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1658,2291328,No significant difference,"There was a non-significant increase in the number of patients having a hospitalization for worsening CHF in the bisoprolol-first group compared with the enalapril-first group (63 vs 51 patients, respectively, HR = 1.25 [0.87â1.81], p = 0.23).", hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1597,2911596,Cannot tell based on the abstract,, HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1597,2911596,Significantly increased,"However, HR values were significantly different in SEVO and ISOF groups 70.6 Â± 13.0 versus 64.9 Â± 11.8, (P < .01), respectively (Figure 2).", HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1608,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Fertilization , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,621,1852268,Cannot tell based on the abstract,, obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,621,1852268,No significant difference,"At the primary efficacy endpoint 2â4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillinâtazobactam were cured (95% confidence interval for the difference, adjusting for strata, â4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,1676,4737200,Cannot tell based on the abstract,, mobility , control condition , barefoot conditions ,0,
edin,1676,4737200,No significant difference,There was no difference in the mobility or barefoot conditions in comparison to the control condition., mobility , control condition , barefoot conditions ,0,
edin,1655,2291328,Cannot tell based on the abstract,, heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1655,2291328,Significantly increased,Bisoprolol produced a significant reduction in heart rate associated with a non-significant increase in peak oxygen consumption., heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1601,5434251,Cannot tell based on the abstract,, SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1601,5434251,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1571,4924222,No significant difference,"After adjustment for baseline measurements there was no time by treatment effect for central systolic or diastolic BP, AIx or cfPWV.", Augmentation index (AIx) , Usual diet ," Increased intake of fruits, vegetables and dairy ",0,
edin,1663,3489577,Significantly decreased,"Total-, LDL-cholesterol and waist circumference decreased significantly in the oat group compared to the control.", total cholesterol and LDL-C  , 100 grams of wheat flour-based noodles , 100 grams of instant oat cereal ,0,
edin,1647,5498096,Cannot tell based on the abstract,, pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1647,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1578,5074260,Cannot tell based on the abstract,, Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1578,5074260,Significantly decreased,"At 26âweeks, 77.6% of patients receiving IDeg and 35.5% of those receiving placebo had achieved an HbA1c level <7.0% (<53âmmol/mol); the likelihood of achieving HbA1c <7.0% was significantly higher for participants in the IDeg addâon group [odds ratio 7.79 (95% CI 4.57; 13.27); pâ<â0.0001].", Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1598,5434251,Cannot tell based on the abstract,, Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1598,5434251,No significant difference,"<td colspan=""1"" rowspan=""1"">Number of exercises practiced</td><td colspan=""1"" rowspan=""1"">7.88 (4.92)</td><td colspan=""1"" rowspan=""1"">10.06 (6.80)</td><td colspan=""1"" rowspan=""1"">62.67 (61.64)</td><td colspan=""1"" rowspan=""1"">48.71 (44.28)</td><td colspan=""1"" rowspan=""1""><italic>t</italic><sub>30</sub>=â0.72</td><td colspan=""1"" rowspan=""1"">.48</td><td colspan=""1"" rowspan=""1"">0.25 (â0.45 to 0.96)</td>,The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1679,4737200,Cannot tell based on the abstract,, knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1679,4737200,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot â4.3%, pâ=â0.023; typical wedge â7.95%, pâ<â0.001; supported wedge â5.5%, pâ<â0.001).", knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1580,5074260,Cannot tell based on the abstract,, Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1580,5074260,Significantly increased,"The number of patients experiencing confirmed hypoglycaemia during randomized treatment was higher with IDeg (17.3%) than with placebo (4.7%; Table S3, Supporting Information).", Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1674,4737200,Cannot tell based on the abstract,, early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1674,4737200,Significantly decreased,"When we examined the effects of the conditions on measures of medial loading (Tables 1 and 2, Fig. 3), we found that barefoot walking had the greatest effect on early stance peak EKAM, lowering it by â7.6% (pâ<â0.001 vs. control shoe).", early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1665,5017045,Cannot tell based on the abstract,, The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1665,5017045,No significant difference,The mean consultation duration was not significantly different between the groups (pâ=â0.60)., The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1631,3640164,Cannot tell based on the abstract,, he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1631,3640164,No significant difference,"The anesthesia-related side effects in the spinal anesthesia group were hypotension, bradycardia, shivering, vomiting, postoperative headache, and urinary retension, occurring in 15%, 10%, 5%, 5%, 10%, and 20% of patients, respectively. There was no incidence of side effects in the PSNB group, but it was not statistically significant.", he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1554,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 4.5 MIU dose ,0,
edin,1648,5498096,Cannot tell based on the abstract,, pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1648,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1656,2291328,Cannot tell based on the abstract,," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1656,2291328,Significantly decreased,"Bisoprolol significantly reduced cardiovascular mortality (HR: 0.71 [0.56â0.9]), sudden cardiac death (HR: 0.56 [0.39â0.80]), hospital admission (HR: 0.80 [0.71â0.91]), and hospital admission for worsening heart failure (HR: 0.64 [0.53â0.79]) compared with placebo."," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1584,5642191,Cannot tell based on the abstract,, SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1584,5642191,No significant difference,"There were no differences in any of the SDQ change scores from pre to post between the fish and meat or fish and supplement group, neither before nor after adjusting for the participantsâ baseline scores or baseline and compliance scores (Table 2).Table 2.", SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1555,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 7.5 MIU dose ,0,
edin,1636,5420386,Cannot tell based on the abstract,, all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1636,5420386,Significantly increased,"<td colspan=""5"">MEQ30</td>", all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1537,5941723,Cannot tell based on the abstract,, Severe adverse events , Placebo , Acupuncture ,0,
edin,1537,5941723,No significant difference,There were no critical adverse events., Severe adverse events , Placebo , Acupuncture ,0,
edin,1616,3430047,Cannot tell based on the abstract,, PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1616,3430047,Significantly decreased,"Supplemental opioid demand, PHS criteria and bupivacaine consumption were statistically significant, as, rate of IV opioid consumption, PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).", PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1649,2856148,Cannot tell based on the abstract,, acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1649,2856148,No significant difference,"No significant difference between the two groups in duration of MV (6.20 Â± 5.20 days vs. 7.47 Â± 6.38 days, P > 0.05), duration of weaning (35.17 Â± 16.98 and 47.05 Â± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 Â± 4.79 and 10.80 Â± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.", acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1596,2911596,Cannot tell based on the abstract,," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1596,2911596,No significant difference,"MAC and SE values were similar in SEVO and ISOF groups before fentanyl boluses [0.74 Â± 0.12 versus 0.77 Â± 0.17, (P = .32) and 43.5 Â± 8.1 versus 45.2 Â± 8.3, (P = .47), resp.]."," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1573,5791393,Cannot tell based on the abstract,, Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1573,5791393,Significantly increased,It was confirmed that the catheterised patients had sensed more intensive pain than the non-catheterised subjects., Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1721,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1845,5599918,Cannot tell based on the abstract,, Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1845,5599918,Significantly increased,"Apart from the total administered dose of remifentanil and ephedrine, there were no significant differences among the 3 groups. The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P < 0.001, respectively).", Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1688,5362210,Cannot tell based on the abstract,, Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1688,5362210,Significantly decreased,"Correlation analyses of the following variables showed a significant correlation (p<0.05) between gestational age, birth weight, clinical chorioamnionitis, surfactant, mechanical ventilation, use of vasopressors, blood transfusions, and the burden of cerebral hypoxia within the 4th quartile on one hand and the composite outcome of severe brain injury or death on the other.,As described in the methods, centre, gestational age below 26 weeks, and intervention were forced-entry variables in the model. The following variables remained statistically significant: intervention (OR (95% CI) 0.29 (0.12â0.69; p = 0.003,)), gestational age below 26 weeks (3.33 (1.38â8.06; p = 0.007)), use of vasopressors (3.26 (1.26â8.44; p = 0.014)), and blood transfusion (2.97 (1.22â7.23; p = 0.016)).", Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1797,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1716,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1694,3600348,Significantly increased,Five (83%) of the patients who failed the SBT in ATC group were reintubated. This represented a higher negative predictive value for ATC of 83% than for PSV which was 56%, Causes of reintubation , Pressure support ventilation , Automatic tube compensation ,0,
edin,1844,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1745,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1745,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1809,3154934,Cannot tell based on the abstract,, Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1809,3154934,No significant difference,"There were no baseline differences between the children who had received neonatal VAS or placebo, continued to live in the study area and were met at follow-up (Table 1).", Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1753,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1753,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1766,4526979,Cannot tell based on the abstract,, Treatment categories change scores , Nonusers , Website users ,0,
edin,1766,4526979,No significant difference,"Summary change scores for treatment categories were also obtained. Between the intervention group and nonusers, there were minimal differences that did not reach statistical significance in core treatments (change scores 10.3% vs 4.7%, P=.17), adjunct treatments (change scores 3.1% vs 1.2%, P=.54), pharmacological treatments (change scores â1.7% vs â2.4%, P=.35), and nonpharmacological treatments (change scores 9.5% vs 4.0%, P=.29).", Treatment categories change scores , Nonusers , Website users ,0,
edin,1709,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1709,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1722,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1722,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1697,4045368,Cannot tell based on the abstract,, Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1697,4045368,No significant difference,No significant differences were found between the two groups in the severity of the tibial plateau fractures according to the Schatzker (P = 0.556) or AO (P = 0.257) classifications systems (Figures 2 and 3)., Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1689,5362210,Significantly increased,"Significantly more infants with a cerebral burden of hypoxia within the 4th quartile versus infants within quartile 1â3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia.", Burden of hypoxia within the 4th quartile versus quartile 1Ã¢â¬â3 , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1821,5003869,Cannot tell based on the abstract,," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1821,5003869,No significant difference,"For patients starting with RAS-inhibitors 22.6% of the patients in the intervention arm discontinued therapy compared to 27.9% of patients with usual care which is significantly lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-analysis is comparable but not statistically significant. For statins and bisphosphonate users, discontinuation rates were not significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively 0.73, 95% CI 0.56, 1.02)."," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1707,5556332,Cannot tell based on the abstract,, Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1707,5556332,Significantly increased,Surgeons reported more satisfaction with pain control in the medication group in 24 and 48 hours after surgery (P = 0.001) (Table 2)., Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1704,5556332,Significantly decreased,"Patients in the PAN group had significantly lower UPAT scores at 0, 2, 4, 6, 12, 24 and 48 hours after the surgery than those in the control group (P = 0.008, 0.021, 0.008, 0.047, 0.004, 0.001, and 0.001).", UPAT scores , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1817,5003869,Cannot tell based on the abstract,, Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1817,5003869,No significant difference,In the overall ITT analysis we found a mean adherence rate (MPRm) of 74.7% (SD 37.5) for intervention patients and 74.5% (SD 37.9) for control patients (see Table 2)., Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1759,4199180,Cannot tell based on the abstract,, Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1759,4199180,No significant difference,The morbidity/complication profiles among the two groups were comparable [Table 2]., Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1720,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1720,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1729,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1729,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1802,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1836,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1836,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1696,4045368,Cannot tell based on the abstract,, Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1696,4045368,No significant difference,"No difference was observed in the duration of follow-up between the locking plate and nonlocking plate groups (10.61 Â± 3.05 months versus 12.95 Â± 2.63 months, P = 0.158).", Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1765,4526979,No significant difference,"With the exception of health service navigation, mean effect sizes from all other heiQ domains showed a positive trend for My Joint Pain users compared to the nonusers, although the differences between groups did not reach statistical significance.", Domains examined for the heiQ , Nonusers , Website users ,0,
edin,1728,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1728,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531)", Subjective well-being , Placebo , Haloperidol ,0,
edin,1841,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1841,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1782,5697397,Significantly increased,Native whey ingestion induced a greater phosphorylation of p70S6K than milk 180Â min after exercise (Pâ=â0.03)., Phosphorylation of p70S6K 3 hours after exercise , Milk protein  , Native whey protein ,0,
edin,1813,5003869,Cannot tell based on the abstract,"Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1813,5003869,No significant difference,"The mean adherence rate in patients in the intervention arm starting with RAS-inhibitors was 84.1% (SD 31.6) compared to 78.5% (SD 36.6) in the usual care arm which is a significant improvement with a adherence difference based on mixed-effect models of 5.16% (95% CI 1.17, 10.03) (See,In statin users, patients in the intervention arm had a mean adherence rate of 80.5% (32.4) compared to 75.1% (36.8) in the usual care arm, which is a non-significant adherence difference of 4.08% (95% CI â0.81, 6.62).,n patients starting with bisphosphonates, the mean adherence rate in intervention arm (75.2%) was not different from the usual care arm (73.3%) neither was the proportion of adherent patients (70.2% respectively 67.1%)."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1780,4137650,Significantly decreased,The rise in HR (P = 0.08481) and rate pressure product (P = 0.0666) at the time of intubation were minimal and was statistically significant up to 15 min in Group D., Mean rate pressure product up to 15 min after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1718,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1718,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1705,5556332,Significantly decreased,The mean dose of postoperative morphine consumption in the PAN group was 37% less than the control group (P = 0.001)., Consumption of morphine after the surgery , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1755,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1755,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1756,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1711,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1837,5599918,Significantly decreased,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.", Pain intensity after surgery , Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1834,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1786,4878364,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007),", Gait speed , No exercise , Exercise program ,0,
edin,1778,4137650,Significantly increased,The mean arterial pressure was significantly increased in patients receiving placebo (P < 0.0001) and esmolol (P < 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294). T, Mean systolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1792,3798206,Significantly increased,"In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1.30, 95% confidence interval [CI] 0.96â1.76 for dabigatran 110 mg twice daily and OR 1.42, 95% CI 1.07â1.88 for dabigatran 150 mg twice daily).", Rates of myocardial infarction  , Warfarin , Dabigatran ,0,
edin,1814,5003869,Cannot tell based on the abstract,, Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1814,5003869,No significant difference,"For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9).", Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1808,111193,Cannot tell based on the abstract,, Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1808,111193,No significant difference,Fifty percent in the ANH group received homologous blood transfusion during the hospital stay (771 mL pr. patient transfused) vs. 42 % in non-ANH group (800 mL pr. patient transfused) (ns)., Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1763,4526979,No significant difference,"Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs â6%, P=.03) measured on the OAQI."," Self-management as measured on the OAQI, after 12 months ", Nonusers , Website users ,0,
edin,1822,3388481,Significantly increased,In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful ECV procedure than NLP (P = 0.05) and hypnosis and NLP (P = 0.03)., Success of external cephalic version (ECV) procedure , Standard medical care alone , Hypnosis and Neurolinguistic Programming (NLP) ,0,
edin,1826,4733710,Cannot tell based on the abstract,, Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1826,4733710,No significant difference,"Peri-operative Transfusion Trigger Score of Emergency group and control group were compared in age, gender, body mass index, ASA score, and operation area; Heart rate, mean arterial pressure, SpO2, body temperature, and shock index when entering into the operation room; there was no statistical difference between the two groups for Hb values and APACHE II scores after entering into the operation room,Table 4
The two groups of patients are compared in vital signs and Hb (mean Â± SD)", Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1831,2967098,No significant difference,Comparison of the improvement rate in both study groups revealed no significant difference., Improvement rate , Low dose (5 mg/day) haloperidol , High dose (20 mg/day) haloperidol ,0,
edin,1767,4780150,No significant difference,"fter intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Total body stores of vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1768,4780150,No significant difference,"After intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Vitamin A concentrations in the liver , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1757,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1757,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1805,111193,Cannot tell based on the abstract,, Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1805,111193,No significant difference,Time used for anaesthesia (from patient enters the operating theatre to entering the recovery room) and duration of surgery was identical between groups., Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1779,4137650,Cannot tell based on the abstract,, Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1779,4137650,Significantly increased,The DAP levels in Group D were significantly lower than Groups C and E at all times after intubation., Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1853,5145296,Cannot tell based on the abstract,, chronic cough ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1853,5145296,Significantly decreased,"Based on the results obtained byFisherâs exact test, the statistical difference between the drug and placebo groups in terms of presentationsâ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).,<td colspan=""1"" rowspan=""1"">Chronic cough</td><td colspan=""1"" rowspan=""1"">50 (71.4)</td><td colspan=""1"" rowspan=""1"">12 (17.1)</td><td colspan=""1"" rowspan=""1"">0.001</td><td colspan=""1"" rowspan=""1"">44 (62.9)</td><td colspan=""1"" rowspan=""1"">26 (37.1)</td><td colspan=""1"" rowspan=""1"">0.001</td>", chronic cough ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,2071,3835146,Cannot tell based on the abstract,, C3 levels , placebo ," atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ãâ 9 mg/kg) ",0,
edin,2071,3835146,No significant difference,"C3 levels remained within the normal range throughout the study for most patients. At baseline, only three of 24 patients had C3 values below the normal range (0.9â1.8 g/L): one patient in the 9 mg/kg group, one patient in the 18 mg kg group and one patient in the 2 Ã 9 mg/kg group. All three of these patients showed transient increases in C3 to normal levels during treatment.", C3 levels , placebo ," atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ãâ 9 mg/kg) ",0,
edin,1971,4404560,Cannot tell based on the abstract,, the falls rate in the women only , routine activity , exercise  ,0,
edin,1971,4404560,No significant difference,There was no significant difference in the falls rate reduction in the women only analysis compared to the overall group., the falls rate in the women only , routine activity , exercise  ,0,
edin,2060,5404215,Cannot tell based on the abstract,, flow-mediated dilation (FMD) score at 240 min postconsumption , baseline , 3 ounces (85 g) ground peanuts ,0,
edin,2060,5404215,No significant difference,There were no significant differences in FMD between baseline and 240 min postconsumption of the peanut shake (Figure 2)., flow-mediated dilation (FMD) score at 240 min postconsumption , baseline , 3 ounces (85 g) ground peanuts ,0,
edin,2054,3793419,Cannot tell based on the abstract,, burning sensation ," Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week "," tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week ",0,
edin,2054,3793419,No significant difference,Almost all the patients in both the groups were relieved from burning sensation after treatment., burning sensation ," Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week "," tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week ",0,
edin,1900,5045666,Significantly increased,"The mean serum levels of both HDL-C and vitamin D showed a significant rise following the treatment in the study group (P = 0.007 and P < 0.001, respectively), whereas both variables decreased slightly in the control group (P = 0.27).", Mean serum levels of vitamin D , Placebo , Vitamin D supplement ,0,
edin,1925,4374260,Significantly decreased,Postmicturition dribble annoyed 12.8% of those who received 50 mg tramadol and 33.6% of those who received 100 mg tramadol (P < 0.001)., Postmicturition dribble , placebo  , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,1973,5376493,Significantly increased,"Non-technical skills concerning situation awareness (p<.01, r=0.5) and teamwork (p<.01, r=0.45) improved from simulation I to II in the NTS group.", Non-technical skills concerning situation awareness and teamwork , medical seminar , non-technical skills seminar ,0,
edin,1913,5630555,No significant difference,"Although the titers of GADAb were not significantly different between the S and P groups during the study, the change ratio of the GADAb titers from baseline was significantly inversely correlated with the change ratio of the âC-peptide values from baseline in the S group (pÂ =Â 0.003); in particular, when the GADAb titers decreased from baseline, the âC-peptide values frequently increased.", The titers of GADAb , pioglitazone , sitagliptin ,0,
edin,1891,3687261,Cannot tell based on the abstract,, incremental areas under the curve ," placebo and sucralose, or sitagliptin and sucralose "," placebo and d-xylose, or sitagliptin and d-xylose ",0,
edin,1891,3687261,Invalid Prompt,, incremental areas under the curve ," placebo and sucralose, or sitagliptin and sucralose "," placebo and d-xylose, or sitagliptin and d-xylose ",1, incremental areas under the curve is mentioned in the methods section of the article. I was not able to find any data in results or conclusion section
edin,2093,5452066,Cannot tell based on the abstract,, Median OS , topotecan , PM01183 ,0,
edin,2093,5452066,No significant difference,"Median OS was 9.7âmonths (95% CI, 7.7â19.3âmonths) with PM01183, and 8.5âmonths (95% CI, 3.3â15.6âmonths) with topotecan (Pâ=â0.2871).", Median OS , topotecan , PM01183 ,0,
edin,2081,4628236,Cannot tell based on the abstract,, the slope of EDPVR , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2081,4628236,Significantly decreased,"In comparison with Co group the slope of EDPVR tended to increase (PÂ =Â 0.063) in diabetic animals, which was significantly reduced by cinaciguat (Fig.Â 6b).", the slope of EDPVR , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2039,4882968,No significant difference,"Before intervention, mean severity of mania in the experimental group (23.50 Â± 7.02) and control group (23.70 Â± 8.09) was not significant (P â¤ 0.89).", mean severity of mania , placebo , omega-3 supplement ,0,
edin,1999,5012042,No significant difference,"Circumferential and radial strains derived from FG acquisitions were slightly reduced compared to NF acquisitions (â16âÂ±â2Â % vs â17âÂ±â2Â %, pâ<â0.001; 40âÂ±â10Â % vs 44âÂ±â11Â %, pâ=â0.005, respectively).", Circumferential and radial strains , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF)  , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG) ,0,
edin,1901,5045666,Cannot tell based on the abstract,, Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D , Placebo , Vitamin D supplement ,0,
edin,1901,5045666,No significant difference,"There was no statistically significant difference in the mean serum levels of HDL-C and vitamin D between the two groups after the intervention (P = 0.11 and P = 0.20, respectively).", Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D , Placebo , Vitamin D supplement ,0,
edin,2079,4628236,Cannot tell based on the abstract,, Expression of MMP-9 and MMP-2 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2079,4628236,No significant difference,"DM was associated with dysregulation of the MMP system indicated by markedly increased MMP-9/TIMP-1 and reduced MMP-2/TIMP-2 gene expression ratios (Fig.Â 4a).,Expression of MMP-9 showed a twofold increase in DM, while MMP-2 remained unchanged (Fig.Â 4c).,Cinaciguat did not significantly alter these parameters (Fig.Â 4c).", Expression of MMP-9 and MMP-2 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2059,3655565,Cannot tell based on the abstract,," heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T) ", standard care  , two-day adjunctive acupressure with standard care  ,0,
edin,2059,3655565,No significant difference,"As Table 2 shows, there were no statistically significant differences between the three treatment arms on the outcome variables of interest at baseline.,To the best of our knowledge, this trial was the first to investigate the potential benefits of adjunctive acupressure on weaning indices in a group of stable, mechanically ventilated coma patients."," heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T) ", standard care  , two-day adjunctive acupressure with standard care  ,0,
edin,2026,3178704,Cannot tell based on the abstract,," body weight, BMI, body fat, muscle mass and VFA ", baseline , diet with resistance training (RT) ,0,
edin,2026,3178704,Significantly increased,"The RT group had increases in body weight, BMI, body fat, muscle mass and VFA as measured by CT following the 12-week program."," body weight, BMI, body fat, muscle mass and VFA ", baseline , diet with resistance training (RT) ,0,
edin,1857,4223282,Cannot tell based on the abstract,, men discussing and using condoms within stable relationships , no intervention , SASA! community mobilization intervention program ,0,
edin,1857,4223282,Significantly increased,"Positive impacts include increased discussion about, and use of, condoms within regular partnerships in the past year with men in intervention communities twice as likely to report condom use with their partner at last intercourse than men in control communities (aRR 2.03, 95% CI 1.22â3.39).", men discussing and using condoms within stable relationships , no intervention , SASA! community mobilization intervention program ,0,
edin,1944,4481831,Cannot tell based on the abstract,, durations of the gait phases , baseline , after Ice application ,0,
edin,1944,4481831,Cannot tell based on the abstract,, durations of the gait phases , baseline , after Ice application ,0,
edin,1944,4481831,No significant difference,Ice application did not affect the durations of the gait phases (Table 2)., durations of the gait phases , baseline , after Ice application ,0,
edin,1889,3687261,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P < 0.01 for each) and were lowest after SX (P < 0.05 for each), while overall blood glucose was lower after SX than PC (P < 0.05).", peak blood glucose , placebo and sucralose , sitagliptin and d-xylose ,0,
edin,1876,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016). In study 2, the test meal exhibited significantly lower AUCg and AUCi values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P = 0.0005), 0-60 min (P = 0.0002, P = 0.0025), and 0-90 min (P = 0.0396, P = 0.0246)."," AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, and 0-90 min in study 2 ", sucrose-containing meal , xylose-containing test meal ,0,
edin,1881,5291156,Cannot tell based on the abstract,, pain evaluated by VAS in the presence of sedation , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1881,5291156,No significant difference,"There were almost no differences in pain evaluated by VAS (2.27âÂ±â2.88 vs. 2.33âÂ±â2.63, Pâ=â0.85), pharyngeal observation time (72.0âÂ±â34.7 vs. 67.0âÂ±â27.8 seconds, Pâ=â0.15), and the number of gag reflexes (2.12âÂ±â2.58 vs. 1.68âÂ±â2.27, Pâ=â0.10) in the two groups.,Subgroup analysis for presence of sedation (223 cases) revealed almost no differences between the 2 groups in the number of pharyngeal observation sites (8.48âÂ±â2.16 vs. 8.79âÂ±â1.85, Pâ=â0.25), pain evaluated by VAS (1.08âÂ±â2.06 vs. 1.33âÂ±â2.16, Pâ=â0.79), pharyngeal observation time (73.3âÂ±â36.6 vs. 68.3âÂ±â30.9 seconds, Pâ=â0.14), and number of gag reflexes (2.02âÂ±â2.44 vs. 1.86âÂ±â2.45, Pâ=â0.63) (Tableâ4).", pain evaluated by VAS in the presence of sedation , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1916,3276929,Significantly decreased,Morning stiffness decreased more (P<0.001) in yoga (post 1=68.6% and post 2=98.1%) than control group (post 1=38.6% and post 2=71.6%)., Morning stiffness in participants with OA knees , control , yoga ,0,
edin,1855,5145296,Cannot tell based on the abstract,, foreign body sensation ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1855,5145296,Significantly increased,"Based on the results obtained byFisherâs exact test, the statistical difference between the drug and placebo groups in terms of presentationsâ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).", foreign body sensation ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1940,5340016,Significantly decreased,"However, weekly PE has a higher response rate and superior down-staging effects.", down-staging effect , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,2072,3921228,Significantly increased,Significant pre-post scan decreases in anxiety ratings and increases in happiness ratings were evident in the experimental versus control group., happiness  , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,1992,3232004,Cannot tell based on the abstract,, The response rate , placebo , sertraline ,0,
edin,1992,3232004,No significant difference,"The response rate was slightly higher for sertraline than for placebo, but this difference was not statistically significant (25/43 (58%) vs 18/46 (39%) responders, Ï2(1)=1.39, P=0.24).", The response rate , placebo , sertraline ,0,
edin,1976,5376493,Cannot tell based on the abstract,," Ã¢â¬Ëcommand roles and responsibilitiesÃ¢â¬â¢, Ã¢â¬Ëspeaking upÃ¢â¬â¢, Ã¢â¬ËdebriefingÃ¢â¬â¢, Ã¢â¬Ëfeedback and critiqueÃ¢â¬â¢, Ã¢â¬Ërealistic appraisal of stressÃ¢â¬â¢, and Ã¢â¬Ëdenial of stressÃ¢â¬â¢ ", medical seminar , non-technical skills seminar ,0,
edin,1976,5376493,No significant difference,"Data for âcommand roles and responsibilitiesâ, âspeaking upâ, âdebriefingâ, âfeedback and critiqueâ, ârealistic appraisal of stressâ, and âdenial of stressâ showed no significant effects between or within groups over time (.06"," Ã¢â¬Ëcommand roles and responsibilitiesÃ¢â¬â¢, Ã¢â¬Ëspeaking upÃ¢â¬â¢, Ã¢â¬ËdebriefingÃ¢â¬â¢, Ã¢â¬Ëfeedback and critiqueÃ¢â¬â¢, Ã¢â¬Ërealistic appraisal of stressÃ¢â¬â¢, and Ã¢â¬Ëdenial of stressÃ¢â¬â¢ ", medical seminar , non-technical skills seminar ,0,
edin,1886,4188762,Cannot tell based on the abstract,, heart rate ," normal saline, lidocaine, or ketamine ", remifentanil ,0,
edin,1886,4188762,No significant difference,There were no significant differences in mean blood pressure and heart rate before injection of pretreatment drugs among the groups (Figs. 1 and 2)., heart rate ," normal saline, lidocaine, or ketamine ", remifentanil ,0,
edin,2095,5360580,No significant difference,"In an intention-to-treat analysis including both mild AD (20Â â¤Â MMSE-JÂ â¤Â 23) and MCI (24Â â¤Â MMSE-JÂ â¤Â 27), no significant difference was shown between the treatment and placebo groups in the primary and secondary outcomes, with no severe adverse events in either group.", occurrence of adverse events , placebo , 1 mg/day of Pls purified from scallop ,0,
edin,1996,5808396,No significant difference,"Participants receiving CPT experienced moderate reductions in felt stigma relative to those in individual support (Cohenâs Dâ=â0.44, pâ=âvalueâ=â0.02) following the end of treatment, though this difference was no longer significant six-months later (Cohenâs Dâ=â0.45, pâ=âvalueâ=â0.12).", felt stigma after 6 months of treatment , baseline , Cognitive Processing Therapy or individual support ,0,
edin,1965,4723180,Cannot tell based on the abstract,, passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1965,4723180,Significantly decreased,"Regarding the swimmerâs head position, passive drag was found to be significantly lower in the LA condition (with the arms in front of the head) for the HD and HM than the HU at all speeds (Figure 2).", passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1951,3085176,Significantly increased,"In the group receiving 100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin, the RMR increased by 183 kcal, an increase that was statistically significant with respect to the placebo control (p<0.02).", Resting metabolic rates (RMR) , placebo , 1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin ,0,
edin,1932,4175246,Cannot tell based on the abstract,, anterior reach , baeeline , control group ,0,
edin,1932,4175246,Significantly increased,"After the intervention, anterior reach was significantly higher (p<0.05) in the control group.", anterior reach , baeeline , control group ,0,
edin,1959,4048120,Significantly increased,"At the moment of prosthetic loading, keratinized mucosa width and probing depth were higher in immediate implants than delayed implants, with statistically significant differences.", Keratinized mucosa width , implants were placed in healed sites , received implants immediately after extraction ,0,
edin,2094,5360580,Significantly increased,Patients with mild AD showed a significantly greater decrease in plasma PlsPE in the placebo group than in the treatment group., Plasma PlsPE , placebo , 1 mg/day of Pls purified from scallop ,0,
edin,2003,4845428,Significantly decreased,The levels of decompression determined by MRI + (PM or DTI) in the experimental group were significantly less than that determined by MRI + NE in the control group (pâ=â0.000)., levels of decompression  ,  MRI + NE , MRI + (PM or DTI) ,0,
edin,2032,4747995,No significant difference,"Productsâ systemic exposures were comparable, with 90Â % CIs around ratios for AUCinf (0.96; 90Â % CI 0.88â1.04) and Cmax (1.04; 90Â % CI 0.98â1.11) within standard bioequivalence bounds (90Â % CI 0.80â1.25).", Cmax , ch14.18-NCI , ch14.18-UTC ,0,
edin,2105,4760045,Significantly decreased,Postoperative VAS value at 18 h were significantly lower in group RD (P < 0.05)., VAS score , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,1945,4481831,Cannot tell based on the abstract,, peak value immediately after contact of the foot with the ground (PVF1) , baseline , after Ice application ,0,
edin,1945,4481831,Significantly increased,"The application of ice to the sole and calf increased PVF1 immediately following application (Table 3).,<td colspan=""1"" rowspan=""1""> PVF1 â Calf (BW)</td><td colspan=""1"" rowspan=""1""> 1.020Â±0.045</td><td colspan=""1"" rowspan=""1""> 1.030Â±0.045*</td><td colspan=""1"" rowspan=""1""> 1.017Â±0.039<sup>#</sup>
</td>", peak value immediately after contact of the foot with the ground (PVF1) , baseline , after Ice application ,0,
edin,1918,3276929,Significantly decreased,Diastolic blood pressure reduced (P<0.001) better in yoga group (post 1=â7.6% and post 2=â16.4%) than the control group (post 1=â2.1% and post 2=â5.0%)., Diastolic blood pressure , control , yoga ,0,
edin,1923,4374260,Significantly decreased,"On multivariate logistic regression analysis, baseline IELT was the only predictor of successful treatment of PE with both tramadol 50 mg (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.03-1.07, P < 0.001) and tramadol 100 mg (OR: 1.07, 95% CI: 1.04-1.11, P < 0.001).,PE was successfully treated in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 100 mg tramadol, respectively (P < 0.001 for all comparisons).", premature ejaculation (PE). , placebo  , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,2045,4121500,Cannot tell based on the abstract,," oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2045,4121500,No significant difference,"Incidence of oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine did not show any significant differences."," oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2034,3101755,Significantly decreased,Total epidural dose of fentanyl and bupivacaine required in Group A was significantly lower in comparison with Group B in 24 hours., Total epidural dose of fentanyl and bupivacaine , control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,1887,2742700,No significant difference,"Of the 24 subjects who completed the study, only 20% achieved the target blood pressure of <130/80 and there was no statistical difference in mean systolic and diastolic blood pressures among the three groups (p > 0.05).", mean systolic and diastolic blood pressure , usual care , nurse educator-conducted class and home blood pressure monitorization ,0,
edin,1897,5389230,Cannot tell based on the abstract,, Extubation times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,1897,5389230,No significant difference,"There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P > 0.05 [Table 4].", Extubation times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2098,3190091,Cannot tell based on the abstract,, seeing HIV prevention posters displayed on the walls , control , study-specific prevention activities ,0,
edin,2098,3190091,No significant difference,"As expected, high proportions of patrons at both intervention and control beer halls reported seeing HIV prevention posters displayed on the walls (74.2 vs. 65.5%, respectively, PÂ =Â 0.005), as these were placed in both intervention and control beer halls.", seeing HIV prevention posters displayed on the walls , control , study-specific prevention activities ,0,
edin,2044,4121500,Cannot tell based on the abstract,," bradycardia, hypoxemia, hypotension and hypertension ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2044,4121500,No significant difference,"There were no significant differences between two groups in the incidence of bradycardia, hypoxemia, hypotension and hypertension (Table 3)."," bradycardia, hypoxemia, hypotension and hypertension ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,1214,3743198,No significant difference,"The admission rate decreased by 8.3% in the intervention group (adjusted odds ratio 0.31, 95% confidence interval 0.13-0.70, p=0.005).", Admission rate , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
edin,1880,5291156,Cannot tell based on the abstract,, percentage of images of suitable quality at the right pyriform sinus , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1880,5291156,Significantly decreased,"The percentage of suitable quality images at the right pyriform sinus was significantly lower in the spray group compared to the combination group (82.8â% vs. 91.2â%, Pâ=â0.02).", percentage of images of suitable quality at the right pyriform sinus , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,2001,5012042,No significant difference,"Using the FG improved average navigator efficiency from 33âÂ±â15 to 58âÂ±â13Â % (pâ<â0.001) and improved SNR by 5Â % (pâ=â0.01) compared to acquisitions with NF.,There was no difference in navigator efficiency (pâ=â0.90) or SNR (pâ=â0.77) between untrained and trained participants for FG acquisitions.", navigator efficiency and signal-to-noise ratio (SNR) , no off-scanner training , xtensive off-scanner training with the FG using a MRI simulator ,0,
edin,2104,4760045,Cannot tell based on the abstract,, suffered from bradycardia , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,2104,4760045,Significantly increased,"Again group RD suffered from bradycardia, which was statistically higher (P < 0.05) than group RC.", suffered from bradycardia , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,1898,5389230,No significant difference,"Extubation, emergence, and discharge times were comparable in both groups, and none of the subjects reported any adverse effects.", Discharge times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2036,5609057,Cannot tell based on the abstract,, Mean score of general symptoms , placebo , extract of three Cretan herbs ,0,
edin,2036,5609057,Significantly decreased,"Mean score of general symptoms was 19.1 (SE: 0.9) in day one, dropping to 8.6 (SE: 0.6) and 3.1 (SE: 0.4) in days 4 and 7 respectively, illustrating a decrease by 55.0% in day 4 and by 83.8% in day 7 (pÂ <Â 0.001 for all paired differences).", Mean score of general symptoms , placebo , extract of three Cretan herbs ,0,
edin,1905,3000449,Cannot tell based on the abstract,, Patient being held responsible for the weight-related symptoms , Interaction with a non-obese patient in a digital environment , Interaction with an obese patient in a digital environment ,0,
edin,1905,3000449,Significantly increased,"That is, the obese patient was held significantly more responsible for causing her shortness of breath, F(1,73)=26.37, p<.0001, and her knee pain, F(1,73)=36.11, p<.0001, but there was no difference in student ratings of the obese and non-obese patients' responsibility for causing the eczema.", Patient being held responsible for the weight-related symptoms , Interaction with a non-obese patient in a digital environment , Interaction with an obese patient in a digital environment ,0,
edin,1875,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016).", glucose concentration at 120 minutes in study 1 , sucrose solution , xylose-containing solution ,0,
edin,2000,5012042,No significant difference,There were no differences in longitudinal strain (pâ=â0.38)., longitudinal strain , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF)  , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG) ,0,
edin,2037,4477402,Significantly decreased,Length of ICU stay was significantly higher in late extubation group (4.2 Â± 1.2 days) than the UFE group (1.72 Â± 1.5 days) (P = 0.02)., Length of ICU , Late extubation  , Ultra fast-track extubation (UFE) ,0,
edin,2073,3921228,Cannot tell based on the abstract,, POMS depression , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2073,3921228,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">POMS</td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>,The increase in happiness was significantly greater in the experimental compared to control group (t(19)â=â2.33, pâ=â0.01), while the change in POMS depression between groups failed to reach significance (t(19)â=â1.33, pâ=â0.10).", POMS depression , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2074,3921228,Cannot tell based on the abstract,Significant pre-post scan decreases in anxiety ratings and increases in happiness ratings were evident in the experimental versus control group., state anxiety , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2074,3921228,Significantly decreased,"Significant decreases were also found within the experimental group for ratings of POMS anger (t(13)â=â2.42, pâ=â0.015), trait anxiety (STAI-Trait subscale; t(13)â=â2.62, pâ=â0.01), state anxiety (STAI-Trait subscale; t(13)â=â2.34, pâ=â0.02), and VAS ratings of restlessness (t(13)â=â2.23, pâ=â0.02), anxiety (t(13)â=â4.37, p<0.001), and irritability (t(13)â=â2.14, pâ=â0.025), and the difference between the groups on state anxiety was significant t(19)â=â2.58, pâ=â0.03).", state anxiety , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,1878,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016)."," AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, 0-90 min, and 0-120 min in study 1 ", sucrose solution , 5 g xylose-containing solution ,0,
edin,2035,3101755,Cannot tell based on the abstract,," pruritus, nausea, vomiting during first 24 h ", control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2035,3101755,Significantly decreased,Pruritus was significantly less in Group A compared with Group B. The incidence of nausea and vomiting was also significantly less in Group A in comparison with the control.," pruritus, nausea, vomiting during first 24 h ", control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2021,5614293,Significantly increased,"The mean score of final visual acuity was 0.293Â±0.11 in the IVT group, 0.25Â±0.10 in the IVB group and 0.48Â±0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p<0.001).", The mean score of final visual acuity , intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB) , combination of IVT and IVB ,0,
edin,1894,5389230,Cannot tell based on the abstract,, Emergence agitation  , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,1894,5389230,Significantly decreased,The median four-point agitation scales and the median scores of FLACC pain scales of Group D were significantly lower than those of Group C at the all six time points with P < 0.05., Emergence agitation  , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2091,5452066,Cannot tell based on the abstract,, median PFS (Progression-free survival) , topotecan , PM01183 ,0,
edin,2091,5452066,Significantly increased,"Median PFS was 4.0âmonths (95% CI, 2.7â5.6âmonths) (Figure 2A). Median OS was 10.6âmonths (95% CI, 9.5â18.1âmonths). Table 2,In the second randomized stage, median PFS was significantly longer with PM01183: 3.9âmonths (95% CI, 2.5â5.7âmonths) versus 2.0âmonths (95% CI, 1.4â2.8âmonths) with topotecan (Pâ=â0.0067).", median PFS (Progression-free survival) , topotecan , PM01183 ,0,
edin,2057,4045752,No significant difference,The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (pâ=â0.34) from the level in the control group., The anti-HBs level  , The control group received no paracetamol. , paracetamol for 6 hours after (therapeutic use)  vaccination ,0,
edin,1870,3657931,No significant difference,No significant difference in the induction dose of propofol was observed when assessed clinically (loss of verbal response) or by BIS monitoring., mean dose of propofol required for induction , propofol induction guided by clinical signs , propofol induction guided by BIS ,0,
edin,2086,4342682,Significantly increased,"A logistic regression analysis indicated that the odds of participants choosing the best treatment were 2.25 times higher in the unconscious-thought condition compared to the immediate-decision condition (b=.81, Wald=4.32, P=.04, 95% CI 1.048-4.836), and 2.39 times greater compared to the conscious-thought condition (b=.87, Wald=4.87, P=.027, 95% CI 1.103-5.186).", choosing the best treatment , conscious-thought condition , unconscious-thought condition ,0,
edin,2068,5659064,Cannot tell based on the abstract,, Inspiratory muscle strength , PLACEBO ," oral nutritional supplementation, enriched with leucine, vitamin D, and omegaÃ¢â¬ï¿½3 fatty acids (NUTRITION) ",0,
edin,2068,5659064,Significantly increased,Inspiratory muscle strength improved significantly only in NUTRITION (Figure 4)., Inspiratory muscle strength , PLACEBO ," oral nutritional supplementation, enriched with leucine, vitamin D, and omegaÃ¢â¬ï¿½3 fatty acids (NUTRITION) ",0,
edin,1938,5340016,Significantly decreased,"The overall clinical response rate was significantly higher in the PE arm than in the FEC arm (76.06% vs. 59.95%, PÂ =Â 0.001).", The clinical response rates , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,2024,3178704,Cannot tell based on the abstract,," weight, BMI, body fat, waist circumference, and visceral fat area (VFA) ", baseline , the diet only (DO) ,0,
edin,2024,3178704,Significantly increased,"Significant increases in weight, BMI, body fat, waist circumference, and visceral fat area (VFA) as measured by CT were observed in the DO group while their glucose area under the curve (AUC) decreased from the baseline value."," weight, BMI, body fat, waist circumference, and visceral fat area (VFA) ", baseline , the diet only (DO) ,0,
edin,1977,5376493,Cannot tell based on the abstract,, Ã¢â¬ËTeamworkÃ¢â¬â¢ over time , medical seminar , non-technical skills seminar ,0,
edin,1977,5376493,Significantly decreased,"Teamworkâ decreased significantly over time in the NTS group (t(42) = 2.26, p = .03, r = 0.33), but not in the control group (t(33) = 1.15, p=.26, r=0.20).", Ã¢â¬ËTeamworkÃ¢â¬â¢ over time , medical seminar , non-technical skills seminar ,0,
edin,2089,4471244,Cannot tell based on the abstract,, Mortality , placebo , thiamine ,0,
edin,2089,4471244,No significant difference,"Mortality in the thiamine and placebo groups was 13% and 46%, respectively (P = 0.10).", Mortality , placebo , thiamine ,0,
edin,1943,5340016,Significantly increased,"Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm (PÂ <Â 0.001).", the post-chemotherapy pathologic T and N stages , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,1309,3258678,Cannot tell based on the abstract,, Clinical Dementia Rating â Sum of Boxes (CDR-SB) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1309,3258678,No significant difference,"Neither the planned G Ã V interaction (P = 0.573) nor the planned contrast for the primary CDR-SB outcome at Week 78 (100 mg vs. Placebo: P = 0.405; 150 mg vs. Placebo: P = 0.837) revealed a statistically significant treatment effect.,No statistical difference relative to placebo was observed for any of the secondary CDR-SB outcomes.", Clinical Dementia Rating â Sum of Boxes (CDR-SB) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1988,5193306,No significant difference,"All the participants in this study improved their IBS symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms."," irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea) ", standard Ã¢â¬Ëgut-directedÃ¢â¬â¢ hypnotherapy , Ã¢â¬ËindividualisedÃ¢â¬â¢ (holistic) hypnotherapy ,0,
edin,1937,4094699,Significantly increased,"By comparing the physical fitness indices, it was found that the increase of the results of sit-and-reach test in the intervention group had statistical significance (P = 0.001).", the results of sit-and-reach test , control , Baduanjin exercise ,0,
edin,2031,4747995,No significant difference,"Productsâ systemic exposures were comparable, with 90Â % CIs around ratios for AUCinf (0.96; 90Â % CI 0.88â1.04) and Cmax (1.04; 90Â % CI 0.98â1.11) within standard bioequivalence bounds (90Â % CI 0.80â1.25).", AUCinf , ch14.18-NCI , ch14.18-UTC ,0,
edin,1982,4227976,Significantly increased,A significant difference between the two groups regarding sexual satisfaction after the intervention (p=0.003) compared to the beginning of the study (p=0.356)., mean score of sexual satisfaction , control , Sildenafil citrate and Elaeagnus angustifolia flower extract ,0,
edin,1967,4723180,Cannot tell based on the abstract,, passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1967,4723180,Significantly decreased,"Regarding the swimmerâs head position, passive drag was found to be significantly lower in the LA condition (with the arms in front of the head) for the HD and HM than the HU at all speeds (Figure 2).", passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,2038,4477402,No significant difference,"In survival analysis there was no significant difference between ultra-fast and late extubation groups (Log-rank test, P = 0.9).", The length of survival , Late extubation  , Ultra fast-track extubation (UFE) ,0,
edin,1893,3687261,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P < 0.01 for each) and were lowest after SX (P < 0.05 for each), while overall blood glucose was lower after SX than PC (P < 0.05).", amplitude of glycemic excursion , placebo and sucralose , sitagliptin and d-xylose ,0,
edin,2076,4628236,Cannot tell based on the abstract,, expression of PDE-5 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2076,4628236,Significantly decreased,"Application of cinaciguat in diabetic animals significantly reduced the expression of PDE-5, markedly increased PKG activity (as indicated by elevated p-VASP/VASP ratio) (Fig.Â 3a), while the expression of PKG did not differ between the two diabetic groups (Fig.Â 3a).Fig.Â 3", expression of PDE-5 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,1964,3293139,Significantly decreased,"Responses to the COS-LC collected before the incidence round were statistically significantly different on the scales âanxietyâ, âbehaviourâ, âdejectionâ, âself-blameâ, âfocus on airway symptomsâ and âintrovertâ, with the control group reporting higher negative psychosocial consequences.", negative psychosocial consequences , control group , screen group ,0,
edin,1931,4175246,Cannot tell based on the abstract,," anterior, non-paretic and paretic reach ", baseline ,"  task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ",0,
edin,1931,4175246,Significantly increased,"After intervention, anterior, non-paretic and paretic reach were significantly higher in the experimental group (p<0.05)."," anterior, non-paretic and paretic reach ", baseline ,"  task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ",0,
edin,1924,4374260,Significantly increased,"Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of those using 50 and 100 mg tramadol, respectively (P = 0.002).", Weak scanty ejaculation , placebo , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,1960,4048120,No significant difference,"Peri-implant health showed no statistically significant differences for any of the studied parameters (crevicular fluid volume, plaque index, gingival retraction, keratinized mucosa, probing depth, modified gingival index and presence of mucositis) at the twelve-month follow-up.", Modified gingival index , implants were placed in healed sites , received implants immediately after extraction ,0,
edin,2019,4235088,Significantly decreased,"PHES significantly improved after medication in all the three groups (Gp-LPr: â3.8 Â± 3.9 to â1.6 Â± 3.0; Gp-L: â4.8 Â± 4.1 to â1.6 Â± 2.9; and Gp-Pr: â4.9 Â± 3.7 to â2.1 Â± 2.5, P < 0.001). After 8 weeks follow-up, improvement was maintained in Gp-LPr and Gp-Pr, but there was deterioration in those who did not receive probiotics (Gp-L: PHES score reversed to â4.8 Â± 4.2).", psychometric hepatic encephalopathy score (PHES) after 8 weeks , baseline , receive lactulose (30Ã¢â¬â60 mL/day) + probiotic (200 million colony forming units of seven bacteria species/day) (Gp-LPr)  or probiotic alone (Gp-Pr) ,0,
edin,2033,3101755,Significantly increased,A significant increase in the mean and maximum duration of analgesia in Group A in comparison with Group B (P<0.05) was observed., the mean and maximum duration of analgesia , control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2119,5437665,Significantly decreased,"In addition, the physical activity level was significantly decreased in patients from simvastatin group when compared to those from red yeast rice group.", Level of physical activity , Red yeast rice , Simvastatin ,0,
edin,2207,4064763,Cannot tell based on the abstract,, Mean drug dose , 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2207,4064763,Significantly increased,"Mean drug dose was 28.98 drops in group A, and 24.29 drops in group B, and the difference between the two groups was statistically significant (p= 0.042).", Mean drug dose , 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2282,5589093,Cannot tell based on the abstract,, cardiorespiratory complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2282,5589093,No significant difference,"A difference between the proportions of cardiorespiratory complications in the usual care group (54%) compared to GDT (27%) was noticed, which did not achieve statistical significance (p = 0.066).", cardiorespiratory complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2199,5320759,No significant difference,"The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05),"," The intubation success rates at the first, second, and third attempt ",  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2252,3467590,Significantly increased,"For A1c control, medication intensification increased in both groups (intervention, pre 26.4% vs post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%, p=0.033) (intervention, adjusted OR (AOR) 1.37; 95% CI 1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89)); however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948).", medication intensification , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2305,3747462,Cannot tell based on the abstract,," RBCs count, PCV %, and Hb concentration ", control , Vaccinated group ,0,
edin,2305,3747462,Significantly increased,"Compared to normal control group (1) before challenge, red blood cell count (RBC), packed cell volume (PCV) %, and haemoglobin (Hb) concentration showed significant increase in glycyrrhizin-treated group (2) from the 1st till the 3rd week. G"," RBCs count, PCV %, and Hb concentration ", control , Vaccinated group ,0,
edin,2300,5509597,Significantly increased,he experimental group showed significant improvements in the variations of muscle activity and proprioception compared to the control group., muscle activity and proprioception , neurodevelopmental treatment , motor imagery training  ,0,
edin,2223,3804449,Significantly increased,"All caregiver outcome variables improved in the intervention group more than in the control. Home safety was significant at P â¤ 0.001, caregiver strain at P â¤ 0.001, and caregiver self-efficacy at P = 0.002.", caregiver self-efficacy , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2212,5308129,Significantly increased,"In comparison with lactulose alone, PEG-lactulose could improve HESA score in 24 hours more effectively (p =0.04).", Hepatic Encephalopathy Scoring Algorithm (HESA) score ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes  ",0,
edin,2281,5589093,Cannot tell based on the abstract,, electrolyte derangements , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2281,5589093,Significantly decreased,Patients in the usual care group were significantly more likely to develop electrolyte derangements: GDT (27%) vs. usual care (62%) (p = 0.012)., electrolyte derangements , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2271,5589093,Cannot tell based on the abstract,, intraoperative ephedrine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2271,5589093,No significant difference,Eleven patients (42%) received intraoperative ephedrine in the GDT group vs. 7 patients (27%) in the usual care (p = 0.125)., intraoperative ephedrine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2162,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2143,5867479,Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P<0.01)., Levels of NGF , Normal saline (control group) , Dexmedetomidine ,0,
edin,2217,3556334,Significantly decreased,"After 12âweeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain (kg)â+â3.75, (3.16 â 4.34) versusâ+â2.61 (95% CI 1.99 â 3.23) p 0.009 and lesser residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), p 0.035.", number of zones involved , placebo for 2 doses ," 600,000Ã¢â¬â°IU of Intramuscular vitamin D3 ",0,
edin,2157,5174811,Significantly decreased,"ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2133,4860224,No significant difference,"Most were Hispanic (68%), single (61%), primiparous (39%), and without high school diploma (44%). 35 (21%) neonates in the intervention group and 41 (27%) in the control group were brought at least once for a NUC to the ED (p = 0.12).", Nonurgent ED visit , Routine anticipatory guidance program , Intensified anticipatory guidance program ,0,
edin,2175,5174811,Significantly decreased,"Data for 1792 patients were evaluated. E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2299,5509597,No significant difference,"Only the experimental group showed significant improvements in proprioception.,The experimental group showed significant improvements in the variations of muscle activity and proprioception compared to the control group.", improvement in proprioception , baseline , control group ,0,
edin,2187,4509558,No significant difference,"At the end point, 22 patients (78.6Â %) in SG group and 23 patients (85.2Â %) in RYGB group achieved complete remission of diabetes mellitus with HbA1câ<â6.0Â % (Pâ=â0.525)", Glycated hemoglobin A1c (HbA1c) , Roux-en-Y gastric bypass (RYGB) procedure , laparoscopic sleeve gastrectomy (SG) ,0,
edin,2176,5174811,Significantly decreased,"n the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (â0.19 vs â0.02; p<0.01) and phlegm (â0.19 vs â0.02; p<0.05).", Morning cough severity and phlegm , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2274,5589093,Cannot tell based on the abstract,, volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2 , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2274,5589093,No significant difference,"<td align=""left"" colspan=""5"" rowspan=""1""><bold>Day 2</bold></td>", volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2 , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2231,4056626,Cannot tell based on the abstract,, cough reflex , propofol and remifentanil , 100 ÃÂ³/kg/min of racemic ketamine for 10&amp;nbsp;minutes  ,0,
edin,2231,4056626,Significantly decreased,"Following ketamine administration (T2), ICP did not modify (11.7âÂ±â7.3 vs. 11.0âÂ±â6.4Â mmHg; Pâ=â0.28); after ETS (T3) cough reflex was significantly reduced in comparison with controls (cough score 4 (IQR 3 to 4) vs. 2 (IQR1 to 2); P <0.0001) (FigureÂ 6).", cough reflex , propofol and remifentanil , 100 ÃÂ³/kg/min of racemic ketamine for 10&amp;nbsp;minutes  ,0,
edin,2286,5337766,Significantly increased,A significantly higher number of large-sized follicles was observed in group D than in group B (P=0.036)., number of large-sized follicles , groups B(hFSH) and C (rFSH) , group D Human Follicle Stimulating Hormone/ Recombinant human follicle stimulating hormone (hFSH/rFSH) ,0,
edin,2130,5787910,Cannot tell based on the abstract,, Frequency of side effects , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2130,5787910,Significantly increased,"As shown in Table 1, considering the significance level of 5%, a significant difference can be seen in the frequency of side effects dry mouth, dry nose, repeated rhinorrhea, and hair thinning and loss in both groups (P < 0.05), so that the frequency of side effects in the group receiving a higher dose of the drug (the second group) was more than the group receiving the low dose of the drug (the first group).", Frequency of side effects , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2269,5589093,Cannot tell based on the abstract,, intraoperative metaraminol , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2269,5589093,Significantly decreased,Three patients (12%) in the GDT group received intraoperative metaraminol vs. 23 patients (88%) in the usual care group (p<0.0001)., intraoperative metaraminol , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2147,5029935,No significant difference,"Higher LTOT duration analyzed as a continuous variable was not associated with any change in mortality rate (hazard ratio [HR] 1.00; (95% confidence interval [CI], 0.98 to 1.02) per 1 h/day increase above 15 h/day.,Mortality was similar between the groups for all-cause, respiratory and cardiovascular mortality.", Mortality rates , Long-term oxygen therapy 24 h/day , Long-term oxygen therapy 15 h/day ,0,
edin,2129,5787910,Cannot tell based on the abstract,, Patients' satisfaction score , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2129,5787910,Significantly decreased,"Considering the significance level of 5%, a significant difference can be observed between patients' satisfaction in the two treatment groups (P < 0.05), so the average of patients' satisfaction score in the first group (mean = 4.78, SD = 0.4) was significantly higher than the second group (mean = 4.43, SD = 0.6) (P = 0.02), which shows that the satisfaction of patients treated with lower doses of medication (Group I) was higher than patients treated with higher doses of the drug (Group II).", Patients' satisfaction score , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2296,5337626,Cannot tell based on the abstract,, the proportions of R0 resections ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2296,5337626,No significant difference,"When the comparison was repeated including only patients who underwent a resection (R0 vs R1), the proportions of R0 resections were again similar between the groups (321 [75%] of 429 patients in the chemotherapy alone group vs 305 [75%] of 405 in the chemotherapy plus bevacizumab group).", the proportions of R0 resections ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2246,5372977,Significantly increased,Six days of BR ingestion effectively improves high-intensity intermittent type exercise performance in trained soccer players., High-intensity intermittent running performance as assessed by the Yo-Yo IR1 , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2244,5372977,Significantly increased,"Six days of BR ingestion increased plasma and salivary nitrate and nitrite concentrations in comparison to PLA (p < 0.001), and enhanced Yo-Yo IR1 test performance by 3.4 Â± 1.3% (from 1574 Â± 47 to 1623 Â± 48 m; p = 0.027).", plasma and salivary nitrate and nitrite concentrations , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2256,3467590,Cannot tell based on the abstract,, haemogloblin A1c (%) among patients with worse glucose control - &amp;gt;9% , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2256,3467590,Significantly increased,"In the unadjusted analysis and among patients with worse glucose control (A1c >9%), intensification of medications to control A1c increased in both trial arms between baseline and follow-up (intervention, pre 34.8% vs post 62.5%, p=0.002; control, pre 35.7% vs post 61.4%, p=0.008; figure 3 top panel).", haemogloblin A1c (%) among patients with worse glucose control - &amp;gt;9% , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2289,5695666,Cannot tell based on the abstract,, weight  after 1 year , baseline , moderate-to-vigorous intensity physical activity (MVPA) ,0,
edin,2289,5695666,Significantly decreased,"Year 1 PA was significantly associated with 1-year weight change (r=0.23, p<0.0001), and this relationship was further strengthened after controlling for baseline PA and demographic factors (r=0.34, p<0.0001).", weight  after 1 year , baseline , moderate-to-vigorous intensity physical activity (MVPA) ,0,
edin,2292,1971065,Significantly increased,"At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were significantly greater (Fisher's exact test), and SIGH-SAD scores, as percent individual score at randomization, were significantly lower (t-test), with active treatment than with control, both in an intent-to-treat analysis and an observed cases analysis.", amount of remission of Seasonal Affective Disorder (SAD) , control treatment , efficient light-emitting diodes (LEDs) ,0,
edin,2221,3804449,Cannot tell based on the abstract,, home environmental safety , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2221,3804449,Significantly increased,"After controlling for the effects of caregiver age, and baseline measures of caregiver self-efficacy, baseline caregiver strain, and baseline home safety, caregivers who receive the Home Safety Toolkit will have improved home environmental safety higher postintervention self-efficacy, and lower postintervention caregiver strain than the control group which receives standard patient education.,Caregivers in the intervention group had significantly improved home environmental safety (P â¤ 0.000) higher caregiver self-efficacy (P â¤ 0.002), and lower caregiver strain (P â¤ 0.000) than caregivers in the control group.", home environmental safety , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2227,4477338,Cannot tell based on the abstract,, percent suppression of Endogenous Glucose Production (EGP) , placebo ,  3.9 g/day EPA+DHA ,0,
edin,2227,4477338,Significantly increased,"Hepatic insulin sensitivity, determined from the suppression of endogenous glucose production by insulin, exhibited a small but significant improvement with EPA+DHA compared with placebo.", percent suppression of Endogenous Glucose Production (EGP) , placebo ,  3.9 g/day EPA+DHA ,0,
edin,2153,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2173,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2290,5695666,Cannot tell based on the abstract,, weight  after 1 year , moderate-to-vigorous intensity physical activity (MVPA) &amp;lt;50 min/week  , moderate-to-vigorous intensity physical activity (MVPA) 50 - 150 min/week  ,0,
edin,2290,5695666,Significantly decreased,"Year 1 PA was significantly associated with 1-year weight change (r=0.23, p<0.0001), and this relationship was further strengthened after controlling for baseline PA and demographic factors (r=0.34, p<0.0001).,The PA groups were as follows: <50 min/week (n=188), 50 to <150 min/week (n=167), 150 to <250 min/week (n=83), and â¥250 min/week (n=115). Participants engaging in 150 to <250 or â¥250 min/week of MVPA had significantly greater WL at 1-year compared to those engaging in <50 or 50 to <150 min/week. Similar findings were observed when the change in PA from baseline to 1-year was examined â participants with greater improvements in PA also had better WL at Year 1 (adjusted r=0.34, p<0.001).", weight  after 1 year , moderate-to-vigorous intensity physical activity (MVPA) &amp;lt;50 min/week  , moderate-to-vigorous intensity physical activity (MVPA) 50 - 150 min/week  ,0,
edin,2206,4064763,No significant difference,"After intervention, variables including: induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation), in the two groups, were found to be the same (P < 0.05)."," induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation) ", 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2169,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2302,4025600,Cannot tell based on the abstract,," HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides  ", low-carbohydrate diet (LCD) , traditional low-fat diet (LFD) ,0,
edin,2302,4025600,No significant difference,"<td colspan=""1"" rowspan=""1"">â
<italic>P</italic> within group</td><td colspan=""1"" rowspan=""1"">NS</td><td colspan=""1"" rowspan=""1"">NS</td><td colspan=""1"" rowspan=""1""></td>"," HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides  ", low-carbohydrate diet (LCD) , traditional low-fat diet (LFD) ,0,
edin,2266,5589093,Significantly decreased,Intraoperative fluid balance was 1005mL (475:1873) in the GDT group vs. 3300mL (2474:3874) in the usual care group (p<0.0001)., intraoperative fluid balance , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2214,5308129,Cannot tell based on the abstract,, blood level of ammonia ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ",0,
edin,2214,5308129,No significant difference,"In addition, baseline lab data including blood level of ammonia was similar between PEG-lactulose group and lactulose group (tables 2 and 3).,<td colspan=""1"" rowspan=""1"">Length of hospital stay, mean (SE), day</td><td colspan=""1"" rowspan=""1"">7.8 (0.4)</td><td colspan=""1"" rowspan=""1"">8.9 (0.7)</td><td colspan=""1"" rowspan=""1"">6.8 (0.5)</td><td colspan=""1"" rowspan=""1"">*0.03</td>,There was no significant change in the blood level of ammonia after 24 hours between the treatment groups (p =0.858, table 3).", blood level of ammonia ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ",0,
edin,2248,3373832,Cannot tell based on the abstract,, PRTEE , Waitlist , dextrose prolotherapy ,0,
edin,2248,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05), and improved pain and function PRTEE subscale scores (p<0.05) at 4 and 16 weeks, respectively.", PRTEE , Waitlist , dextrose prolotherapy ,0,
edin,2215,4313493,Significantly decreased,IOP lowering with bimatoprost (8.9 Â± 1.598 mm Hg) was significantly (P < 0.0001) higher than brimonidine (6.55 Â± 1.26 mm Hg)., IOP (intraocular pressure) , group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks , group A bimatoprost 0.03% eye drops once daily for a period of 4 weeks ,0,
edin,2291,1971065,Significantly increased,"At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were significantly greater (Fisher's exact test),", amount of remission of Seasonal Affective Disorder (SAD) , control treatment , efficient light-emitting diodes (LEDs) ,0,
edin,2184,3118076,No significant difference,"The success rate in group I was found to be 80%, which was lower than the success rate in group II which was found to be 90%. On comparison, there is no statistically significant difference in success rate between the two study groups.", Rate of success , Delayed loading implants (group II) , Immediate loading implants (group I) ,0,
edin,2285,5337766,Significantly increased,The serum estradiol level was significantly higher in group D than in groups B and C (P=0.005)., The serum estradiol level , groups B ( hFSH) and C(rFSH) , group D Human Follicle Stimulating Hormone/  Recombinant human follicle stimulating hormone (hFSH/rFSH) ,0,
edin,2158,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2197,5320759,No significant difference,The overall success rate of intubation was not significantly different between the two groups (P > 0.05)., success rate of intubation ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2194,3735552,Significantly decreased,"Mean duration of antibiotic exposure was reduced from 6.3 to 4.5 days under PCT guidance (â1.8 days; 95% CI â3.1, â0.5; Pâ=â0.039) for all LRTI and from 9.1 to 5.7 days for pneumonia (â3.4 days 95% CI â4.9, â1.7; P<0.001).", The mean duration of antibiotic exposure in the subgroup of community-acquired pneumonia (CAP) patients , standard care clinical guidelines , PCT guidance algorithm established for adult LRTI in the subgroup of community-acquired pneumonia (CAP) patients ,0,
edin,2254,3467590,No significant difference,"A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.", intensification of medications to control BP , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2114,5437665,Significantly increased,"At the end of study, the fatigue score was significantly increased in patients treated with simvastatin, whereas no significant change was observed in patients receiving red yeast rice.", Fatigue score at week 4 , Red yeast rice , Simvastatin ,0,
edin,2307,3747462,Cannot tell based on the abstract,, activities of AST and ALT , control , Vaccinated group ,0,
edin,2307,3747462,Significantly increased,"Before challenge, compared to normal control group (1), activities of AST and ALT showed significant increases in vaccinated groups (3) at the 1st and 2nd weeks.", activities of AST and ALT , control , Vaccinated group ,0,
edin,2142,5867479,Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P<0.01)., Levels of S100B , Normal saline (control group) , Dexmedetomidine ,0,
edin,2188,4509558,No significant difference,"Change in HbA1c, FBG and C peptide were comparable in the two groups."," HbA1c, FBG and C peptid ", Roux-en-Y gastric bypass (RYGB) procedure , laparoscopic sleeve gastrectomy (SG) ,0,
edin,2170,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2279,5589093,Cannot tell based on the abstract,, delayed gastric emptying , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2279,5589093,No significant difference,Three patients (12%) in the GDT group developed delayed gastric emptying vs. 6 patients (23%) in the usual care group (p = 0.213)., delayed gastric emptying , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2306,3747462,Cannot tell based on the abstract,, Serum Creatinine and Uric Acid , control , Vaccinated group ,0,
edin,2306,3747462,Significantly increased,"Before challenge, compared to normal control group (1), vaccinated group (3) showed significant increase in uric acid and creatinine at the 1st week and at the 1st and 2nd weeks, respectively.", Serum Creatinine and Uric Acid , control , Vaccinated group ,0,
edin,2262,4379665,Significantly increased,The following post hoc Tukey's test confirmed that Group 2 (SAF) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested., debris extrusion ," Group 2: Self-adjusting file (SAF; ReDent-Nova, RaÃ¢â¬â¢anana, Israel) (1.5 mm) Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25/06) "," Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25/08),  ",0,
edin,2249,3373832,Cannot tell based on the abstract,, pain and function PRTEE subscale scores at 4 and 16 weeks , Waitlist , dextrose prolotherapy ,0,
edin,2249,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05),", pain and function PRTEE subscale scores at 4 and 16 weeks , Waitlist , dextrose prolotherapy ,0,
edin,2202,5372065,Cannot tell based on the abstract,, weight loss , baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2202,5372065,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Weight, kg</td><td colspan=""1"" rowspan=""1"">248</td><td colspan=""1"" rowspan=""1"">â0.7 (â1.2 to â0.3)**</td><td colspan=""1"" rowspan=""1"">250</td><td colspan=""1"" rowspan=""1"">â1.7 (â2.5 to â1.0)***</td><td colspan=""1"" rowspan=""1"">247</td><td colspan=""1"" rowspan=""1"">â1.6 (â2.5 to â0.8)***</td>,*p<0.05; **p<0.01; ***p<0.001.,Participants with diabetes had significant, sustained, and progressive weight loss compared with baseline at 6, 12, and 24âmonths (mean â1.2âkg, â1.5âkg, and â3.7âkg, respectively) across all intervention groups.,At 24-month follow-up (data not shown), it was â5.2âkg (95% CI â9.6 to â0.8, p=0.2) for the group weight loss program (n=18); â2.2âkg (95% CI â4.6 to 0.1, p=0.06) for the combination weight loss program (n=25); and â3.8âkg (95% CI â5.9 to â1.8, p<0.001) for the maintenance of lifestyle intervention program (n=50).", weight loss , baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2228,3329148,Significantly increased,The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05)., H. pylori eradication rate ," Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2272,5589093,Cannot tell based on the abstract,, dopamine and/or dobutamine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2272,5589093,Significantly increased,"Similarly, the use of dopamine and/or dobutamine was significantly higher in the GDT group compared to the usual care group: 12 patients (46%) vs. 1 patient (4%) (p = 0.007). Use of intraoperative beta-blockers was similar between groups.", dopamine and/or dobutamine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2222,3804449,Significantly increased,"All caregiver outcome variables improved in the intervention group more than in the control. Home safety was significant at P â¤ 0.001, caregiver strain at P â¤ 0.001, and caregiver self-efficacy at P = 0.002.", caregiver strain  , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2238,3210325,Cannot tell based on the abstract,, Depression ratings , received an Attention bias modification procedure designed to induce a bias in attention toward negative material , received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures ,0,
edin,2238,3210325,Significantly decreased,"Depression ratings also increased more following negative ABM [t(56) = â7.1, p < .001, Cohen's d = .95] than positive ABM [t(58) = â3.6, p < .001, Cohen's d = .47].", Depression ratings , received an Attention bias modification procedure designed to induce a bias in attention toward negative material , received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures ,0,
edin,2198,5320759,Significantly increased,"The incidences of dry throat, sore throat, and hoarseness were higher in the T group (all P < 0.05)."," the frequencies of dry throat, sore throat and hoarseness ",  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2127,5787910,No significant difference,The average severity of acne in the two treatment groups did not differ significantly within any of the study periods., Mean acne severity , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2203,5372065,Cannot tell based on the abstract,," Systolic BP, mmÃ¢â¬â¦Hg ", baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2203,5372065,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Systolic BP, mmâHg</td><td colspan=""1"" rowspan=""1"">249</td><td colspan=""1"" rowspan=""1"">â6.4 (â8.7 to â4.1)***</td><td colspan=""1"" rowspan=""1"">251</td><td colspan=""1"" rowspan=""1"">â6.2 (â9.0 to â3.3)***</td><td colspan=""1"" rowspan=""1"">250</td><td colspan=""1"" rowspan=""1"">â7.3 (â9.9 to â4.6)***</td>,Among all participants, there was a statistically significant reduction in systolic BP of about 6 to 7âmmHg across all follow-up time points."," Systolic BP, mmÃ¢â¬â¦Hg ", baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2179,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2200,5320759,Significantly increased,"he intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).", The intubation time at the second attempt ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2295,5337626,Cannot tell based on the abstract,, patients achieving pathological tumour responses ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2295,5337626,No significant difference,The proportion of patients achieving pathological tumour responses were also similar between the groups (147 [33%] of 452 patients in the chemotherapy alone group vs 135 [30%] of 443 in the chemotherapy plus bevacizumab group; p=0Â·51)., patients achieving pathological tumour responses ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2284,5337766,Significantly increased,The duration of stimulation was significantly longer in group C than in groups A and D (P=0.030)., The duration of stimulation , groups A (hMG) and D (hFSH/rFSH) , group C Human Follicle Stimulating Hormone (hFSH) ,0,
edin,2250,3373832,Cannot tell based on the abstract,, pain and function PRTEE subscale scores at 4 and 16 weeks , baseline , dextrose prolotherapy ,0,
edin,2250,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05), and improved pain and function PRTEE subscale scores (p<0.05) at 4 and 16 weeks, respectively.", pain and function PRTEE subscale scores at 4 and 16 weeks , baseline , dextrose prolotherapy ,0,
edin,2165,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2230,3329148,No significant difference,There was no significant difference in total score descending of symptoms between each group (P > 0.05)., total score descending of symptoms ," Group C received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for standard 10-day therapy. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days and Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2118,5437665,Significantly increased,"At the end of study, the fatigue score was significantly increased in patients treated with simvastatin, whereas no significant change was observed in patients receiving red yeast rice.", Fatigue score at week 4 , Red yeast rice , Simvastatin ,0,
edin,2196,5320759,No significant difference,"Among the cases of successful intubation, the intubation time was not significantly different between the two groups (P > 0.05).", intubation time ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2178,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2229,3329148,Significantly increased,The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05)., H. pylori eradication rate ," Group C received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for standard 10-day therapy. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days and Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2258,5223669,Significantly increased,"With all available data (n=233), applying the cLDA model yielded an LDL improvement of 8.9âmg/dL (95% CI â16.7 to â1.0; p=0.03) for GMC compared with usual care.", LDL measured by cLDA , usual care , Group Medical Clinics (GMC) ,0,
edin,2123,2815285,Cannot tell based on the abstract,, Blood volume in the retroperitoneal hematoma , Hypertonic saline plus dextran (group III) , Lactated Ringer (group II)  ,0,
edin,2123,2815285,Significantly increased,"Significantly higher VRPH was observed in LR-treated animals when compared to the HSD group, indicating more pronounced rebleeding (p<0.05 NT vs. LR and HSD; p<0.05 LR vs. HSD) (panel C).", Blood volume in the retroperitoneal hematoma , Hypertonic saline plus dextran (group III) , Lactated Ringer (group II)  ,0,
edin,2121,5437665,Cannot tell based on the abstract,," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2121,5437665,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm (Fig. 4)."," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2273,5589093,Cannot tell based on the abstract,, intraoperative beta-blockers , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2273,5589093,No significant difference,Use of intraoperative beta-blockers was similar between groups., intraoperative beta-blockers , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2141,5387905,Cannot tell based on the abstract,, Mean pain scores 2 hours after the procedure ,  Ibuprofen group , Diclofenac potassium group and paracetamol group ,0,
edin,2141,5387905,No significant difference,"For both paracetamol and diclofenac potassium groups at 2 hours postoperatively, there were no significant decreases in mean pain scores compared with the ibuprofen group (p-values from one-way ANOVA: 1.000, 0.06, Table 1).", Mean pain scores 2 hours after the procedure ,  Ibuprofen group , Diclofenac potassium group and paracetamol group ,0,
edin,2259,5223669,No significant difference,"The less efficient, LDA analysis yielded an LDL improvement of 7.2âmg/dL (95% CI â17.2 to 2.8; p=0.15) for GMC compared with usual care.", LDL measured by LDA  , usual care , Group Medical Clinics (GMC) ,0,
edin,2226,4477338,Cannot tell based on the abstract,," Total cholesterol, HDL and LDL ", placebo ,  3.9 g/day EPA+DHA ,0,
edin,2226,4477338,No significant difference,"Total cholesterol, HDL and LDL, did not change in either group."," Total cholesterol, HDL and LDL ", placebo ,  3.9 g/day EPA+DHA ,0,
edin,2255,3467590,No significant difference,"A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.", intensification of medications to control LDL , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2182,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2154,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2120,5437665,Cannot tell based on the abstract,, Effects in reduction of lipids levels , Red yeast rice , Simvastatin ,0,
edin,2120,5437665,No significant difference,"The administration of both simvastatin (20Â mg daily) or red yeast rice (1200Â mg daily) resulted in significant reductions in TC (â19.6% vs. -18.5% of baseline level for simvastatin and red yeast rice groups respectively, PÂ <Â .001 vs. baseline for both) and LDL-C (â30.9% vs.-33.4% of baseline level for simvastatin and red yeast rice groups respectively, PÂ <Â .001 vs. baseline for both) after 4Â weeks of treatment (Fig. 3a-b) that were not significantly different between the two groups (PÂ =Â 0.84 for the comparison of the percentage drop in the TC level and PÂ =Â 0.64 for the comparison of the percentage drop in the LDL-C level; Fig. 3c). The improvements in TG and HDL-C concentrations were not significant in either treatment group (Fig. 3a-b).Fig. 3,Comparison of lipid levels at week 4 and baseline in the simvastatin and red yeast rice groups (meanÂ Â±Â SD). No significant changes in TG or HDL levels were observed in either arm;", Effects in reduction of lipids levels , Red yeast rice , Simvastatin ,0,
edin,2280,5589093,Cannot tell based on the abstract,, blood transfusion , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2280,5589093,Significantly decreased,Patients in the usual care group were significantly more likely to receive blood transfusion: GDT (nil) vs. usual care (35%) (p = 0.0005)., blood transfusion , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2167,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2277,5589093,Cannot tell based on the abstract,, most severe complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2277,5589093,No significant difference,Assessment of most severe complications demonstrated no significant differences between the GDT group and usual care group (p = 0.414)., most severe complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2136,5444773,Cannot tell based on the abstract,,  Surfactant protein B expression , Pressure-controlled ventilation (PCV) , Pressure support ventilation (PSV) ,0,
edin,2136,5444773,Significantly increased,"In the presence of IAH, PSV improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to PCV.",  Surfactant protein B expression , Pressure-controlled ventilation (PCV) , Pressure support ventilation (PSV) ,0,
edin,2309,3065646,Cannot tell based on the abstract,," Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS) ", conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV &amp;lt;50 mL ,0,
edin,2309,3065646,Significantly increased,"<td align=""left"" colspan=""4"">mRS</td>"," Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS) ", conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV &amp;lt;50 mL ,0,
edin,2117,5437665,Cannot tell based on the abstract,," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2117,5437665,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm (Fig. 4)."," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2310,3065646,Cannot tell based on the abstract,, case fatality 1 year after stroke , conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) ,0,
edin,2310,3065646,No significant difference,"There were no sharp differences in case fatality between the MISPTT group and the CC group 1Â year after stroke (17.2 and 25.9%, respectively, PÂ =Â 0.243);", case fatality 1 year after stroke , conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) ,0,
edin,2245,5372977,Significantly decreased,Mean HR was lower in the BR (172 Â± 2) vs. PLA trial (175 Â± 2; p = 0.014)., Mean HR , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2418,3771300,Significantly decreased,"The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099).", index lesion cure rate after 6 months follow-up ," WR 279,396 (15% paromomycin + 0.5% gentamicin) ", Paromomycin Alone (15% paromomycin) for 20 days ,0,
edin,2428,3614647,Significantly decreased,"Maca-GO significantly reduced both frequency and severity of individual menopausal symptoms (hot flushes and night sweating in particular) resulting in significant (P<0.001) alleviation of KMI (from 22 to 10), thus, offering an attractive non-hormonal addition to the choices available to early-postmenopausal women in the form of a natural plant alternative to Hormone Replacement Therapy (HRT) â hence, reducing dependence on hormone therapy programs.", severity of individual menopausal symptoms (hot flushes and night sweating in particular) , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2465,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", C-reactive protein , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2385,2662857,Significantly increased,"After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as ""very much improved"" or ""much improved"" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).", mean physician Clinical Global Impression (CGI) scale - eye contact , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2472,4365008,No significant difference,"Similarly, the antioxidant enzymes GPx and SOD activity were unchanged by treatments.", glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels , 10 mg rosuvastatin over 4 months , 10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 ÃÂ¼g/d) supplementation. ,0,
edin,2443,2001223,Significantly increased,"Furthermore, when analyzed by Ki67 immunohistochemistry, letrozole was significantly more effective than tamoxifen in reducing tumor proliferation (PÂ =Â 0.0009).", reducing tumor proliferation , tamoxifen , aromatase inhibitors (AIs) - letrozole ,0,
edin,2497,3661884,Significantly increased,Both groups showed significant increases in flexibility but in different joints (SSGpre vs. SSGpost; PIGpre vs. PIGpost)., flexibility of joints , baseline , the static stretching (SSG) or passive interval (PIG) ,0,
edin,2349,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Intercellular adhesion molecule-1 (ICAM-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2506,5738810,No significant difference,"The three other parameters evaluated by veterinary subjective assessment (lameness, pain at palpation and joint mobility) did not show statistical differences."," lameness, pain at palpation and joint mobility at T0 and T3 ", an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2505,5738810,Significantly decreased,"After 3Â months of feeding, there was a significant reduction of pain at manipulation in the CCOT group, but not in the control group.", Pain at manipulation , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2523,4759876,Cannot tell based on the abstract,, The total blood loss after Total knee arthroplasty (TKA) , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2523,4759876,Significantly decreased,The total blood loss after TKA was significantly different between two groups (P = 0.04). The total blood loss (visible drained blood + hidden loss) was less in subcutaneous drainage group., The total blood loss after Total knee arthroplasty (TKA) , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2451,4574984,Cannot tell based on the abstract,, numbers overall complications ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2451,4574984,No significant difference,Overall complications occurred in 74% of the patients. There was no difference between intervention and control group (p = 0.79)., numbers overall complications ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2445,2639700,Cannot tell based on the abstract,, mean weekly steps during the first month ," groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW) ", non-exercise control group ,0,
edin,2445,2639700,Significantly increased,"There were no significant differences in mean weekly steps during the first month among any of the exercise intervention groups, but the non-exercise control group (6098 (2065)) had significantly (P<0.05 for each) more steps compared to all of the exercise groups.", mean weekly steps during the first month ," groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW) ", non-exercise control group ,0,
edin,2386,2662857,Significantly increased,"Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).", Mean parental CGI scores - overall functioning  , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2496,3661884,No significant difference,"Both groups showed significant increases in strength (SSGpre vs. SSGpost; PIGpre vs. PIGpost) in the same exercises for leg extension (LE) and Low Row (LR). Specifically, in the SSG group, the parameters for LE were (p = 0.0015 and ES = 2.28 - Large), and the parameters for LR were (p = 0.002 and ES = 1.95 - Large). Moreover, in the PIG group, the parameters for LE were (p = 0.009 and ES = 1.95 - Large), and the parameters for LR were (p = 0.0001 and ES = 2.88 - Large). No differences were found between the groups (SSGpost vs. PIGpost).", strength in the exercises for leg extension (LE) and Low Row (LR) , passive interval (PIG) , the static stretching (SSG)  ,0,
edin,2414,4842481,Cannot tell based on the abstract,, compliance coefficient (CC) , control group , WBV training ,0,
edin,2414,4842481,No significant difference,"Similarly, there was no significant interaction effect (p = 0.237) or main effect for compliance coefficient (CC) (Table 2) between the WBV and control groups (p = 0.496).", compliance coefficient (CC) , control group , WBV training ,0,
edin,2332,4602159,Cannot tell based on the abstract,," apnea, laryngospasm, bronchospasm, vomiting ", intravenous lidocaine , topical lidocaine ,0,
edin,2332,4602159,No significant difference,"Other variables including apnea, laryngospasm, bronchospasm, desaturation, and vomiting were not statistically different."," apnea, laryngospasm, bronchospasm, vomiting ", intravenous lidocaine , topical lidocaine ,0,
edin,2501,4266420,Cannot tell based on the abstract,The subjective fatigue of the MBT group was lower than that of the CON (P<0.05) or trail running shoe groups (P<0.05) on day 3., The subjective fatigue on day 3. , control , trail running shoes  ,0,
edin,2501,4266420,No significant difference,No difference between the CON and TR groups was found (P=0.64; Figure 2)., The subjective fatigue on day 3. , control , trail running shoes  ,0,
edin,2340,4749757,Significantly increased,"132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.", Improvement in Berg Balance Scale (BBS) Score  during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2467,5622764,Cannot tell based on the abstract,, coefficient of variation , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2467,5622764,Significantly increased,"Indeed, whereas glucose variability tended to increase between the first and last two CGM days on Plac (coefficient of variation from 34.3 Â± 1.9 to 39.1 Â± 3.0%; p < 0.05), it remained unchanged on Î²-glucan (from 38.2 Â± 3.2 to 38.9 Â± 2.1%; p = ns (non-significant)), suggesting a time dependent positive effect in maintaining a stable glucose level.", coefficient of variation , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2508,5738810,Cannot tell based on the abstract,, Coll2Ã¢â¬â1 and Coll2Ã¢â¬â1 NO2 serum concentrations , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2508,5738810,No significant difference,Coll2â1 and Coll2â1 NO2 serum concentrations were not significantly different between control and CCOT groups at T0 and T3., Coll2Ã¢â¬â1 and Coll2Ã¢â¬â1 NO2 serum concentrations , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2406,2806387,Significantly increased,The intensity of the unpleasant sensation was rated significantly higher after injection of saline from prefilled syringes compared to saline from polyethylene (p = 0.001)., The intensity of an unpleasant sensation , saline 9 mg/ml for injection in polyethylene package , saline 9 mg/ml syringes ,0,
edin,2390,2662857,Significantly increased,"On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.", Aberrant Behavior Checklist (ABC) total score - irritability , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2502,5738810,Cannot tell based on the abstract,, change in dogsÃ¢â¬â¢ body weight , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2502,5738810,No significant difference,There was no significant change in dogsâ body weight nor evidence of side effects over the duration of the study., change in dogsÃ¢â¬â¢ body weight , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2367,4763632,Significantly increased,New dot/globule formation was observed more frequently in the covered and uncovered nevi of PUVA group., Formation of new dot-globule  , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2339,4749757,Significantly increased,"PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.", Improvement in Timed Up and Go (TUG) speed  during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2417,4662683,Significantly increased,"Onset time of swallowing therapy after stroke was effective on swallowing recovery on the main outcome variables. So that in first group patients, recovery was rather than other groups P < 0.050.", recovery ,  (3) late group (1-month after stroke) with swallowing therapy  ,  (2) medium group (2 weeks after stroke) with swallowing therapy  ,0,
edin,2357,5331772,Cannot tell based on the abstract,, VO2max , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2357,5331772,Significantly increased,"The KruskalâWallis test showed VO2max changes (pre- to post-test) were significantly different between groups (P < 0.001).,Tukey's post hoc test revealed increased VO2max in both âexercise + gingerâ (P < 0.000) and âexercise + placeboâ (P < 0.000) groups, in comparison to âgingerâ group.", VO2max , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2351,5331772,Cannot tell based on the abstract,, Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2351,5331772,No significant difference,There was no significant difference between three groups regarding the baseline characteristics [Tables 1 and 2]., Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2355,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Serum interleukin-10 (IL-10) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2425,3614647,Significantly increased,"Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood FSH, increase (P<0.05) in HDL.", estradiol (E2) level  in group APMM , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2318,3668955,Cannot tell based on the abstract,, Relief of plantar pain , sham trigger point dry needling , real trigger point dry needling ,0,
edin,2318,3668955,No significant difference,"At the primary end-point, significant effects favored real dry needling over sham dry needling for pain (adjusted mean difference: VAS first-step pain -14.4 mm, 95% CI -23.5 to -5.2, p=0.002; FHSQ foot pain 10.0 points, 95% CI 1.0 to 19.1, p=0.029), although the between-group difference was lower than the minimal important difference.", Relief of plantar pain , sham trigger point dry needling , real trigger point dry needling ,0,
edin,2398,3210361,Significantly decreased,"Critically, ketamine also impaired accuracy on the perceptual timing task while having no effect on performance of the colour perception task.", accuracy in the timing task , placebo , ketamine (100&amp;nbsp;ng/ml blood plasma level) ,0,
edin,2478,5742427,Significantly decreased,"The experimental group and control group showed a significant difference in perceived stress (F = 60.11, p < .001),,The results revealed that aromatherapy alleviated stress and improved sleep quality in intensive care unit patients after 2 days of the experimental treatment.", perceived stress , sleep without receiving the lavender aroma oil , deep breathing with essential oils ,0,
edin,2391,2662857,Significantly increased,"On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group."," Aberrant Behavior Checklist (ABC) total score - irritability, stereotypy, hyperactivity, and speech ", baseline and control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2348,5331772,Significantly decreased,Paired t-test revealed a significant decrease in the density of type 1 monocytes chemo tactic protein (MCP-1) in HIIT + ginger (P = 0.026) and HIIT + placebo (P = 0.001) groups., Density of type 1 monocytes chemo tactic protein (MCP-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2354,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Intercellular adhesion molecule-1 (ICAM-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2356,5331772,Cannot tell based on the abstract,, Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2356,5331772,No significant difference,There was no significant difference between three groups regarding the baseline characteristics [Tables 1 and 2]., Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2315,5031764,Significantly increased,Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group., decrease in the levels of impulsivity and aggressiveness in experimental group , decrease in the levels of impulsivity and aggressiveness in control grup , mindfulness training psycho-educative program ,0,
edin,2453,4574984,Cannot tell based on the abstract,, overall mortality ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2453,4574984,No significant difference,The overall mortality did not differ significantly between the two groups (Log-Rank-test p = 0.197) (Fig 7)., overall mortality ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2462,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", interleukin-6 , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2323,5300822,Cannot tell based on the abstract,, reduce muscle damage. , post-exercise  vibration stimulation  , pre-exercise vibration stimulation ,0,
edin,2323,5300822,Significantly increased,Pre-induced muscle damage vibration stimulation is more effective than post-induced muscle damage vibration stimulation for preventing muscle damage., reduce muscle damage. , post-exercise  vibration stimulation  , pre-exercise vibration stimulation ,0,
edin,2456,5482825,No significant difference,"Low AGE diets did not change systolic (pâ=â0.2) and diastolic blood pressure (pâ=â0.3), mean arterial pressure (pâ=â0.8) and pulse pressure (pâ=â0.2) compared to high AGE diets.", mean arterial pressure , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2392,2662857,Significantly increased,"On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.",  Autism Treatment Evaluation Checklist (ATEC) - sensory/cognitive awareness , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2482,5742427,Significantly decreased,"The experimental group and control group showed a significant difference in perceived stress (F = 60.11, p < .001), objective stress index (F = 25.65, p < .001), systolic blood pressure (F = 9.09, p < .001), diastolic blood pressure (F = 2.47, p = .046), heart rate (F = 5.71, p < .001), and sleep quality (F = 109.46, p < .001).",  heart rate , sleep without receiving the lavender aroma oil , deep breathing with essential oils ,0,
edin,2402,3210361,Cannot tell based on the abstract,,  benefit of temporally valid cues at the short interval , placebo , ketamine (100ng/ml blood plasma level) ,0,
edin,2402,3210361,Significantly increased,"Specifically, the benefit of temporally valid cues was significant at the short (t(10)â=ââ4.71, pâ=â0.001) but not long (t(10)â=ââ0.48, ns) interval (TableÂ 1): when a target does not appear after the short interval as expected it must, by process of elimination, appear at the longer one.",  benefit of temporally valid cues at the short interval , placebo , ketamine (100ng/ml blood plasma level) ,0,
edin,2434,5054611,Cannot tell based on the abstract,, The mean peak inspiratory pressure and plateau pressure , The Laryngeal Tube Suction Disposable (LTS-D)  , the Supreme Laryngeal Mask Airway (SLMA) ,0,
edin,2434,5054611,Significantly decreased,The mean peak inspiratory pressure and plateau pressure in patients with SLMA was significantly lower than in patients with LTS-D (pâ=â0.006) and (pâ=â0.008)., The mean peak inspiratory pressure and plateau pressure , The Laryngeal Tube Suction Disposable (LTS-D)  , the Supreme Laryngeal Mask Airway (SLMA) ,0,
edin,2288,4392900,Significantly decreased,"After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo.", incidence rate of type 2 diabetes , placebo , intent-to-treat population using multiple imputation (ITT-MI)  of subjects with prediabetes and/or MetS ,0,
edin,2338,4749757,Significantly increased,"A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds â©¾7 (p = 0.0275), â©¾8 (p = 0.0153) and â©¾9 points (p = 0.0088) and TUG speed thresholds â©¾10% (p = 0.0021) and â©¾15% (p = 0.0262).", Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2423,3445058,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""center"" colspan=""3"" rowspan=""1"">% MVIC<hr></th><th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th>"," The supraspinatus, infraspinatus, and anterior deltoid muscle electromyographic (EMG) activity ", upright active forward exercises , gravity-minimized exercises  ,0,
edin,2328,4538249,Cannot tell based on the abstract,, Increase of glycaemic control. , A 1-year follow-up of the RxING study , RxING study first six month ,0,
edin,2328,4538249,Significantly increased,"In the RxING study, HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26âweeks, a change of 1.8% (95% CI 1.4 to 2, p<0.001). Twelve months after completing the study, HbA1c increased from 7.3% (SD 0.9) at study end to 8.1% (SD 1.3), a change of 0.8% (95% CI â1.1 to â0.5, p<0.001; figure 2).", Increase of glycaemic control. , A 1-year follow-up of the RxING study , RxING study first six month ,0,
edin,2394,5040779,Cannot tell based on the abstract,," success rate of intubation on the first, second, and third attempts ", Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2394,5040779,Significantly increased,"The success rate of intubation on the first, second, and third attempts increased significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade in the normal airway (P < 0.001 on the first attempt, P < 0.001 on the second attempt, and P = 0.012 on the third attempt)."," success rate of intubation on the first, second, and third attempts ", Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2359,4794540,Cannot tell based on the abstract,, General health , Prescribed medication without yogic intervention , Yogic intervention and medication ,0,
edin,2359,4794540,Significantly increased,"Significant improvement in domains of anxiety (P<0.01), depression (P<0.02), positive well-being (P<0.01), general health (P<0.04) and vitality (P<0.02) in intervention group was noted after six months of yogic intervention when compared to control group (Table 3).", General health , Prescribed medication without yogic intervention , Yogic intervention and medication ,0,
edin,2364,4763632,Cannot tell based on the abstract,Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001)., Demoscopic changes , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2364,4763632,Significantly increased,"The prevalence of overall dermoscopic changes was significantly higher in the PUVA-exposed nevi (100% for PUVA, 88.8% for NB-UVB, P value 0.041).", Demoscopic changes , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2415,4662683,Significantly increased,"Onset time of swallowing therapy after stroke was effective on swallowing recovery on the main outcome variables. So that in first group patients, recovery was rather than other groups P < 0.050.", recovery ,  (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy  , early initiation group (3 days after stroke) with swallowing therapy  ,0,
edin,2316,5031764,Significantly decreased,Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group., impulsivity and aggressiveness dimensions for experiemental group , impulsivity and aggressiveness dimensions for control group , Wilcoxon test ,0,
edin,2452,4574984,Significantly decreased,Patients in the intervention group reported significantly less postoperative pain (p = 0.03) than the control group., level of postoperative pain ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2510,4516063,Significantly increased,"Comparing the shear bond strength values, All Bond 2 (Group III) demonstrated fairly higher bond strength values at different levels of dentin. Generally comparing All Bond 2 with the other two experimental groups revealed highly significant statistical results.", bond strength values ," Group I, II and Group III (positive control) ", All Bond 2 (Group III) ,0,
edin,2341,4749757,Cannot tell based on the abstract,, Adverse Events , Placebo , Prolonged-release fampridine ,0,
edin,2341,4749757,No significant difference,The proportion of patients with any AE was similar in placebo-treated patients (49 (77%)) versus patients receiving PR-fampridine (51 (75%))., Adverse Events , Placebo , Prolonged-release fampridine ,0,
edin,2397,5040779,Significantly increased,"The McGRATH MAC and C-MAC significantly increased the success rate of intubation, improved the Cormack-Lehane grade, and decreased the difficulty score compared to the Macintosh blade in both airway settings.", The Cormack-Lehane grade , Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2469,5622764,Significantly increased,"There was an increase in basic measures of glycaemic control (maximal glucose value 341 Â± 15 vs. 378 Â± 13 mg/dL for Plac and Î²-glucan, p = 0.004), and average daily risk range (62 Â± 5 vs. 79 Â± 4 mg/dL for Plac and Î²-glucan, p = 0.003) favouring Plac over Î²-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.", average daily risk range , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2314,4051747,Cannot tell based on the abstract,,"  prenatal knowledge, attitudes,behaviors and beliefs related to text4baby ","  prenatal knowledge, attitudes,behaviors beliefs in usual care ", Text4baby mHealth program ,0,
edin,2314,4051747,Significantly increased,"There were significant improvements in several outcome attitudes, beliefs, and behaviors from BL to FL.","  prenatal knowledge, attitudes,behaviors and beliefs related to text4baby ","  prenatal knowledge, attitudes,behaviors beliefs in usual care ", Text4baby mHealth program ,0,
edin,2416,4662683,Significantly decreased,"Furthermore, the frequency of pneumonia in the early group was less than other groups and in the early group no patients experienced pneumonia P = 0.002.", number of patients experienced pneumonia ,  (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy  , early initiation group (3 days after stroke) with swallowing therapy  ,0,
edin,2524,4759876,Cannot tell based on the abstract,, The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2524,4759876,Significantly decreased,"The mean visible blood drainage in subcutaneous drainage group was significantly less than intraarticular drainage group, both during the first 24 h and between 24 and 48 h (P < 0.001).", The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2442,2001223,Significantly increased,"Significantly more letrozole-treated patients underwent breast-conserving surgery (45 vs. 35%, respectively; PÂ =Â 0.022).", numbers of breast-conserving surgery , tamoxifen , aromatase inhibitors (AIs) - letrozole ,0,
edin,2514,5038569,Significantly decreased,"he mean Â± standard deviation CMT decreased from 604Â±199 Î¼m at baseline to 319Â±115 Î¼m (P=0.001) at 1 month and to 351Â±205 Î¼m (P=0.026) at 4 months.,The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.", central macular thickness (CMT) at 1 month and at 4 months , baseline , intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) ,0,
edin,2504,5738810,Cannot tell based on the abstract,, PVF change with time , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2504,5738810,No significant difference,The PVF change (Î T3-T0) was not different between groups (pâ=â0.319) (Fig.Â 2).Fig. 2, PVF change with time , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2363,4763632,Significantly increased,Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001)., Demoscopic changes , All covered nevi , All uncovered nevi ,0,
edin,2458,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", total cholesterol , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2329,4538249,Cannot tell based on the abstract,, reduced cardiovascular risk. , base line , RxING study first six month ,0,
edin,2329,4538249,Significantly decreased,"Patientsâ risk of cardiovascular events in the next 10âyears was reduced from 31% (SD 17.3) at baseline to 26.7% (SD 14.5) at study end, an absolute reduction of 4.3% (a 14% relative reduction) (95% CI 0.6 to 9.5, p=0.026).", reduced cardiovascular risk. , base line , RxING study first six month ,0,
edin,2424,3614647,Significantly decreased,"Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood FSH, increase (P<0.05) in HDL.", Follicle Stimulating Hormone (FSH) level in group APMM , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2380,4652407,No significant difference,"No significant differences (pâ>0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C, HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed.", Atherogenic index , Any other food , Commercially produced Scoparia dulcis porridge (SDC) ,0,
edin,2431,5054611,Cannot tell based on the abstract,,  successfull insertion , the Supreme Laryngeal Mask Airway (SLMA) , The Laryngeal Tube Suction Disposable (LTS-D) ,0,
edin,2431,5054611,No significant difference,Gastric tube insertion was successful in all patients in both groups.,  successfull insertion , the Supreme Laryngeal Mask Airway (SLMA) , The Laryngeal Tube Suction Disposable (LTS-D) ,0,
edin,2610,3549413,Cannot tell based on the abstract,, bone mineral density (BMD) At the 6-month time point , baseline , placebo ,0,
edin,2610,3549413,No significant difference,"At the 6-month time point, subjects supplemented with the GBB (nÂ =Â 30) maintained femoral neck BMD, whereas in the placebo group (nÂ =Â 28), BMD significantly decreased (pÂ =Â 0.007, Fig.Â 2a),,The difference in femoral neck BMD between groups remained statistically significant in the intention to treat (ITT) analysis (pÂ =Â 0.05); however, when baseline BMD was factored into the analysis, statistical significance was no longer quite achieved (pÂ =Â 0.058).", bone mineral density (BMD) At the 6-month time point , baseline , placebo ,0,
edin,2632,5767990,Cannot tell based on the abstract,, The mean GI after 3 months , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2632,5767990,Significantly decreased,"The mean GIs in the test and control groups at baseline were 2.60 and 2.57, respectively, and after 3 months were 1.35 and 2.32, respectively, which showed statistically significant results (P < 0.001).,The clinical parameter difference in both the test and control groups from baseline to 3 months showed that the mean GIs in the test and control groups were 1.25 and 0.25, respectively, the mean PDs in the test and control groups were 2.24 and 0.34, respectively, and the mean CALs in the test and control groups were 0.73 and 0.20, respectively, which showed statistically significant results (P < 0.001)", The mean GI after 3 months , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2570,4280425,Significantly decreased,"Total morbidity was 27.5% in the case of patients with conventional surgery, vs. 10.9% with laparoscopic intervention (p < 0.05).", Total morbidity , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2601,3620559,No significant difference,"Stratifying outcomes by anti-MÃ¼llerian hormone (AMH), as indicator of ovarian reserve, and by body mass index (BMI) the oocyte yields, still, did not differ (AMH, r (17)â=ââ0.20, pâ=â0.44; BMI, r (17) =0.02, pâ=â0.96).",  oocyte yield among women with normal ovarian reserve , 17 G/ 35 mm (standard) needle , 20 G/ 35 mm (thin) needle ,0,
edin,2571,4280425,Cannot tell based on the abstract,, Complications , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2571,4280425,Significantly decreased,"We found a statistically significant difference in the number of complications in favour of laparoscopy, 10.9% vs. 27.5% for conventional operations.", Complications , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2625,5446666,No significant difference,"There were also no significant differences between the intervention and control groups at 4 weeks on any of the subscales of the MHC-SF (psychological: P=.95, social: P=.42, emotional: P=.95).", Subscales of Mental Health Continuum-Short Form (MHC-SF) , control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,2537,5057302,Cannot tell based on the abstract,, Improvement in symptom score , Placebo , Sublingual immunotherapy (SLIT) 10 000 AUN/ml ,0,
edin,2537,5057302,Significantly decreased,"Regarding the primary endpoint, in all treatment groups, a decrease in symptom scores after 5 months of treatment compared to the baseline measurement at screening was observed (32.6% in the placebo group up to 58.4% in the 40 000 AUN/ml group; Table 2).", Improvement in symptom score , Placebo , Sublingual immunotherapy (SLIT) 10 000 AUN/ml ,0,
edin,2563,4814821,Significantly decreased,Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23âvs. 0.68/patient; pâ=â0.002) and emergency room visits (0.36âvs. 0.91/patient; pâ=â0.006)., ER visits for all causes , usual group , telemonitoring group ,0,
edin,2592,4590407,Cannot tell based on the abstract,, The EG had increased in the soft tissue (primarily FFM) , baseline , 10 mg Zn/day ,0,
edin,2592,4590407,Significantly increased,The EG had increased in the soft tissue (primarily FFM) body composition after oral zinc supplementation compared with before supplementation (p<0.0001)., The EG had increased in the soft tissue (primarily FFM) , baseline , 10 mg Zn/day ,0,
edin,2631,5767990,Cannot tell based on the abstract,, probing depth (PD) , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2631,5767990,Significantly decreased,"The mean PDs in the test and control groups at baseline were 5.16 and 4.44, respectively, and after 3 months were 2.92 and 4.10, respectively, which showed statistically significant results (P < 0.001).", probing depth (PD) , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2566,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first phase , baseline , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2566,3961219,Significantly increased,"The mean normalized AUC values for subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00Â±0.13, 1.08Â±0.31, 1.60Â±0.27, 2.53Â±0.27 and 2.03Â±0.34, respectively (Fig. 4). The difference among the treatment groups was statistically significant (P=0.006 by one-way ANOVA).,For the first phase I trial, the normalized AUC for the serum BBI level was moderately correlated with the BBIC dose, with a correlation coefficient of 0.65 and a slope value of 0.0007 (Fig. 3).", The mean normalized AUC values for the first phase , baseline , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2591,4590407,Significantly increased,The body mass index-for-age increased after oral zinc supplementation in the EG (p=0.005)., The body mass index-for-age , sorbitol 10% , 10 mg Zn/day ,0,
edin,2623,2409647,Cannot tell based on the abstract,, the bone marker urinary CTx over the 96-week study period , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2623,2409647,Significantly decreased,"Patients receiving oral ibandronate 50âmg showed a significant decrease from baseline in the bone marker urinary CTx over the 96-week study period compared with placebo (median change â77.3% and +11.0%, P<0.001) (Figure 2Figure 2", the bone marker urinary CTx over the 96-week study period , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2572,4884360,No significant difference,"The CARs for weeks 5â52 were 10.0Â %, 12.4Â %, and 15.3Â % in the NRT, NRT+, and VR groups, respectively; no group differences were observed.", carbon monoxide-confirmed continuous abstinence rates (CAR) , varenicline (VR) ," standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+) ",0,
edin,2597,3620559,No significant difference,The standard diameter needle was used to collect a total of 215 oocytes from 355 aspirated follicles (60.6%) compared to 203 oocytes from 352 aspirated follicles (57.7%) with the thinner needle (pâ=â0.23)., The number of oocytes per the number of aspirated follicles , 17 G/ 35 mm (standard) needle , 20 G/ 35 mm (thin) needle ,0,
edin,2552,4714728,Significantly increased,Results indicated that patients in Group B showed higher mean scores (90.3Â±5.4) than Group A (80.4Â±11.5) in terms of ConstantâMurley score (P=0.001)., mean scores of ConstantÃ¢â¬âMurley score , Group A was treated using a hook plate , Group B with autogenous semitendinosus graft and endobutton technique ,0,
edin,2624,5446666,No significant difference,Results demonstrated no significant effect of âThe Toolboxâ intervention on participant well-being at 4 weeks compared with the control group (P=.66)., well-being at 4 weeks , control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,1993,5808396,Significantly decreased,"Participants receiving CPT experienced moderate reductions in felt stigma relative to those in individual support (Cohenâs Dâ=â0.44, pâ=âvalueâ=â0.02) following the end of treatment,", felt stigma after treatment , individual support , Cognitive Processing Therapy ,0,
edin,2575,3400348,Significantly increased,"Treatment with telmisartan-HCTZ induced significantly greater reductions in BP (â31.1/â18.3âmmâHg) than valsartan-HCTZ (â28.4/â16.3âmmâHg; SBP P = 0.0265, diastolic BP P = 0.0041).",  mean reduction in BP for both systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2596,3263888,No significant difference,Lifestyle intervention resulted in higher IS (P = 0.02) and lower unadjusted AIGR0â30 (P = 0.08) during the 4-year follow-up., AIGR0Ã¢â¬â30 during the 4-year follow-up , control  , lifestyle intervention  ,0,
edin,2615,2887326,Significantly increased,The prominent efficacy rate was 19% (7 of 37) in the Hochu-ekki-to group and 5% (2 of 40) in the placebo group (P = 0.06)., The prominent efficacy rate , placebo , Hochu-ekki-to ,0,
edin,2626,5446666,Significantly increased,"Repeat engagement with the study platform resulted in a significant difference in mood, energy, rest, and sleep trajectories between intervention and control groups as measured by EMAs (P<.01)."," mood, energy, rest, and sleep ", control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,2621,2409647,Cannot tell based on the abstract,, the mean number of measurement periods with events per patient , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2621,2409647,Significantly decreased,"Supportive analyses of new bone events demonstrated that the mean number of events and the mean number of measurement periods with events per patient were significantly reduced in the ibandronate group compared with placebo (P=0.008 and 0.015, respectively, Table 3 Table 3", the mean number of measurement periods with events per patient , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2636,3580611,Significantly increased,"The 30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).", The 30-day rate of stroke or death , medical-management group , percutaneous transluminal angioplasty and stenting (PTAS) ,0,
edin,2541,3376507,Significantly decreased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â0.72, SD 1.1 kg/m2, enhanced: â1.0, SD 1.4, control: 0.15, SD 0.82; P < .001)", Body mass index , Wait-list control group , Standard version or enhanced version of commercial Web-based weight-loss program ,0,
edin,2577,3400348,Cannot tell based on the abstract,, DBP change among non-Black patients , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2577,3400348,Significantly increased,"Among non-Black patients, T80/H25 resulted in significantly greater DBP reductions from baseline (adjusted mean DBP change â18.3âmmâHg) than V160/H25 (adjusted mean DBP change â16.5âmmâHg; P = 0.0229).", DBP change among non-Black patients , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2585,4191553,Cannot tell based on the abstract,," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius ", placebo , denosumab 60 mg sc every 6 months ,0,
edin,2585,4191553,Significantly increased,"The difference between the two groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (P < .0001) and 6 months at the distal one third radius (P < .0001).,Mean BMD percentage change from baseline at 24 months was 9.1% and 0.1% at the lumbar spine in the denosumab and placebo groups, 4.6% and â1.1% at the total hip, 4.0% and â1.1% at the femoral neck, and 0.5% and â1.8% at distal one third radius, respectively (Figure 3, AâD),The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (P < .05), at 12 and 24 months at the femoral neck (P < .05), and from 18 months at the distal one third radius (P < .05)."," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius ", placebo , denosumab 60 mg sc every 6 months ,0,
edin,2567,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2567,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2567,3961219,Significantly increased,"The mean normalized AUC value for BBIC-treated subjects (all doses combined) was 1.808 and 1.325 for the first and second clinical trials, respectively, and the difference was statistically significant (P=0.031)", The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2616,2887326,Significantly decreased,The aggravated rate was significantly (P < 0.05) lower in the Hochu-ekki-to group (3%; 1 of 37) than in the placebo group (18%; 7 of 39).," the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study ", placebo , Hochu-ekki-to ,0,
edin,2620,2409647,Cannot tell based on the abstract,, the number of skeletal fractures , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2620,2409647,No significant difference,There was no significant difference in the number of skeletal fractures with ibandronate compared with placebo (P=0.195)., the number of skeletal fractures , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2619,2409647,Cannot tell based on the abstract,, bone events requiring surgery , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2619,2409647,No significant difference,"<td align=""left"" charoff=""50"" valign=""top"">Need for surgery</td><td align=""center"" char=""."" charoff=""50"" valign=""top"">0.44</td><td align=""center"" char=""."" charoff=""50"" valign=""top"">0.40, <italic>P</italic>=0.098<sup>*</sup></td>", bone events requiring surgery , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2531,3881871,Significantly increased,A statistically significant increase in a* and b* chromatic parameters of the MTA Fillapex Group was measured., Chromatic alterations , ZnOE-based sealer (Roth-811) , MTA Fillapex sealer ,0,
edin,2612,3549413,Cannot tell based on the abstract,, Endometrial Thickness , baseline , calcium only or the geniVidaÃ¢âÂ¢ bone blend (GBB) ,0,
edin,2612,3549413,No significant difference,At no time point did endometrial thickness (ET) differ between the groups., Endometrial Thickness , baseline , calcium only or the geniVidaÃ¢âÂ¢ bone blend (GBB) ,0,
edin,2643,5831281,Cannot tell based on the abstract,, the mean intensity of pruritus , placebo , 1 week with clemastine and levocetirizine ,0,
edin,2643,5831281,No significant difference,"Regarding the studied subgroups, the mean intensity of pruritus according to the VAS before treatment was 5.6 Â±2.7 points in the clemastine group, 4.7 Â±3.2 points in the levocetirizine group and 3.6 Â±1.9 points in the placebo group (p = 0.07).", the mean intensity of pruritus , placebo , 1 week with clemastine and levocetirizine ,0,
edin,2550,2801838,Significantly increased,"At week 12, the human milk group had a sixfold higher geometric mean serum lutein (69.3Â mcg/l; 95% CI 40.3â119) than the unfortified formula group (11.3Â mcg/l; 95% CI 8.1â15.8).", Mean lutein concentration at week 12 , Unfortified formula group , Breastfed infants ,0,
edin,2578,5615289,Cannot tell based on the abstract,, The onset of tolerable and intolerable mucositis  , povidone-iodine , honey mitigates ,0,
edin,2578,5615289,Significantly decreased,The onset of tolerable and intolerable mucositis was delayed in the patients using honey and was significant for week 2 (p < 0.0001) and 3 (p < 0.003)., The onset of tolerable and intolerable mucositis  , povidone-iodine , honey mitigates ,0,
edin,2603,5446455,Significantly decreased,"When the groups were compared at the end of the study, a significant decrease was observed in VAS, PDI and HIT values in the individuals in the BAT and aerobic exercise groups."," Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT) ", baseline , control ,0,
edin,2581,5615289,Cannot tell based on the abstract,, The incidence of intolerable mucositis (only grade 3) at the end of week 7  , povidone-iodine , honey mitigates ,0,
edin,2581,5615289,No significant difference,"The incidence of intolerable mucositis (only grade 3) were seen earlier and at the end of week 3 in controls (16% (4/24), p = 0.03) and reached a peak in both the groups at the end of week 7 (12/24 in controls vs. 8/25 in honey (p = 0.2)).", The incidence of intolerable mucositis (only grade 3) at the end of week 7  , povidone-iodine , honey mitigates ,0,
edin,2589,3850342,Significantly increased,"We observed a significantly higher percentage of excellent embryos in ISM1 (42.7%) compared to G-1TM v5 (39%, p<0.05).", percentage of excellent embryos ," routine lab culture medium (G-1TM v5; Vitrolife, ", culture in ISM1 (MediCult) ,0,
edin,2576,3400348,Cannot tell based on the abstract,, reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2576,3400348,Significantly increased,T80/H25 resulted in significantly greater BP reductions from baseline (adjusted mean SBP/DBP change â31.6/â18.0âmmâHg) than V160/H25 (adjusted mean SBP/DBP change â28.0/â15.8âmmâHg; P = 0.0063 for difference in SBP and P = 0.0041 for DBP)., reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2629,5556716,Significantly decreased,"Likewise, among the Plane II fracture patients, those who underwent ultrasound-guided reduction were less dissatisfied than those who underwent blind reduction (p=0.043).", level of patients dissatisfaction , control group (blind reduction) Plane II fracture , ultrasound-guided reduction Plane II fracture ,0,
edin,2544,3376507,Significantly increased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â0.72, SD 1.1 kg/m2, enhanced: â1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: â2.1, SD 3.3 kg, enhanced: â3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: â2.0, SD 3.5 cm, enhanced: â3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: â0.01, SD 0.02, enhanced: â0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.", Improvement in waist-to-height ratio , Wait-list control group , Standard version or enhanced version of commercial Web-based weight-loss program ,0,
edin,2640,5101645,Significantly increased,The sedation scores were higher in the BD group than in the other two groups at all time points (P < 0.001)., The sedation scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg) , the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2540,5057302,Cannot tell based on the abstract,," Safety laboratory parameters, ECG, and physical exam. ", Placebo , Sublingual immunotherapy (SLIT)  ,0,
edin,2540,5057302,No significant difference,"No clinically significant changes were observed in safety laboratory (haematology and blood chemistry) parameters, urinalysis, vital signs, physical examination and ECG."," Safety laboratory parameters, ECG, and physical exam. ", Placebo , Sublingual immunotherapy (SLIT)  ,0,
edin,2586,4191553,Cannot tell based on the abstract,," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius ", oral alendronate 35 mg weekly , denosumab 60 mg sc every 6 months ,0,
edin,2586,4191553,Significantly increased,"As the referential comparison, the difference between the alendronate and placebo groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (P < .01) and 6 months at the distal one third radius (P < .01). The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (P < .05), at 12 and 24 months at the femoral neck (P < .05), and from 18 months at the distal one third radius (P < .05)."," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius ", oral alendronate 35 mg weekly , denosumab 60 mg sc every 6 months ,0,
edin,2639,5021260,Cannot tell based on the abstract,, The median coverage , low vaccine coverage rings , high coverage rings ,0,
edin,2639,5021260,Significantly increased,"The median coverage in the high coverage rings (coverage â¥ 30%) was 41% (interquartile range 34%â44%), compared to 0% (interquartile range 0%â6%) in the low vaccine coverage rings (coverage â¤ 12%).", The median coverage , low vaccine coverage rings , high coverage rings ,0,
edin,2609,5446455,Cannot tell based on the abstract,, VT: Vitality , baseline , aerobic exercise  ,0,
edin,2609,5446455,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1""><bold>AE Group</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">42.56Â±6.13</td><td align=""center"" colspan=""1"" rowspan=""1"">0.334</td><td align=""center"" colspan=""1"" rowspan=""1"">0.718</td><td align=""center"" colspan=""1"" rowspan=""1"">51.30Â±8.13</td><td align=""center"" colspan=""1"" rowspan=""1"">4.08</td><td align=""center"" colspan=""1"" rowspan=""1"">0.02</td>", VT: Vitality , baseline , aerobic exercise  ,0,
edin,2554,4714728,Significantly increased,"Group B patients scored higher in terms of pain (P=0.002), activities (P=0.02), range of motion (P<0.001), and strength (P=0.004).", activities , Group A was treated using a hook plate , Group B with autogenous semitendinosus graft and endobutton technique ,0,
edin,2647,4639339,Significantly increased,The use of Midazolam as a benzodiazepine with known sedative and muscle relaxant effects can increase the success rate of enema reduction in intussusception., reduction in intussusception , placebo ," Midazolam at the concentration of 1.0 mg/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline ",0,
edin,2569,4280425,Significantly decreased,"The results favour laparoscopy within the group with ASA 1â3 in terms of several parameters, namely: duration of hospitalization â 7.7 days in the case of laparoscopic intervention, vs. 10.6 days for conventional surgery (p < 0.05);", duration of hospitalization , conventional surgery , laparoscopy within the group with ASA 1Ã¢â¬â3 ,0,
edin,2642,5101645,Cannot tell based on the abstract,, the mean pain scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg)  ,  the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2642,5101645,No significant difference,There was no significant difference in the mean postoperative pain scores between different time points in each group., the mean pain scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg)  ,  the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2580,5615289,Cannot tell based on the abstract,,  the incidence of grade 2 mucositis at week 2 , povidone-iodine , honey mitigates ,0,
edin,2580,5615289,Significantly decreased,"With continuation of the treatment, the incidence of grade 2 mucositis appeared only in the controls (32% (8/25) vs. 0% (0/25)) and was significant (p = 0.002) at week 2.",  the incidence of grade 2 mucositis at week 2 , povidone-iodine , honey mitigates ,0,
edin,2602,5446455,Significantly decreased,"When the groups were compared at the end of the study, a significant decrease was observed in VAS, PDI and HIT values in the individuals in the BAT and aerobic exercise groups."," Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT) ", baseline , Body Awareness Therapy (BAT) and aerobic exercise  ,0,
edin,2565,3961219,Cannot tell based on the abstract,, The mean normalized area under the curve (AUC) values for the second phase , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2565,3961219,No significant difference,"For the second phase I trial, the normalized AUC for the serum BBI level was only weakly correlated with the BBIC dose, with a correlation coefficient of 0.36 and a slope value of 0.0003 (Fig. 3).,The mean normalized AUC values for the subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00Â±0.24, 0.91Â±0.39, 1.51Â±0.29, 1.39Â±0.12 and 1.49Â±0.33, respectively (Fig. 4), and the difference was not statistically significant (P=0.446 by one-way ANOVA).", The mean normalized area under the curve (AUC) values for the second phase , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2590,3850342,Significantly increased,Babies born after culture in ISM1 had both higher birth weight (3.03 kg) and length (48.8 cm) compared to G-1TM v5 babies that had a birth weight of 2.66 kg and a length of 46.0 cm (p<0.001 for both).,"  the length, weight babies born  "," routine lab culture medium (G-1TM v5; Vitrolife, ", culture in ISM1 (MediCult) ,0,
edin,2558,4204994,Significantly decreased,Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001)., percentages of migrated isoforms (PMI) on days 4 and 11 , placebo on all days ," low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13) ",0,
edin,2561,4814821,Cannot tell based on the abstract,, time to first COPD-related emergency room (ER) visit , usual group , telemonitoring group ,0,
edin,2561,4814821,Significantly increased,"In addition, telemonitoring intervention was associated with increased time to first COPD-related ER visit (Fig. 3), with an HR of 0.50 (95% CIâ=â0.24â1.04) over the six months of follow-up.", time to first COPD-related emergency room (ER) visit , usual group , telemonitoring group ,0,
edin,2559,4204994,Significantly decreased,"In both rhEPO groups, PMI on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (pâ=â0.029); low-dose Epoetin beta: 73.1 (17.8)% (pâ=â0.039)).", percentages of migrated isoforms (PMI) on day 25 , placebo on all days ," high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13),  ",0,
edin,2583,4191553,Significantly increased,"Denosumab significantly reduced the risk of new or worsening vertebral fracture by 65.7%, with incidences of 3.6% in denosumab and 10.3% in placebo at 24 months (hazard ratio 0.343; 95% confidence interval 0.194â0.606, P = .0001).", the reduction in risk of 24-month incidence of new or worsening vertebral fracture , placebo , denosumab 60 mg sc every 6 months  ,0,
edin,2582,5615289,Cannot tell based on the abstract,, weight loss , povidone-iodine , honey mitigates ,0,
edin,2582,5615289,Significantly decreased,"Additionally, it was observed that when compared to the povidone-iodine (4.86 Â± 1.73) group, the weight loss was less in the honey cohorts (2.77 Â± 0.85) and was statistically significant (p < 0.001).", weight loss , povidone-iodine , honey mitigates ,0,
edin,2608,5446455,Cannot tell based on the abstract,, VT: Vitality , control , aerobic exercise  ,0,
edin,2608,5446455,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1""><bold>AE Group</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">42.56Â±6.13</td><td align=""center"" colspan=""1"" rowspan=""1"">0.334</td><td align=""center"" colspan=""1"" rowspan=""1"">0.718</td><td align=""center"" colspan=""1"" rowspan=""1"">51.30Â±8.13</td><td align=""center"" colspan=""1"" rowspan=""1"">4.08</td><td align=""center"" colspan=""1"" rowspan=""1"">0.02</td>", VT: Vitality , control , aerobic exercise  ,0,
edin,2535,4593658,No significant difference,"The serum Cr increased and GFR decreased significantly during the intervention in three groups (P < 0.010). However, the amounts of these changes were equal between groups (P > 0.050).", Glomerular filtration rate , Only normal saline (Group C) , N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B) ,0,
edin,2634,4802087,Cannot tell based on the abstract,, Forced Expiratory Volume in the first second (FEV1) , placebo ," 100,000 IU of oral vitamin D per month, for 6 months ",0,
edin,2634,4802087,Significantly increased,"Also, after the study, in the study group, FEV1 was increased and the number of COPD exacerbations was decreased significantly (Table 4).,<td align=""left"" colspan=""1"" rowspan=""3"">COPD exacerbation (MÂ±SD)</td><td align=""left"" colspan=""1"" rowspan=""1"">Before</td><td align=""left"" colspan=""1"" rowspan=""1"">18.02Â±3.3</td><td align=""left"" colspan=""1"" rowspan=""1"">18.7Â±3.8</td><td align=""left"" colspan=""1"" rowspan=""1"">0.38</td>", Forced Expiratory Volume in the first second (FEV1) , placebo ," 100,000 IU of oral vitamin D per month, for 6 months ",0,
edin,2698,3919744,Cannot tell based on the abstract,, COP path length in the AP plane , Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV) , Exercises with whole-body vibration (Group I) ,0,
edin,2698,3919744,Significantly increased,Group I was the only group where the COP path length in the AP plane was significantly increased after the last session of the 4-week whole-body vibration training (pâ=â0.046) (fig. 4, COP path length in the AP plane , Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV) , Exercises with whole-body vibration (Group I) ,0,
edin,2784,5579675,Significantly decreased,"VAS scores for hunger, prospective eating, and desire to eat were all reduced (p < 0.05).","  Hunger, Prospective eating, desire to eat (Pre, immediately before, after, and 30 min post exercise). ", placebo (PLC) , 2 g of YM ,0,
edin,2658,3219777,Cannot tell based on the abstract,, Observer's Assessment of Alertness/Sedation scores after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2658,3219777,Significantly decreased,"In the Control group, the VNRS value at 1 min after incision significantly increased and OAA/S values at 3, 5, and 30 min after incision significantly decreased compared to baseline values, while there were no significant changes in the ketamine group.", Observer's Assessment of Alertness/Sedation scores after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2673,5385703,No significant difference,"Despite a continuous reduction in VASI score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo.", Vitiligo Area Scoring Index score , Topical betamethasone valerate cream (Group A) , Betamethasone valerate cream plus oral simvastatin (Group B) ,0,
edin,2655,3137994,No significant difference,There is no significant difference in the mortality rate between the âsurgicalâ and non-âsurgicalâ groups of Iranian patients with SAH., Mortality rate , Medical treatment , Surgical treatment ,0,
edin,2707,3599990,No significant difference,"Mean differences between self-reported and measured weight (pâ=â0.4004), height (pâ=â0.5342) and body mass index (BMI) (pâ=â0.4409) were not statistically different between the informed and uninformed group", Differences between self-reported and measured body mass index , Uninformed group , Informed group ,0,
edin,2778,4972969,Cannot tell based on the abstract,," Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred ", Control , on-site support (OSS) ,0,
edin,2778,4972969,Significantly increased,"Within the No-IMID subgroup, the incremental effect of OSS was statistically significant for only two indicators; increases in the proportion of emergency and priority patients admitted, detained or referred (Indicator 2, aRRRâ=â2.12, 99 % CIâ=â1.05-4.28, pâ=â0.006),"," Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred ", Control , on-site support (OSS) ,0,
edin,2765,4715405,Cannot tell based on the abstract,"In intervention group, mean level of blood glucose, 2 hours after lunch at 28 weeks of pregnancy was significantly lower than the control group (P<0.05).", MeanÃÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2765,4715405,No significant difference,MeanÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy was 124.7Â±13.9 mg/dl in control and 113.2Â±15.8 mg/dl in intervention group (p=0.1)., MeanÃÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2701,3919744,No significant difference,Most changes in the values of the center of pressure (COP) path lengths in the sagittal and frontal plane were statistically insignificant., Sagittal and frontal planes COP path length values , Exercises without the application of concurrent vibration (Group IV) ," Exercises with whole-body vibration (Group I, II and III) ",0,
edin,2660,3219777,Cannot tell based on the abstract,, Satisfaction scale of physicians and patients , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2660,3219777,No significant difference,The satisfaction scale (1 to 4) of the surgeons and the patients were high in both groups (4 vs. 4)., Satisfaction scale of physicians and patients , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2680,4517027,Significantly increased,"Breakfast was also beneficial for appetite control before lunch irrespective of size (all p < 0.05, d > 0.43).", Appetite control , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2762,3688436,No significant difference,"Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS (6.71 units difference, t = â1.44, P = 0.16) or the BPRS scale (1.29 units difference, t = â0.33, P = 0.75) as compared to placebo.", YMRS and the BPRS scale over the course of 4 weeks , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2732,3348688,Significantly increased,"The bending stiffness anterior-posterior (treatment group 17.48 Nm vs. control group 8.3 Nm), medial-lateral (treatment group 18,9 Nm vs. control group 7.92 Nm) and the torsional stiffness (treatment group 41.17N/Â° vs. control group 16.41N/Â°) are significantly higher in the treatment group than in the control group."," The bending stiffness anterior-posterior, medial-lateral and the torsional stiffness  ", no injection (B) , triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A)  ,0,
edin,2720,5856914,Significantly increased,"The CANDEN spine inflammation score had high responsiveness, similar to the SPARCC MRI spine index (Guyattâs responsiveness index 1.88 and 1.67, respectively), and discriminated between adalimumab and placebo treatment already at 6 weeksâ follow-up (P=0.03).", The CANDEN spine inflammation score , placebo , adalimumab ,0,
edin,2712,3452084,Significantly increased,"<td align=""left"" colspan=""4"">TOTPAR</td>", Time course of total pain relief (TOTPAR) ,  placebo (PLA) ," paracetamol 1,000mgÃ¢â¬âcaffeine 130mg (PCF)  and naproxen sodium 550 mg (NAP) ",0,
edin,2699,3919744,Cannot tell based on the abstract,, Vibration frequency , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2699,3919744,No significant difference,"The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p>0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.", Vibration frequency , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2693,1796543,Cannot tell based on the abstract,, Changes in TLR5 and TLR10 , Placebo , Imiquimod 5% cream ,0,
edin,2693,1796543,No significant difference,There was no change in the expression levels of TLR5 and TLR10 upon treatment with imiquimod., Changes in TLR5 and TLR10 , Placebo , Imiquimod 5% cream ,0,
edin,2787,2430617,Cannot tell based on the abstract,, adverse events , placebo ," 30 ÃÂµg YIC, 60 ÃÂµg of YIC ",0,
edin,2787,2430617,No significant difference,"The occurrence of serious adverse events calculated according to the intent-to-treat principle was 5.1% (4/79), 3.6% (3/83), and 5.0% (4/80) in the placebo, 30 Âµg YIC and 60 Âµg YIC groups respectively (p>0.05).", adverse events , placebo ," 30 ÃÂµg YIC, 60 ÃÂµg of YIC ",0,
edin,2683,5529957,No significant difference,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6âL/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2âL/min/m2 (95% CI â0.1 to 0.5; p=0.17).", Improvement of cardiac index in persistent/recurrent patients , Placebo group , Riociguat group ,0,
edin,2745,3604854,No significant difference,The mean preoperative refraction in LDMMC eyes was â3.08 (SD 1.65) sphere and 0.92 (SD 0.88) cylinder. These values for SDMMC eyes were â3.25 (SD 1.80) sphere and 0.81 (SD 0.84) cylinder., The mean preoperative refraction and cylinder , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2665,2806530,Significantly decreased,Results showed significant reductions in TCI after alcohol administration in female participants exclusively., Transcallosal inhibition in women , Placebo , Alcohol ,0,
edin,2713,3843300,Significantly decreased,"The serum level of blood urea nitrogen (BUN) and creatinine (Cr) in the control group increased significantly (P < 0.05), and administration of NAC (150 mg/kg) decreased the serum levels of Cr and BUN.", serum level of blood urea nitrogen (BUN) and creatinine (Cr) , control , sham-operated group ,0,
edin,2740,2212351,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).", fasting blood glucose (FBG) , no intervention , diabetic meal delivery for 12 months (group M) ,0,
edin,2756,4053826,No significant difference,"There was no difference with respect to pain scores on movement, nor with respect to patient satisfaction.", pain score on movement , the 0.9% saline continuous infusion (the control group) , the ropivacaine continuous infusion (the Ropi group) ,0,
edin,2747,3604854,No significant difference,Mean postoperative cylinder 3 and 6 month after PRK was 0.435 (SD 0.218) and 0.423 (SD 0.255)., Mean postoperative cylinder 3 and 6 month after PRK , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2744,2212351,Cannot tell based on the abstract,, serum lipids , conventional dietary education (group C) , individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M) ,0,
edin,2744,2212351,No significant difference,"There were no significant changes in serum lipids levels in the three intervention groups, although serum TG levels were tended to decrease in groups M and D.", serum lipids , conventional dietary education (group C) , individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M) ,0,
edin,2722,4362117,Cannot tell based on the abstract,, percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg) , control group (CG) received only scaling and root planing (SRP) , One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP) ,0,
edin,2722,4362117,Significantly decreased,"One month after the administration of doxycycline, both Pg, and Pi showed significant reduction in the percentage of site for TG compared with CG (p<0.01 and p=0.04).", percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg) , control group (CG) received only scaling and root planing (SRP) , One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP) ,0,
edin,2811,5491994,Cannot tell based on the abstract,, rating the quality of the physicianÃ¢â¬â¢s explanation , control group ," explanation of patients anatomy, disease state, and treatment options using the education model as an aid ",0,
edin,2811,5491994,Significantly increased,"Patient responses in the 3D model group increased significantly when rating the quality of the physicianâs explanation, their own understanding of their anatomy, their own understanding of their disease state, and their understanding of the proposed surgical treatment.", rating the quality of the physicianÃ¢â¬â¢s explanation , control group ," explanation of patients anatomy, disease state, and treatment options using the education model as an aid ",0,
edin,2766,4715405,Significantly increased,Mean differences in levels of fasting blood glucose between 28 weeks and 32 and between 28 and 36 weeks of pregnancy were significantly higher in the intervention than the control group (P<0.05)., MeanÃÂ±SD of differences in levels of fasting blood glucose between 28 and 32 weeks and between 28 and 36 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2798,3329100,Significantly increased,"Findings of the study revealed a significant effect of the interval training program on VO2max, SBP, and DBP and WBC count at P<0.05 and VO2max is negatively related to the WBC count (r=â0.339) at P<0.01."," volume of O2 maximum (VO2max), systolic blood pressure (SBP) , white blood cell (WBC) and diastolic blood pressure (DBP) ", the age-matched controls hypertensive  group , 8-week interval training (60-79% HR max reserve) program of between 45 minutes to 60 minutes ,0,
edin,2678,4517027,Cannot tell based on the abstract,, Alertness after exercise , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2678,4517027,Significantly increased,Energy intake at breakfast prior to exercise was also significantly related to post-exercise alertness (r (43) = 0.315; p = 0.037) and overall mood (r (43) = 0.372; p = 0.013)., Alertness after exercise , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2771,5735486,Cannot tell based on the abstract,, MAP and HR , Group C receiving identical-looking placebo , Group F receiving preoperative flupirtine ,0,
edin,2771,5735486,No significant difference,MAP and HR between two groups were found to be quite comparable among two groups (P > 0.05) [Figures 1 and 2]., MAP and HR , Group C receiving identical-looking placebo , Group F receiving preoperative flupirtine ,0,
edin,2813,4247720,Significantly increased,"The rate of memory retention, computed by dividing Logical Memory delayed recall by immediate recall, showed a significant interaction (pâ<â.05) in analysis of covariance.,Simple main effects showed that the rate of memory retention of the intervention group improved after the program completion (pâ<â.05).", rate of retention , control group , cognitive intervention through a training program for picture book reading for In the participants with mild cognitive impairment (MCI) ,0,
edin,2661,5777197,Significantly increased,Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar., Risk of death in the first four months , Sequential azacitidine and lenalidomide group and azacitidine only group , High-dose continuous lenalidomide group ,0,
edin,2788,4884260,No significant difference,Regarding the difference between groups for analgesic requirement there were two major points - on one hand it was statistically significant p < 0.05 whereas on the other hand time to first analgesic administration was not statistically significant p = 0.40., analgesic requirement , Local Infiltration Group received 0.2 ml/kg 0.25% bupivacaine , Caudal Group received 1 ml/kg of 0.25% bupivacaine ,0,
edin,2689,5529957,Significantly decreased,"Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(â4.7âmmâHg (95% CI â6.9 to â2.6; p<0.0001 and â4.8âmmâHg (â8.2 to â1.5; p=0.0055), respectively).", Mean pulmonary artery pressure , Placebo group , Riociguat group ,0,
edin,2799,4918317,Cannot tell based on the abstract,, The survival times , placebo , Long-chain omega-3 polyunsaturated fatty acids (PUFAs) ,0,
edin,2799,4918317,Significantly increased,"The survival times were significantly different between the treatment groups, with a more rapid conversion time for the placebo group compared with the omega-3 PUFA group (log-rank test: Ï2=9.84, P=0.002) (Fig. 2)", The survival times , placebo , Long-chain omega-3 polyunsaturated fatty acids (PUFAs) ,0,
edin,2797,5079604,Significantly increased,Subjects who remained in remission had a higher DI (P = 0.02) and incremental AUCi (P < 0.001) than those with hyperglycemia relapse without significant changes in Si., Disposition index (DI) and incremental area under the curve for insulin (AUCi)  , patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si) , subjects who remained in remission ,0,
edin,2723,5268424,Cannot tell based on the abstract,, score on the general dimension scale of negative affects (referred to as NA from here onward) , control , view a video featuring individuals that live in extreme poverty ,0,
edin,2723,5268424,Significantly increased,"These tables show that the Poverty treatment yields a higher score on the general dimension scale of negative affects (referred to as NA from here onward), compared to the Neutral treatment (p<0.01).", score on the general dimension scale of negative affects (referred to as NA from here onward) , control , view a video featuring individuals that live in extreme poverty ,0,
edin,2780,5579675,Significantly increased,Combining YM intake with prolonged exercise at targeted âfat-lossââ intensities augments FAO and improves measures of satiety and mood state., fatty acid oxidation (FAO) , placebo (PLC) , 2 g of YM ,0,
edin,2666,2806530,Cannot tell based on the abstract,, Transcallosal inhibition in men , Placebo , Alcohol ,0,
edin,2666,2806530,No significant difference,"Post hoc analyses demonstrated that alcohol significantly reduced TCI in females (F(1, 11)â=â12.52; pâ=â0.005; Î·p2â=â0.53) but not in males (F(1, 9)â=â0.10; pâ=â0.76; Fig.Â 1). Fig.Â 1", Transcallosal inhibition in men , Placebo , Alcohol ,0,
edin,2700,3919744,Cannot tell based on the abstract,, Amplitude parameters , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2700,3919744,No significant difference,"The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p>0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.", Amplitude parameters , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2742,2212351,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).", fasting blood glucose (FBG) levels , no intervention , individual dietary counseling for 12 months (group D) ,0,
edin,2696,3019750,No significant difference,No significant differences were found between G1 and G2 for enamel hardness and wear., Enamel wear , Saliva in situ (G1) , Saliva with fluoride (G2) ,0,
edin,2697,3919744,No significant difference,Most changes in the values of the center of pressure (COP) path lengths in the sagittal and frontal plane were statistically insignificant., Sagittal and frontal planes COP path length values , Exercises without the application of concurrent vibration (Group IV) ," Exercises with whole-body vibration (Group I, II and III) ",0,
edin,2748,3604854,Cannot tell based on the abstract,, haze formation rate , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2748,3604854,No significant difference,Comparison of haze formation rate in these two groups by Mann-Whitney test demonstrated no significant difference in results (P = 0.104 3rd month and P = 0.156 6th month after operation), haze formation rate , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2777,4972969,Cannot tell based on the abstract,, proportion of patients with a negative malaria test result prescribed an antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group , Control , on-site support (OSS) ,0,
edin,2777,4972969,Significantly increased,"Within the IMID-MLP, the incremental effect of OSS was statistically significant for three indicators; increases in estimated proportion of malaria cases who received an appropriate antimalarial (Indicator 5, aRRRâ=â1.26, 99 % CIâ=â1.02-1.56, pâ=â0.005) and estimated proportion of patients with acid-fast bacilli (AFB) smear negative results who received empiric treatment for acute respiratory infection (indicator 11, aRRRâ=â2.04, 99 % CIâ=â1.06-3.94, pâ=â0.005) and decrease in proportion of patients with a negative malaria test result prescribed an antimalarial (Indicator 6, aRRRâ=â0.49, 99 % CIâ=â0.26-0.92, pâ=â0.004).", proportion of patients with a negative malaria test result prescribed an antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group , Control , on-site support (OSS) ,0,
edin,2721,4362117,Cannot tell based on the abstract,, decline in the percentage of sites harboring Tannerella forsythia (Tf) , control group (CG) received only scaling and root planing (SRP) , One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP) ,0,
edin,2721,4362117,Significantly increased,"In the first month after administering doxycycline, a significantly higher decline in the percentage of sites harboring Tf was observed for TG compared with CG (p=0.02).", decline in the percentage of sites harboring Tannerella forsythia (Tf) , control group (CG) received only scaling and root planing (SRP) , One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP) ,0,
edin,2755,4053826,Significantly decreased,Pain scores at rest were lower for the ropivacaine group and reached significance after 8 and 16 hours (P<0.01)., pain scores at rest at 8 hours and at 16 hours  , the 0.9% saline continuous infusion (the control group) , the ropivacaine continuous infusion (the Ropi group) ,0,
edin,2664,2806530,Cannot tell based on the abstract,, Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2664,2806530,Cannot tell based on the abstract,, Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2664,2806530,No significant difference,"BAC values did not differ between males (mean Â± SD, 0.69âÂ±â0.04) and females (mean Â± SD, 0.603âÂ±â0.05; pâ=â0.17).", Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2761,3688436,Significantly increased,"There was a difference of 0.57 units (t = 2.09, P = 0.04) in the speech item and a difference of 0.29 units in the sexual interest item (t = 2.11, P = 0.04) in the donepezil group as compared to the placebo group.", speech item and the sexual interest item , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2657,3219777,Significantly decreased,"The VNRS values at 1, 3, and 5 min after incision and OAA/S scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.", Verbal numerical rating scales after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2760,3688436,No significant difference,"The total YMRS difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07).", Young Mania Rating Scale (YMRS) on the first day , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2843,5422432,Cannot tell based on the abstract,, nominal gains at post-intervention , control , Active experiencing (AE) ,0,
edin,2843,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", nominal gains at post-intervention , control , Active experiencing (AE) ,0,
edin,2870,4112748,Cannot tell based on the abstract,, The frequency of rescue medication , baseline , frovatriptan and rizatriptan ,0,
edin,2870,4112748,No significant difference,"The frequency of rescue medication was lower in patients during frovatriptan treatment (seven of 20) compared to rizatriptan treatment (13 of 20), this difference just failing to reach statistical significance (P=0.058).", The frequency of rescue medication , baseline , frovatriptan and rizatriptan ,0,
edin,2903,4155124,Significantly decreased,"The ND significantly decreased cathepsin S levels (from 20.1 (+/-4.0 SD) to 19.7Â Î¼g/L (+/-4.3 SD)) compared with control group (from 18.2 (+/-2.9 SD) to 19.1Â Î¼g/L (+/-3.8 SD)). This difference remained after adjusting for sex and change in insulin sensitivity (Pâ=â0.03), and near significant after adjusting for baseline cathepsin S levels (Pâ=â0.06), but not for change in weight or LDL-C.", insulin sensitivity , baseline , healthy Nordic diet (ND) ,0,
edin,2864,5126155,Cannot tell based on the abstract,, The stability of pacing during follow-up ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2864,5126155,No significant difference,"The stability of pacing during follow-up was very high (99.0% in trial and 98.1% in control groups), and the difference was not significant (P = 0.621).", The stability of pacing during follow-up ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2825,3831918,Cannot tell based on the abstract,," pulse wave velocit (PWV), elastic modulus (Ep),  forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient  ", pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2825,3831918,Significantly increased,"There were significant differences in PWV, Ep, W2, NA, and RC across conditions (Table 3 and Fig. 1, P < 0.05)."," pulse wave velocit (PWV), elastic modulus (Ep),  forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient  ", pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2845,5422432,Cannot tell based on the abstract,, category fluency at follow-up , control , Active experiencing (AE) ,0,
edin,2845,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", category fluency at follow-up , control , Active experiencing (AE) ,0,
edin,2850,5586978,Significantly increased,"Compared to group B, group A, which had less time on postoperative mechanical ventilation, had a higher VAS score.", The visual analog scale (VAS) scores , baseline , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2857,4631853,Cannot tell based on the abstract,, pain level , propofol (1.5Ã¢â¬â°mg/kg) combination in Group II  ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg), fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ",0,
edin,2857,4631853,Significantly increased,"Also there was statistically significant difference between the groups during the follow-up (monitorization) period in terms of pain levels (p < 0.05). The patients in Group I suffered from the pain most, whereas the patients in Group II had the least pain (Table 3).", pain level , propofol (1.5Ã¢â¬â°mg/kg) combination in Group II  ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg), fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ",0,
edin,2841,5422432,Cannot tell based on the abstract,, Story recall improved at post-intervention , control , Active experiencing (AE) ,0,
edin,2841,5422432,Significantly decreased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", Story recall improved at post-intervention , control , Active experiencing (AE) ,0,
edin,2840,5722109,Cannot tell based on the abstract,, success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis. , epinephrine 1:200000 and 0.4 mL normal saline (A-saline group) , 3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg/mL ketamine hydrochloride (A-ketamine group) ,0,
edin,2840,5722109,No significant difference,The success rate of IANB was 55.0% for A-ketamine and 42.9% for A-saline group. There was no statistically significant difference in success rates between the two groups (P=0.437)., success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis. , epinephrine 1:200000 and 0.4 mL normal saline (A-saline group) , 3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg/mL ketamine hydrochloride (A-ketamine group) ,0,
edin,2922,5771895,Cannot tell based on the abstract,, average severity scores of hot flashes and night sweats , placebo ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  or  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ",0,
edin,2922,5771895,Significantly decreased,"As reported previously for the entire KEEPS cohort,27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (Pâ<â0.001 for both), with no difference between the o-CEE and t-E2 groups (Pâ=â0.343 and Pâ=â0.919, respectively; Table 2).", average severity scores of hot flashes and night sweats , placebo ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  or  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ",0,
edin,2828,5297995,Cannot tell based on the abstract,, coronal growth of approximal gingival margin on the neighboring teeth , stock , zirconia implant abutments ,0,
edin,2828,5297995,Significantly increased,"Clinical examination revealed a significant (Tâ=â24; pâ<â.05) coronal growth of approximal gingival margin (0.32 mm; 95% CI [0,06 mm; 0,58mm]; SD 0.88 mm) on the neighboring teeth after 12 months.", coronal growth of approximal gingival margin on the neighboring teeth , stock , zirconia implant abutments ,0,
edin,2837,4888158,Cannot tell based on the abstract,, residual antimicrobial activity of CHX at one week and at three and six weeks ,  Resilon/RealSeal SE samples , gutta-percha/AH26  ,0,
edin,2837,4888158,Significantly increased,"The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).", residual antimicrobial activity of CHX at one week and at three and six weeks ,  Resilon/RealSeal SE samples , gutta-percha/AH26  ,0,
edin,2844,5422432,Cannot tell based on the abstract,, nominal gains at follow-up , control , Active experiencing (AE) ,0,
edin,2844,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", nominal gains at follow-up , control , Active experiencing (AE) ,0,
edin,2895,3267052,Significantly decreased,The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the FV group (p < 0.05)., cumulative plaque scores , placebo , fruit/vegetable (FV) ,0,
edin,2923,5771895,Cannot tell based on the abstract,, average severity scores of hot flashes and night sweats , oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)   ",0,
edin,2923,5771895,Significantly decreased,"As reported previously for the entire KEEPS cohort,27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (Pâ<â0.001 for both), with no difference between the o-CEE and t-E2 groups (Pâ=â0.343 and Pâ=â0.919, respectively; Table 2).", average severity scores of hot flashes and night sweats , oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)   ",0,
edin,2919,5771895,Cannot tell based on the abstract,, the number of women with improved sleep quality ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  or placebo (PBO) ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2919,5771895,Significantly increased,"When compared with PBO, the reduction in the percentage of women with poor sleep quality (ie, the number of women with improved sleep quality) was significantly greater in the t-E2 group (Pâ=â0.003) and modestly but not significantly greater in the o-CEE group (Pâ=â0.07).", the number of women with improved sleep quality ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  or placebo (PBO) ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2831,5297995,Cannot tell based on the abstract,, coronal growth of approximal gingival margin on the neighboring teeth , After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2831,5297995,Significantly increased,"Clinical examination revealed a significant (Tâ=â24; pâ<â.05) coronal growth of approximal gingival margin (0.32 mm; 95% CI [0,06 mm; 0,58mm]; SD 0.88 mm) on the neighboring teeth after 12 months.", coronal growth of approximal gingival margin on the neighboring teeth , After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2894,3267052,Significantly decreased,"Gingival crevicular fluid volumes diminished more in supplement groups than placebo (FVB; p < 0.05) at 2 months, but not at later times.", Gingival crevicular fluid (GCF) volumes , placebo , fruit/vegetable (FV) and FVB ,0,
edin,2829,5297995,Cannot tell based on the abstract,," embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant ", After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2829,5297995,Significantly decreased,"Patients experienced significantly less embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant at T 1 (pâ<â.01) and T 12 (pâ<â.05) than they had expected at T 0."," embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant ", After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2877,5106877,Significantly increased,"There is no difference between serums Vit D level in case and control group at the beginning of the study, however at the end of the study serum Vit D level was significantly higher in the case group.", serums Vit D level , placebo , Vit D as 50 000 IU/week ,0,
edin,2822,3831918,Cannot tell based on the abstract,," retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate ", baseline ," pneumatic cuff was applied to the calf and inflated to 0, 35, and 70 mmHg ",0,
edin,2822,3831918,Significantly decreased,"There were significant differences in retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate across conditions (Table 3 and Fig. 1, P < 0.05).,<td align=""left"" colspan=""1"" rowspan=""1"">Mean shear rate, sec<sup>â1</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">102 Â± 9</td><td align=""center"" colspan=""1"" rowspan=""1"">69 Â± 7<xref ref-type=""table-fn"" rid=""tf3-1"">1</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">37 Â± 8<xref ref-type=""table-fn"" rid=""tf3-1"">1</xref>,<xref ref-type=""table-fn"" rid=""tf3-2"">2</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">0.001</td>"," retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate ", baseline ," pneumatic cuff was applied to the calf and inflated to 0, 35, and 70 mmHg ",0,
edin,2830,5297995,Cannot tell based on the abstract,, bone apposition , stock , zirconia implant abutments ,0,
edin,2830,5297995,No significant difference,"The difference in bone apposition between the 2 groups (stock: 0.06 mm, 95% CI [â0.05 mm; 0.16 mm], standard deviation 0.23mm versus CAD/CAM customized: 0.11 mm, 95% CI [0.02 mm; 0.20 mm]; standard deviation 0.20 mm) was not statistically significant.", bone apposition , stock , zirconia implant abutments ,0,
edin,2921,5771895,Cannot tell based on the abstract,, sleep disturbances ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2921,5771895,Significantly increased,"Among the three domains, only sleep disturbances showed a statistically significant difference between the two HT formulations (Pâ=â0.029), with t-E2 improving more during follow-up than o-CEE (Table 2).", sleep disturbances ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2852,5586978,Cannot tell based on the abstract,,  the VAS scores after surgery , conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2852,5586978,Significantly decreased,"After surgery, the VAS scores in group A were better than that in group B (P<0.05), while the Cobb angle and ESR of the two groups showed no difference.",  the VAS scores after surgery , conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2859,5870330,Significantly increased,"Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05),", fracture resistance , G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth , G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width ,0,
edin,2892,3267052,Significantly decreased,The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the FV group (p < 0.05)., bleeding on probing (% BOP) and cumulative plaque scores  ," fruit/vegetable/berry (FVB), placebo ", fruit/vegetable (FV) ,0,
edin,2890,3267052,Significantly increased,"Clinical outcomes improved in all groups at 2 months, with additional improvement in PPD versus placebo for FV (p < 0.03).", mean probing pocket depth (PPD) , placebo ,"  fruit/vegetable (FV), fruit/vegetable/berry (FVB) ",0,
edin,2913,5459456,Cannot tell based on the abstract,," inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments ", control , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC ,0,
edin,2913,5459456,No significant difference,"There were no significant differences among the control, ACVC, and ACVC-HA groups inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments."," inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments ", control , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC ,0,
edin,2915,5459456,Cannot tell based on the abstract,, new bone formation around the screws and bone-implant contact (BIC) in both sections , ACVC , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating ,0,
edin,2915,5459456,Significantly increased,"In the sections located at the self-drilling fixation screw level (Fig 8E and 8G), we found significantly more new bone formation around the screws for the ACVC-HA group (Fig 8G) than for the ACVC group (Fig 8E).,These findings indicate that, compared with the ACVC group, the ACVC-HA group had a significantly higher bone-implant contact (BIC) in both sections respectively located at the vertebral body component and screw level (Fig 8I), which is an appropriate index for measuring bone ingrowth into the implant.", new bone formation around the screws and bone-implant contact (BIC) in both sections , ACVC , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating ,0,
edin,2918,4021263,Cannot tell based on the abstract,, M. tuberculosis or nontuberculous mycobacteria detection , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2918,4021263,No significant difference,"Among the 51 confirmed APTB cases, M. tuberculosis or nontuberculous mycobacteria was identified in one or more samples from 27 (52.9%) patients, 14 (58.3%) from the SI group and 13 (48.1%) from the ES group (p=0.46).", M. tuberculosis or nontuberculous mycobacteria detection , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2842,5422432,Cannot tell based on the abstract,, thematic recall , control , Active experiencing (AE) ,0,
edin,2842,5422432,Significantly increased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", thematic recall , control , Active experiencing (AE) ,0,
edin,2881,5129820,No significant difference,"There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI and FACT-O scores in the overall, BRCAm and germline BRCAm populations.", The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI) , placebo , olaparib 400Ã¢â¬â°mg b.i.d. (capsules) ,0,
edin,2866,4112748,No significant difference,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).", the time to maximum concentration , rizatriptan , frovatriptan ,0,
edin,2874,4776123,Cannot tell based on the abstract,, global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2874,4776123,Cannot tell based on the abstract,, global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2874,4776123,Significantly increased,"After the Fisher r-to-z translation, a repeated measure ANOVA revealed that both groups improved their LCFs in CereN as indicated by a significant main effect of time (F = 6.903, p = 0.015).,Paired-sample t-tests revealed that the global LCF of CereN (T = 2.30, p = 0.03) was significantly increased after the training scan compared with the before-training scan in the control group but not in the training group.", global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2909,4069273,Cannot tell based on the abstract,, Exercise , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2909,4069273,Significantly increased,"Exercise had a statistically significant difference between the intervention and the control groups (pâ<â0.001).,After 3Â month follow up, the percentage of participants who exercised more than 5 times/week in the intervention group (29.2%) was more than the control group (9.2%).", Exercise , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2920,5771895,Cannot tell based on the abstract,," domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction ",  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2920,5771895,No significant difference,"There were no significant differences between groups for the changes in domain scores pertaining to sleep efficiency (Pâ=â0.45), sleep duration (Pâ=â0.38), or daytime dysfunction (Pâ=â0.26) across follow-up."," domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction ",  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2863,5126155,Cannot tell based on the abstract,, The effective sensitivity rate ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2863,5126155,No significant difference,"The effective sensitivity rate immediately after the procedure was 94.8% and 93.6% in the trial and control groups, respectively, with no significant difference (P = 0.716).", The effective sensitivity rate ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2885,4249579,Significantly increased,"Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (Cmax), area under the concentration-time curve from 0 h to the end of the study (AUC0âlast), and area under the concentration-time curve from 0 h to infinity (AUC0ââ) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively.", maximum observed plasma concentration after oral administration (Cmax) and predicted area under the plasma concentration time curve after the last dose from zero time to infinity (AUC0Ã¢â¬âlast)values , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2823,3831918,Significantly increased,Cuff inflation resulted in stepwise increases in retrograde shear rate (P < 0.05 for main effect)., retrograde shear , pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2821,4450208,Significantly increased,"Regarding the effect of the program on both genders, the change was very similar, but the boys increased assertive social interaction strategies, attention, and emotional clarity significantly more than the girls."," assertive social interaction strategies, attention, and emotional clarity ",  a program of emotional intelligence (EI) 20 one-hour sessions - girls ,  a program of emotional intelligence (EI) 20 one-hour sessions - boys ,0,
edin,2856,4631853,Cannot tell based on the abstract,, total propofol doses , fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group II ",0,
edin,2856,4631853,Significantly decreased,"In terms of total propofol doses administered during the follow-up (monitorization), the difference between Group I and Group II and between Group I and Group III and Groups II and III was statistically significant (p < 0.001) (p < 0.003).,The comparison of the groups in terms of the total dose of propofol revealed that it was 375âmg in Group I, 150âmg in Group II, and 245âmg in Group III (Figure 1).", total propofol doses , fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group II ",0,
edin,2908,4069273,Significantly decreased,"Participants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), plaque index score, gingival index score, pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) when compared to the control group."," pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) ", received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2818,4450208,Cannot tell based on the abstract,, the effects of the program 1 year after completing the intervention , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2818,4450208,Significantly increased,"Subsequently, in order to assess the maintenance of the effects of the program 1 year after completing the intervention, the pretest-follow-up change was analyzed.,The results of the descriptive analysis (mean and SD) and pretest-follow-up ANCOVAs (with the pretest scores as covariates, see Table 4) confirmed statistically significant differences in the pretest-follow-up change between the experimental and control groups.,In particular, we noted a significant increase in the mean scores of the experimental group (Me) compared with the control group (Mc) in EI due to the significant improvement in all three factors, emotional attention (Me = 2.43, Mc = -1.26), emotional clarity (Me = 2.86, Mc = 0.02), and emotional repair (Me = 3.24, Mc = 0.05).", the effects of the program 1 year after completing the intervention , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2872,4776123,Cannot tell based on the abstract,,   improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN) , baseline , right- and left- frontoparietal networks (FPNs) and control ,0,
edin,2872,4776123,Significantly increased,"After the Fisher r-to-z translation, a repeated measure ANOVA revealed that both groups improved their LCFs in CereN as indicated by a significant main effect of time (F = 6.903, p = 0.015).",   improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN) , baseline , right- and left- frontoparietal networks (FPNs) and control ,0,
edin,2873,4776123,Cannot tell based on the abstract,,   improving of level laterality cofactor (LCF)  , baseline , right lateral  frontoparietal networks (rFPN) left lateral  frontoparietal networks (lFPN) ,0,
edin,2873,4776123,Significantly increased,"In addition, a significant training main effect on the LCF in rFPN (F = 5.897, p = 0.021) and lFPN (F = 7.641, p = 0.01), as well as interactions of LCF of lFPN (F = 8.908, p = 0.006), were observed.",   improving of level laterality cofactor (LCF)  , baseline , right lateral  frontoparietal networks (rFPN) left lateral  frontoparietal networks (lFPN) ,0,
edin,2848,5422432,Cannot tell based on the abstract,, story recall at post-intervention , baseline , Active Control ,0,
edin,2848,5422432,Significantly increased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", story recall at post-intervention , baseline , Active Control ,0,
edin,2906,4069273,Significantly decreased,"articipants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), plaque index score, gingival index score, pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) when compared to the control group.", the plaque index score and gingival index score , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2910,4069273,Cannot tell based on the abstract,, The percentage of participants who modified diet , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2910,4069273,Significantly increased,he percentage of participants in the intervention group (93.8%) who modified diet was higher than the control group (70.8%) with a statistically significant difference (pâ=â0.001)., The percentage of participants who modified diet , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2889,4249579,Cannot tell based on the abstract,, t1/2 , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2889,4249579,Significantly decreased,"Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0âlast (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone. Geometric mean ratios (90% CI) of primaquine administered with and without dihydroartemisinin-piperaquine for Cmax, AUC0âlast, and AUC0ââ were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively (Fig. 2).", t1/2 , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2897,4729786,Cannot tell based on the abstract,," mood scales, stress scales ", positive training (vice versa) ," negative training (pull negative, push positive pictures) ",0,
edin,2897,4729786,No significant difference,The analyses revealed neither an immediate training effect on the mood scales nor on the stress scales (pÂ >Â .398).," mood scales, stress scales ", positive training (vice versa) ," negative training (pull negative, push positive pictures) ",0,
edin,2916,4021263,Significantly increased,"Among the APTB, more adequate specimens were collected from SI (41/65, 63.1%) than ES (34/80, 42.5%) (p=0.01).", APTB adequate specimens collection  , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2862,5126155,No significant difference,"Effective pacing rates of trial and control groups were comparable both in the full analysis set and the per protocol set (81.4% vs. 79.5%, P = 0.712 and 95.4% vs. 89.5%, P = 0.143, respectively).", The effective pacing rate immediately after the procedure ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2820,4450208,Significantly decreased,"In the follow-up phase, the positive effects of the intervention were generally maintained and, moreover, the use of aggressive strategies as an interpersonal conflict-resolution technique was significantly reduced.", the use of aggressive strategies as an interpersonal conflict-resolution technique , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2836,4888158,Cannot tell based on the abstract,"The antimicrobial activity of CHX gradually decreased in a time-dependent manner but it maintained over 95% of its antimicrobial activity after six weeks. Moreover, Resilon/RealSeal SE significantly decreased the antimicrobial activity of CHX in comparison with gutta-percha/AH26 (P<0.05).", The antimicrobial activity , baseline , 2% CHX ,0,
edin,2836,4888158,Significantly increased,"The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).", The antimicrobial activity , baseline , 2% CHX ,0,
edin,3064,5377263,Significantly increased,"Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased. The levels of IL-2 and TNF-Î± were also observed to be significantly elevated, yet IL-10 decreased.", IL-2 and TNF-ÃÂ± , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,2935,5601935,No significant difference,"Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05).", Quality of fetuses , Human menopausal gonadotropin (HMG) plus r-FSH , Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH) ,0,
edin,2949,5600923,Significantly decreased,"The rate of local recurrence was 44.9 and 68.7% in AG and CG, respectively (P < 0.01).", Rate of local recurrence , Placebo (CG group) , Alginate oligosaccharide (AOS; AG group) ,0,
edin,2940,2744923,Cannot tell based on the abstract,, Effectiveness at day 42 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2940,2744923,No significant difference,"<td align=""center"" colspan=""6""><bold>CPD</bold></td>", Effectiveness at day 42 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2999,3220859,Cannot tell based on the abstract,, glucose infusion rate (GIR) ," glargine, NPH insuline ",  detemir ,0,
edin,2999,3220859,Significantly decreased,"Bivariate correlations of BMI and GIR split by treatment showed an inverse correlation that was significant only with detemir (r = â0.68, P = 0.003), but not with glargine (r = â0.41, P = 0.11) and NPH (r = â0.37, P = 0.15) (Supplementary Fig. 1),On the basis of BMI status, with all three basal insulins, GIR was lower in people with BMI >29 kg/m2 compared with people with BMI <29 kg/m2 (Fig. 1), but statistical significance was achieved with detemir treatment only (598 Â± 604 and 1,564 Â± 649 mg/kg, respectively; P = 0.03) and not with NPH (1,058 Â± 859 and 1,282 Â± 532 mg/kg) and glargine (1,408 Â± 563 and 1,668 Â± 807 mg/kg) (both P > 0.2).", glucose infusion rate (GIR) ," glargine, NPH insuline ",  detemir ,0,
edin,3067,5377263,Cannot tell based on the abstract,, implant infection , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3067,5377263,No significant difference,"There were 3 cases of implant infection in control group (9.4%), 1 case in observation group (3.1%), there was no statistical significance (P=0.306, unilateral) by Fisher's exact probability method.", implant infection , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3035,3506580,Cannot tell based on the abstract,, mean pain intensity , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3035,3506580,No significant difference,"There was no significant difference of the perceived mean pain intensity before and after tDCS stimulation for the factors time (PREPOST: F(1,13)â=â0.85; pâ=â0.374) and stimulation modality (STIM: F(2,26)â=â0.93; pâ=â0.379) and no interaction between STIM*PREPOST (F(2,26)â=â1.18; pâ=â0.323).", mean pain intensity , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3072,5870915,Cannot tell based on the abstract,, The daily body weight gain from SD 1 to SD 29 , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3072,5870915,Significantly increased,The daily body weight gain from SD 1 to SD 29 was significantly higher in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Fig. 5, The daily body weight gain from SD 1 to SD 29 , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3084,5148913,Cannot tell based on the abstract,, abnormalities in haematology or blood chemistry parameters , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3084,5148913,No significant difference,No clinically significant abnormalities in haematology or blood chemistry parameters were reported during the study., abnormalities in haematology or blood chemistry parameters , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3032,5864139,No significant difference,"Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28â1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years).", Cases of pancreatic cancer , placebo ," sitagliptin, 23 (0.3%) ",0,
edin,2925,4286912,Cannot tell based on the abstract,, Antigens of co-administered vaccines , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,2925,4286912,No significant difference,"Co-administered vaccine antigens
One month post-primary and post-booster vaccination, all children were seroprotected against diphtheria, tetanus and poliovirus types 1, 2 and 3, and all infants were seropositive for antibodies against the three pertussis antigens and polyribosylribitol phosphate from Hib. All infants except one were seroprotected against hepatitis B surface antigen (HBs) at one month post-primary vaccination. Three children had anti-HBs antibody concentrations which were initially measured between 10 and 100 mIU/mL. Out of these 3 children, upon retesting using Immuliteâ¢, one was found to be seroprotected while the other 2 had anti-HBs antibody concentrations <10 mIU/mL. This was further followed up by investigators and one child was subsequently re-vaccinated. Efforts to reach the other child for re-vaccination were unsuccessful. Three months after the second dose of the HRV vaccine, â¥81.9% of infants were seropositive for anti-HRV antibodies (data not shown).", Antigens of co-administered vaccines , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,3074,3650212,Cannot tell based on the abstract,, The tipping , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3074,3650212,Significantly increased,"The tipping was only significant in group 1, and it was significantly larger in this group than in group 2 (p < 0.001).", The tipping , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3001,4730432,Significantly increased,"A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.", intention to seek information about clinical trials , baseline , church-based educational intervention ,0,
edin,3051,3177395,Cannot tell based on the abstract,, dental plaque on smooth and approximal tooth surfaces after 14 days , baseline , received herbal extract dentifrices or used a conventional dentifrice ,0,
edin,3051,3177395,Significantly decreased,"After 14 days, significant reduction of dental plaque on smooth and approximal tooth surfaces compared to baseline was observed in all groups (P <60; 0.001).", dental plaque on smooth and approximal tooth surfaces after 14 days , baseline , received herbal extract dentifrices or used a conventional dentifrice ,0,
edin,2992,3671204,Significantly increased,"After six weeks, pain scores increased from 5.3 to 6.6 (p=0.04).", pain scores after six weeks , baseline ,  physical activity (PA) program for patients with knee and/or hip osteoarthritis (OA) ,0,
edin,3063,5377263,Significantly increased,"Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased.", Th1 and Th1/Th2 , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3044,3321528,Cannot tell based on the abstract,, handgrip strength , non-dominant hand , dominant hand ,0,
edin,3044,3321528,No significant difference,"A significant difference was found in handgrip strength between patients diagnosed with ICU-AW in comparison to those without an ICU-AW diagnosis (6.6 Â± 4.4 versus 23.4 Â± 8.9âkg, P < 0.01), even when the comparison was adjusted for gender and age (P < 0.01). This was also the case when handgrip performance was expressed in relative values (29.0 Â± 22.4% predicted versus 66.0 Â± 22.2% predicted, P < 0.01).

In concern to between-sides comparison, patients tended to perform better with the dominant rather than the non-dominant hand (16.2 Â± 11.1 versus 14.2 Â± 9.9âkg, resp., P = 0.09).", handgrip strength , non-dominant hand , dominant hand ,0,
edin,3076,3650212,Cannot tell based on the abstract,, Treatment time , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3076,3650212,Significantly increased,Treatment time was significantly greater in group 1 than in group 2 (7.44 Â± 1.30 months versus 6.27 Â± 1.11 months; p < 0.001)., Treatment time , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3013,3636767,Cannot tell based on the abstract,," patients, who achieve the BP target of systolic/diastolic BP &amp;lt; 140/90 mmHg ", telmisartan 80 mg  , telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) ,0,
edin,3013,3636767,Significantly increased,"Across the entire study population, at week 7, single-pill T80/H25 combination therapy significantly reduced the adjusted mean Â± standard error seated trough cuff systolic/diastolic BP from baseline (â37.0 Â± 0.62/â18.6 Â± 0.38 mmHg) as compared with T80 monotherapy (â28.5 Â± 0.88/â15.4 Â± 0.55 mmHg [adjusted mean difference â8.5/â3.2 mmHg; 95% CI â10.6, â6.4/â4.5, â1.9; P < 0.0001]) and allowed more patients to achieve the BP target of systolic/diastolic BP < 140/90 mmHg (55.5% versus 34.7%; OR, 2.39; 95% CI 1.76, 3.26; P < 0.0001).9"," patients, who achieve the BP target of systolic/diastolic BP &amp;lt; 140/90 mmHg ", telmisartan 80 mg  , telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) ,0,
edin,2968,4152682,Significantly decreased,"Pulse rate (95.9 Â± 11.2 bpm vs. 102.9 Â± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N.", Pulse rate and blood pressure after surgery , Normal saline followed by general anesthesia (Group N) , Transversus abdominis plane block with 0.25% bupivacaine (Group B) ,0,
edin,2998,4586379,Cannot tell based on the abstract,," The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels ", control , Hydroxychloroquine (HCQ) ,0,
edin,2998,4586379,Significantly increased,"The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels were significantly better in CKD mice treated with HCQ. *P < 0.05 compared with CKD placebo mice."," The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels ", control , Hydroxychloroquine (HCQ) ,0,
edin,2987,2836298,No significant difference,"Continued abstinence at 12 months confirmed through CO was 7.4% in the III, 5.4% in the IGI, and 1% in the MI. No significant differences were noted between III and MI on the one hand, and between IGI and MI on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].,No differences were noted between IGI and III [RR 0.7 (0.2-2.2)].", Continued abstinence at 1 year , Intensive individual intervention (III) , Intensive group intervention (IGI) ,0,
edin,2982,4323894,No significant difference,"here were 63.2% of patients in cooling group attained good GOS at 6 months compared to only 15.4% in noncooling group (P = 0.007). Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good GOS, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).", Improvement in Glasgow outcome score at 6 months post-trauma , Mild-cooling , Deep-cooling ,0,
edin,3052,3177395,Cannot tell based on the abstract,, mean values of plaque indices after 14 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,3052,3177395,Significantly decreased,"However, in the conventional group, mean values of plaque indices were significantly higher than in the herbal groups.", mean values of plaque indices after 14 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,2927,4286912,Cannot tell based on the abstract,, Reactogenicity and safety profiles , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,2927,4286912,Invalid Prompt,, Reactogenicity and safety profiles , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,1, Reactogenicity and safety profiles are mentioned in the methods and materials section of the article but there is no significant information in results or conclusion section. Results section contains only a list of complications. 
edin,2983,4323894,No significant difference,"There were 63.2% of patients in cooling group attained good GOS at 6 months compared to only 15.4% in noncooling group (P = 0.007).,Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good GOS, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).", Improvement in Glasgow outcome score at 6 months post-trauma , No cooling , Deep-cooling ,0,
edin,2946,4993942,Cannot tell based on the abstract,, Complications , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,2946,4993942,No significant difference,No complication occurred in both groups during laser and in follow-up period., Complications , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,3024,4240932,Cannot tell based on the abstract,"he significant change value on the before-after BICAMS points were considered to be 8, 13, and 7 points for the symbol digit modality test (SDMT), the California verbal learning test (CVLT), and the brief visual-spatial memory test revised (BVMT-R), respectively.", Brief International Cognitive Assessment for MS (BICAMS) test , placebo ," B. papyrifera (capsule 300 mg, twice a day) ",0,
edin,3024,4240932,Significantly increased,"BICAMS battery changes were considered as significant if SDMT changed 8 points, CVLT, 13 points, and BVMT-R, 7 points.,We observed that 12 patients (31.6%) from the treatment group and 8 patients (21.1%) from the placebo group had a significant change value in SDMT test.

CVLT test also showed a significant change in 17 and 12 patients (44.7% and 31.6%) in the treatment and placebo groups, respectively.

BVMT-R was improved significantly in 13 patients (34.2%) who took BP compared to the placebo group which had no improvement at all.,Although the number of patients who improved after receiving the drug in the treatment group was more than the placebo group in CVLT and SDMT, such a difference was not statistically significant (P = 0.2000 for SDMT, P = 0.1700 for CVLT); regarding BVMT-R, our findings were statistically significant (P < 0.001).", Brief International Cognitive Assessment for MS (BICAMS) test , placebo ," B. papyrifera (capsule 300 mg, twice a day) ",0,
edin,3048,5735476,Significantly increased,"Time for rescue analgesia in Group D5-377.46 Â± 60.05, in Group D10-401.60 Â± 61.11, and in Group D15-517.96 Â± 97.30, which is statistically highly significant (P < 0.000).", Time for rescue analgesia ," Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ", Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml) ,0,
edin,2939,2744923,Cannot tell based on the abstract,, Effectiveness at day 28 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2939,2744923,Significantly increased,"<td align=""center"" colspan=""6""><bold>AL</bold></td>", Effectiveness at day 28 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,3020,3152513,Cannot tell based on the abstract,, MADRS remission rates in patients with baseline MADRS total scores Ã¢â°Â¥20 ," placebo, or oral olanzapine 5-20 mg once daily for 3 weeks ", flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter) ,0,
edin,3020,3152513,Significantly increased,"In patients with baseline MADRS total scores â¥20, MADRS remission rates (defined as MADRS total score â¤12) with asenapine were significantly greater than placebo on days 7 (57% vs 17%; P = 0.004) and 21 (70% vs 33%; P = 0.012); remission rate with asenapine on day 7 was significantly greater than olanzapine (57% vs 25%; P = 0.006) and showed a trend towards statistical significance on day 21 (70% vs 48%; P = 0.066).", MADRS remission rates in patients with baseline MADRS total scores Ã¢â°Â¥20 ," placebo, or oral olanzapine 5-20 mg once daily for 3 weeks ", flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter) ,0,
edin,3027,5156617,Significantly decreased,"A total of 19 subjects (31 eyes) completed the trial after five subjects (eight eyes) dropped out. In the patients who completed the study by wearing lenses for 4 weeks, the myopic refractive error decreased significantly by 2.60 Â± 2.21 D (p < 0.001), from -3.65 Â± 1.62 to -1.05 Â± 1.64 D. The astigmatic refractive error were also significantly decreased by 0.63 Â± 0.98 D (p = 0.001), from 2.07 Â± 0.83 to 1.44 Â± 0.99 D.", The mean astigmatic refractive error , baseline , astigmatism of 1.25 to 4.0 D ,0,
edin,3002,4730432,No significant difference,"A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.", intention to seek information about clinical trials , baseline , control ,0,
edin,3087,4530661,Significantly decreased,"Although soy milk did not have any effect on BP, probiotic soymilk significantly decreased systolic (14.7 Â± 0.48 vs. 13.05 Â± 0.16, P = 0.001) and diastolic BP (10 Â± 0.7 vs. 9.1 Â± 1, P = 0.031).", systolic and diastolic BP , consumed 200 ml/day of soy milk for 8 weeks , consumed 200 ml/day of probiotic soy milk containing Lactobacillus planetarium A7  for 8 weeks ,0,
edin,2967,4152682,Significantly decreased,"Pulse rate (95.9 Â± 11.2 bpm vs. 102.9 Â± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N.", Pulse rate during surgery , Normal saline followed by general anesthesia (Group N) , Transversus abdominis plane block with 0.25% bupivacaine (Group B) ,0,
edin,3050,5735476,Cannot tell based on the abstract,, mean arterial pressure (MAP) falls , baseline ," Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ",0,
edin,3050,5735476,Significantly increased,"MAP falls significantly at 30th, 45th, and 60th min from basal rate within the groups, we have noticed hypotension in 4 (13.3%) patients in Group D5, 6 (20.0%) patients in Group D10, 13 (43.3%) patients in Group D15, which is statistically significant (P = 0.020) [Table 3].", mean arterial pressure (MAP) falls , baseline ," Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ",0,
edin,3071,5870915,Cannot tell based on the abstract,, the number of days with diarrhoea and the number of piglets that had diarrhoea , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3071,5870915,Significantly decreased,"The area under the curve for the FS, the number of days with diarrhoea and the number of piglets that had diarrhoea were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).Fig. 3", the number of days with diarrhoea and the number of piglets that had diarrhoea , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,2958,3597059,Cannot tell based on the abstract,, Baseline characteristics , Control (C group) , Crystalloid (RS group) and colloid (HES group) ,0,
edin,2958,3597059,No significant difference,Baseline hemodynamic variables were comparable among the groups (P > 0.05)., Baseline characteristics , Control (C group) , Crystalloid (RS group) and colloid (HES group) ,0,
edin,3016,4630743,Significantly decreased,Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia., Pain on cervical dilatation , 400 mg of metronidazole tablets (as a placebo) , 400 ÃÂ¼g of misoprostol ,0,
edin,2948,5600923,Significantly decreased,"After 2-year therapy, the mean tumor volume was 214.6 Â± 145.7 c.c. in AG and 467.2 Â± 225.3 c.c in CG (P < 0.01).", Tumor volume after 2 years of therapy , Placebo (CG group) , Alginate oligosaccharide (AOS; AG group) ,0,
edin,2964,4770250,No significant difference,"DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.", Systemic adverse events , Placebo , Dual release ciprofloxacin for inhalation (DRCFI) ,0,
edin,3012,5043523,No significant difference,"There were no significant differences between the three groups in terms of changes in folate intakes from baseline to month 6. Similarly, there were no changes in reported intake of food groups high in folate.", folate intakes , control or not at risk , knowledge of MTHFR 677CÃ¢â¬â°Ã¢â âÃ¢â¬â°T genotype ,0,
edin,3031,4483405,No significant difference,"Both groups exhibited significant decreases in pain post-intervention. Moreover, the range of motion of internal and external rotation increased significantly post-intervention in both groups. However, there was no significant difference between groups with respect to pain improvement or range of motion.", pain or  range of motion (ROM) improvement , Kaltenborn mobilization , Maitland mobilization ,0,
edin,3070,5870915,Cannot tell based on the abstract,, the number of piglets that excreted countable oocyst numbers , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3070,5870915,No significant difference,"The area under the curve for OpG, the number of days with McMaster countable excretion and the number of piglets that excreted countable oocyst numbers were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).", the number of piglets that excreted countable oocyst numbers , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,2926,4286912,No significant difference,No serious adverse events considered causally related to vaccination were reported throughout the study., Serious adverse events , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,3036,3506580,Cannot tell based on the abstract,, heat pain thresholds (HPT) , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3036,3506580,No significant difference,"There were no significant differences of HPT before and after tDCS (PREPOST: F(1,9)â=â0.82; pâ=â0.389) and between treatment modalities (STIM: F(2,18)â=â1.27; pâ=â0.306).", heat pain thresholds (HPT) , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,2943,4993942,Significantly increased,"The mean subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increased significantly in each eye 6 weeks after PRP (P values in red laser group: <0.01, 0.03, and <0.01, resp., and in green laser group <0.01, <0.01, and <0.01).", Subfoveal choroidal thickness , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,3062,4726501,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Intention-to-treat analysis</td><td align=""center"" colspan=""1"" rowspan=""1""></td><td align=""right"" colspan=""1"" rowspan=""1""></td><td align=""center"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>", the incidence of positive urine dipstick albumin , no aspirin ," receive aspirin (81 mg or 100 mg daily, ",0,
edin,3054,3177395,Cannot tell based on the abstract,, Mean values of the SBI after 42 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,3054,3177395,Significantly decreased,"The most anti inflammatory effect had been achieved in herbal test groups, where mean values of GI and SBI indices were significantly lower than those of the conventional group (P <60; 0.001).", Mean values of the SBI after 42 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,2995,5980459,Significantly increased,Abomasal outflow fluid pH was higher in steers treated with famotidine for up to 4 hours after a single dose but the effect decreased with subsequent doses., pH of abomasal outflow fluid for 4 hours , saline control , famotidine administered at 0.4 mg/kg ,0,
edin,2945,4993942,No significant difference,"There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after PRP (P values: 0.184, 0.404, and 0.726, resp.).", Peripapillary nerve fiber layer thickness , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,2974,5452353,Significantly increased,"Plasma NO3 â were 10.3Â Î¼mol greater with POMx vs. PLAC (95% CI, 0.8, 19.7,F 1,7â=â7.83, pâ<â0.04).", Levels of NO3 Ã¢Ëâ in plasma , Placebo (PLAC) , Pomegranate extract (POMx) ,0,
edin,3081,5148913,Significantly increased,"The primary endpoint [change from baseline over the entire treatment period in average pre-dose morning peak expiratory flow (PEF)] demonstrated the superiority of BDP/FF over BDP monotherapy, with an adjusted mean difference of 19Â L/min, which is above the minimal important clinical difference reported for this parameter. O", adjusted mean change of PEF , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3005,4347450,Cannot tell based on the abstract,, Judge 2's performance quality ratings between time 2 and 3 , waitlist condition , cognitive behavioral (CB) group-delivered intervention ,0,
edin,3005,4347450,No significant difference,"For Judge 2's performance quality ratings, both the interaction between group and time [F(2, 120) = 0.36, p > 0.05] and main effect for group were not significant [F(1, 60) = 1.36, p > 0.05].", Judge 2's performance quality ratings between time 2 and 3 , waitlist condition , cognitive behavioral (CB) group-delivered intervention ,0,
edin,2860,5870330,Significantly increased,"G1 showed the highest fracture resistance value (1737.1 N) while G3 had the lowest mean value (522.9 N). Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05), where in both groups, the preparation of the occlusal extension mostly remained in the enamel layer.", fracture resistance , G6: The occlusal extension was 2 mm in depth and 1 mm in width. , G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width ,0,
edin,3028,5156617,Cannot tell based on the abstract,"The mean uncorrected and corrected visual acuities before wearing the lenses were 2.14 Â± 0.80 logarithm of the logMAR (logMAR) and 0.05 Â± 0.13 logMAR, respectively, which changed to 0.12 Â± 0.30 logarithm of the logMAR (p < 0.001) and 0.01 Â± 0.04 logMAR (p = 0.156) after 4 weeks.", The mean uncorrected and corrected visual acuities , baseline , myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D ,0,
edin,3028,5156617,No significant difference,"The mean uncorrected and corrected visual acuities at the screening visit were 2.14 Â± 0.80 and 0.05 Â± 0.13 logMAR, respectively. The equivalent values after wearing the toric orthokeratology lenses for 4 weeks were 0.12 Â± 0.30 and 0.01 Â± 0.04 logarithm of the minimal angle of resolution (logMAR), respectively. The difference in uncorrected visual acuity was -2.03 Â± 0.91 logMAR, which was statistically significant (p < 0.001). The difference in corrected visual acuity was -0.04 Â± 0.14 logMAR, which was not statistically significant (p = 0.156) (Table 3).", The mean uncorrected and corrected visual acuities , baseline , myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D ,0,
edin,3165,3652505,Cannot tell based on the abstract,The number sized framing effect was also tested to be significant (P < 0.01)., number size framing effect ," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? "," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose? ",0,
edin,3165,3652505,Significantly decreased,"Table 5 described the effect of number size framing. The results revealed that the number size framing effect was significant in medical situation (t = -7.5, P < 0.001).

Table 1,<td colspan=""1"" rowspan=""1"">Framing 2: Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? </td><td colspan=""1"" rowspan=""1"">4.14 Â± 1.39</td>", number size framing effect ," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? "," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose? ",0,
edin,3181,4563303,Cannot tell based on the abstract,, Timed Up and Go (TUG) (sec)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3181,4563303,Significantly decreased,"Changes in TUG and BBS between pre-test and post-test were statistically significant in both groups and there was an interaction between the groups and time.,<td align=""left"" colspan=""1"" rowspan=""1"">TUG (sec)<sup>â¡</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">15.62Â±4.89</td><td align=""center"" colspan=""1"" rowspan=""1"">9.93Â±3.93<sup>â </sup></td><td align=""center"" colspan=""1"" rowspan=""1"">21.84Â±12.61</td><td align=""center"" colspan=""1"" rowspan=""1"">19.33Â±12.07<sup>â </sup></td>", Timed Up and Go (TUG) (sec)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3153,5094682,No significant difference,"The mean changes in eGFR were 0 Â± 14 and â7 Â± 16 mL/min/1.73 m2 (p = 0.09, between groups) for the acarbose and pioglitazone groups, respectively.", glomerular filtration rate (eGFR) , pioglitazone , acarbose ,0,
edin,3157,5094682,Significantly increased,"Significant body weight gain was observed in the pioglitazone group as compared with the acarbose group (1.3 Â± 2.8 vs. â0.6 Â± 1.5 kg, p = 0.002).


Conclusion", body weight , acarbose ,  pioglitazone ,0,
edin,3201,4787139,Cannot tell based on the abstract,, heart rate (HR) , baseline ," MDZ:FEN, DEX 0.25 Î¼g/kg (DEX half) ",0,
edin,3201,4787139,Significantly decreased,"HR values in âDEX fullâ group were significantly lower than in MDZ:FEN and âDEX halfâ group at 10 min (P = 0.001). MDZ: FEN group patients had lower HR than DEX full and DEX half group patients in the post-operative period (150, 180, 210 min) [Figure 1]. Two cases in the âDex fullâ group required injection atropine for treatment of HR less than 50/min.", heart rate (HR) , baseline ," MDZ:FEN, DEX 0.25 Î¼g/kg (DEX half) ",0,
edin,3126,5200917,Cannot tell based on the abstract,, reaction time in simple speeded response task  , placebo , tolcapone ,0,
edin,3126,5200917,No significant difference,"Moreover, in a simple speeded response task, no difference was seen in reaction time for either visual or auditory responding on tolcapone compared to placebo (all T(14)Â â¤Â 1.1, pÂ â¥Â 0.3),", reaction time in simple speeded response task  , placebo , tolcapone ,0,
edin,3141,3845560,Cannot tell based on the abstract,, Distant metastasis , flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy , 2 cycles of sinusoidal chronomodulated infusion (Arm A) ,0,
edin,3141,3845560,No significant difference,Distant metastasis represented the major failure pattern and occurred in 27 (21.8%) patients: 16 (25.4%) in Arm A and 11 (18.0%) in Arm B (P = 0.597) (Table 4)., Distant metastasis , flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy , 2 cycles of sinusoidal chronomodulated infusion (Arm A) ,0,
edin,3208,2784386,Significantly increased,"In non-ICU subjects, treatment success was significantly higher for micafungin versus liposomal amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/136); P = 0.0113).", treatment success in non-ICU subjects , liposomal amphotericin B (3 mg/kg/day) , micafungin (100 mg/day for subjects &amp;gt; 40 kg; 2 mg/kg/day for subjects â¤ 40 kg) ,0,
edin,3170,3536709,Cannot tell based on the abstract,, difference in the weight ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3170,3536709,No significant difference,In spite of lower energy intake during LPVD there was no difference in the weight of the subjects compared to ND (75.6 Â± 7.9 kg vs. 76.2 Â± 7.6 kg)., difference in the weight ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3160,5842771,No significant difference,"After 12 weeks of treatment, the average MMSE scores, ADL scores, and CDR scores in the two groups were significantly improved. But, compared to the control group, the experimental group had a significantly higher average MMSE score (p<0.00001), lower average ADL score (p=0.00002), and lower average CDR score (p=0.030).", Clinical Dementia Rating Scale (CDR) score , memantine 5â20 mg/d ," Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â20 mg/d ",0,
edin,3174,3503942,Significantly decreased,"The changes in visual analog scale were estimated to be 6.86Â±0.90 before first therapy, 2.86Â±0.90 after first therapy, and 1.86Â±0.69 after third therapy in case of ESWT group, whereas the figures were estimated to be 7.20Â±1.30 before first therapy, 4.60Â±0.55 after first therapy, and 2.80Â±0.84 after third therapy in case of TPI+TENS group, and the changes between the groups were significantly different (p=0.010).", The changes in visual analog scale ,  trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS) , extracorporeal shock wave therapy (ESWT) ,0,
edin,3162,3652505,Cannot tell based on the abstract,Doctorsâ advices were respectively described in a baneful or beneficial frame and the former one resulted in a better compliance (P < 0.05)., better compliance ," question:  Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? "," question:  Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon? ",0,
edin,3162,3652505,Significantly increased,"As shown in Table 2 that if the doctorâ advise was respectively described in the benefit of compliance and the aftermath of violation, the former one lead to a better compliance (t = 2.14, P = 0.035).,<td colspan=""1"" rowspan=""1"">Negative: Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? </td><td colspan=""1"" rowspan=""1"">2.10 Â± 0.89</td>", better compliance ," question:  Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? "," question:  Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon? ",0,
edin,3132,4078065,Cannot tell based on the abstract,, ApoA-I and HDL-mediated cholesterol effluxes , placebo , 3.2 g/day citrulline ,0,
edin,3132,4078065,Significantly increased,"Citrulline enhanced both apoA-I- and HDL-mediated cholesterol efflux from THP-1 macrophages by 96.1Â Â±Â 26.1% (p<0.05) and 14.4Â Â±Â 2.5% (p<0.05), respectively, compared to control (Fig.Â 3A and B).", ApoA-I and HDL-mediated cholesterol effluxes , placebo , 3.2 g/day citrulline ,0,
edin,3171,3536709,No significant difference,"Diet caused no significant difference in venous blood pH, strong ion difference (SID), total concentration of weak acids (Atot), partial pressure of CO2 (pCO2) or HCO3- at rest or during cycling between LPVD and ND.", strong ion difference (SID) ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3119,4188585,No significant difference,No differences in SPID between treatments were observed at 2 and 3 months after patch application., The maximum difference in summed pain intensity differences (SPID) , placebo , capsaicin ,0,
edin,3204,4787139,Significantly increased,"DEX fullâ group had a higher incidence of bradycardia, hypotension, level 4 sedation (Ramsay Sedation Scale) and lower surgeon satisfaction."," bradycardia, hypotension and level 4 sedation ", baseline , DEX full ,0,
edin,3175,3503942,No significant difference,The changes in McGill pain questionnaire (p=0.816) and pain rating scale (p=0.644) between the groups were not significantly different., The changes in McGill pain questionnaire ,  trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS) , extracorporeal shock wave therapy (ESWT) ,0,
edin,3146,4435250,Significantly increased,"omen in the MHC/WHC arm were more likely to report increases in relationship equity, relative to those in the CHC arm, and had a higher odds of reporting no victimization during the previous 3 months (MHC/WHC vs WHC: odds ratio =3.05, 95% CI: 1.55, 6.0, P=0.001; CHC vs MHC/WHC: odds ratio =0.38, 95% CI: 0.20, 0.74, P=0.004).", relationship equity , Couples Health CoOp [CHC] ,  females in group Menâs Health CoOp/Womenâs Health CoOp [MHC/WHC] ,0,
edin,3095,5091897,Cannot tell based on the abstract,, household smoking bans follow up 3 and 6 months  , Control Group , Intervention group ,0,
edin,3095,5091897,Significantly increased,"<td align=""center"" colspan=""9"" rowspan=""1""><bold>Primary outcome</bold></td>", household smoking bans follow up 3 and 6 months  , Control Group , Intervention group ,0,
edin,3191,4836241,Significantly decreased,"The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05)."," follicle-stimulating hormone (FSH), luteinizing hormone (LH) "," Kuntai, Control "," Tibolone,  ",0,
edin,3199,4568196,No significant difference,"Despite the significant effect of HDEL on increasing TAC in 3 weeks [P = 0.050 (4%)], the level of TAC remained the same in 6 weeks.",  total antioxidant capacity (TAC) , baseline ,  hypocaloric diet enriched with legumes (HDEL) ,0,
edin,3166,3536709,Cannot tell based on the abstract,, Energy intake ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3166,3536709,Significantly decreased,"Energy intake was significantly lower during LPVD compared to ND (2400 Â± 338 kcal vs. 2793 Â± 554 kcal, p=0.033).", Energy intake ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3097,5306984,Significantly increased,We conclude that arm training using the AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training in subacute phase of stroke., subacute stroke patients , conventional arm training (control group) , ArmAssist (AA group) ,0,
edin,3107,3994428,Significantly decreased,"Six-month mortality was 6.5% in the ICP group and 9.1% in the control group (Pâ<â0.05),", Mortality , control group , ICP monitoring ,0,
edin,3135,5156970,Significantly increased,"The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group.", relief of overall symptoms , baseline , azithromycin ,0,
edin,3113,5516192,Cannot tell based on the abstract,, The incision length , traditional cold instruments (scalpel and scissors) , electrosurgical device ,0,
edin,3113,5516192,No significant difference,"The incision length was not significantly different; cold 15.7 (5.2) cm, electroincision 15.6 (4.2) cm, 95% CI â1.6â1.8, Pâ=â.91.", The incision length , traditional cold instruments (scalpel and scissors) , electrosurgical device ,0,
edin,3127,5200917,Cannot tell based on the abstract,, blood pressure , placebo , tolcapone ,0,
edin,3127,5200917,No significant difference,"Finally, no differential changes in blood pressure were seen on tolcapone versus placebo (T(15)Â =Â 1.31, pÂ =Â 0.21),", blood pressure , placebo , tolcapone ,0,
edin,3098,5306984,Significantly increased,We conclude that arm training using the AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training in subacute phase of stroke., subacute stroke patients , conventional arm training (control group) , ArmAssist AA group ,0,
edin,3123,3775615,Cannot tell based on the abstract,,  HBeAg levels , adefovir (ADV) (10 mg/day) , lamivudine (LAM) (100 mg/day ,0,
edin,3123,3775615,No significant difference,"As described in Figure 2, HBeAg levels in the LAM + ADV group were 1.81Â±1.01, 1.52Â±0.86, 1.26Â±0.93, and 0.71Â±0.93 at weeks 12, 24, 52, and 104 of treatment, respectively.,In the ETV group, the levels of HBeAg were 1.66Â±0.99, 1.43Â±0.92, 1.12Â±0.91, and 0.69Â±0.83 at weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).",  HBeAg levels , adefovir (ADV) (10 mg/day) , lamivudine (LAM) (100 mg/day ,0,
edin,3180,4563303,Cannot tell based on the abstract,, Right (cm)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3180,4563303,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">Right (cm)<sup>â¡</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">3.40Â±1.58</td><td align=""center"" colspan=""1"" rowspan=""1"">4.11Â±2.35<sup>â </sup></td><td align=""center"" colspan=""1"" rowspan=""1"">1.95Â±0.92</td><td align=""center"" colspan=""1"" rowspan=""1"">3.16Â±1.15<sup>â </sup></td>", Right (cm)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3103,4450164,Cannot tell based on the abstract,, ureteropelvic junction obstruction , stentless cases , internal drainage group ,0,
edin,3103,4450164,No significant difference,"Intraoperative assessments showed ureteropelvic junction segmental atresia in 45 cases and aberrant vessels in 25 patients.,One patient had distal ureter obstruction because of distal ureter stone, that was treated by Trans-ureteral lithotripsy (TULP) and stent support.", ureteropelvic junction obstruction , stentless cases , internal drainage group ,0,
edin,3195,3661337,No significant difference,The SPTT group showed fewer subjects having any fall (19.23% vs. 33.33% Standard PT; pâ<â0.227) and fewer having an injurious fall (7.69% vs. 18.18%; pâ<â0.243).,  fewer having an injurious fall , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3125,4815378,Significantly increased,Mean weight changes of neonates 7 weeks after the intervention compared to those in the beginning of the intervention were significantly more in palady group compared to the cup group (cup = 146.7 and palady = 198.8; P < 0.001)., Mean weight changes of neonates 7 weeks , cup ,  palady ,0,
edin,3190,4836241,Significantly increased,"After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P < 0.05),", estradiol (E2) leve ," Kuntai, Control "," Tibolone,  ",0,
edin,3158,5842771,Significantly increased,"But, compared to the control group, the experimental group had a significantly higher average MMSE score (p<0.00001),", The Mini Mental State Examination (MMSE) , memantine 5â20 mg/d ," Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â20 mg/d ",0,
edin,3194,3661337,Cannot tell based on the abstract,, falls , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3194,3661337,No significant difference,"Over a period of 3Â months, 5 of 26 (19.2%) subjects in the SPTT group and 11 of 33 (33.3%) subjects in the Standard PT group had fallen at least once (Chi2â=â1.46; pâ<â0.23); 2 of 26 (7.7%) in the SPTT group and 6 of 33 (18.2%) in the Standard PT group had an injurious fall (Chi2â=â1.37; pâ<â0.25) (see FigureÂ 2).", falls , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3187,4836241,Significantly increased,"At the 4th week after GnRH-a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > Tibolone group (P < 0.05);", KMI and hot flash/sweating score ," Kuntai, Tibolone ",  Control ,0,
edin,3169,3536709,Cannot tell based on the abstract,,  the amount of fat ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3169,3536709,Significantly decreased,"As well, the amount of fat differed between LPVD and ND (24.7 Â± 2.3% vs. 28.1 Â± 3.1%, p=0.015).",  the amount of fat ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3142,5014878,Significantly increased,Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (pÂ <Â 0.001)., Mean antibody reactivity against the associated HPV , baseline , quadrivalent HPV vaccine (GardasilÂ®) ,0,
edin,3148,4083640,Significantly decreased,"On postoperative day 5, the self-reported pain intensity was significantly lower in the NBP group than in the CT group (visual analog scale score, 1.50 vs. 3.29; p = 0.04).", postoperative pain on day 5 , conventional thoracotomy (CT) , neurovascular bundle preservation (NBP) ,0,
